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2.1 Criteria to judge all PDB structures for entry into Binding MOAD.
The scripts evaluate each structure - one at a time - against all crite-
ria, but this step-by-step diagram is given to show the impact of each
criterion. The numbers shown are taken from the first public release
of Binding MOAD. . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.2 Currently, 4078 protein families exist over all EC classes. Our routine
for grouping proteins by EC number and 90% sequence identity is
shown schematically below. The dashed arrows represent a protein
with two EC numbers being added to two EC classes. The bold
arrows show how a protein with no EC number is added to an EC
class by sequence identity. The bold arrows represent a protein that is
nearly identical to the dashed protein, so it is added to the same two
classes. The gray arrow notes that the homologous protein families
are compared in the end, and entries found multiple in families are
corrected. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.3 Distribution of the current 6213 unique ligands by molecular weight.
The average ligand in Binding MOAD is 455 g/mol. The largest are
small chains of sugars, amino acids, and nucleic acids. . . . . . . . 32
2.4 Histogram of the homologous protein families shows that most fami-
lies have only a few complexes. There is a near-exponential decrease
in the number of larger and larger families. This trend is basically
the same for clustering at 100% sequence identity (blue), 90% (red),
75% (yellow), and 50% (gray). . . . . . . . . . . . . . . . . . . . . . 34
2.5 The distribution of binding-affinity data within Binding MOAD. Data
is available as K d (red), K i (blue), or IC50 (yellow). For this his-
togram, binding data were converted to free energies by -RT ln (data).
Though not strictly appropriate for many K i or IC50, this simply pro-
vides a comparison for the reader. . . . . . . . . . . . . . . . . . . . 36
viii
2.6 Screenshot of the data page for 3ERK, showing the additional lig-
and data and the connectivity to proteins with similar structure and
function. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2.7 EolasViewer for 3ERK. The SB4 ligand is shown in ball in stick inside
the pocket. The surfaces shown are the ligand surface in blue, the
binding site in red and the solvent-exposed regions of the binding site
are in green. (Top) The protein backbone is shown as a gray ribbon,
and in the close-up (Bottom), the backbone is colored by B-factors. 39
3.1 Determining the boundary of an open cavity using ELS. (Left) A
ligand molecule (black) is bound in an open protein cleft (gray). The
dashed line is the ELS, determined by adding 2.8 Å to the radii.
A probe rolls over the vdw surfaces of the protein atoms and the
inward-facing surface of the ELS. The resulting surface of the cavity
is shown as a bold, black line. The solvent-exposed portion of the
cavity surface is defined as the section of bold, black line that is
defined only by the ELS in the opening of the binding site. . . . . . 48
3.2 The use of an ELS does not create inappropriate boundaries for
open or closed cavities that contain bridging water molecules. Ex-
amples are given for completely buried cavities (1ECM and 1KDK)
and solvent-exposed pockets (1AZ8 and 1GFY). (left) Binding site
and ligand surfaces calculated with GoCAV, employing an ELS cut-
off. (right) The resulting surfaces when the noted bridging water
molecules within the cavity are included in the calculation as addi-
tional protein atoms. The ligand surface is blue, and the binding site
surface is red and gray. The red regions are buried, and the gray
region denotes the solvent-exposed or ELS surface of the cavity. Pro-
tein atoms are not shown for clarity. This figure was created using
the GoCAVviewer on the Binding MOAD website. . . . . . . . . . . 49
ix
3.3 The datapage for the HIV-1 protease complex 1MTR. The page starts
with the general information from the PDB file. The ligand HET
codes are single-click searches that pull up all other structures with
that ligand. All ligands are listed as valid or invalid, and binding affin-
ity data is provided when available. Warnings are provided when the
number of atoms in the structure do not match the formula section
of the PDB file. Clicking the thumbnail launches the GoCAVviewer.
Links to the right of the thumbnail take the user to the equivalent
datapage at the PDB and to the crystallography paper on Pubmed.
Various sets of structural and binding data are available for down-
load. At the bottom of the page, the structure is linked to other
entries with the same functional class, and all other members of its
protein family are listed with ligand information (over 100 HIV-1 pro-
tease structures are included in Binding MOAD and the user needs
to scroll down the page to see all the data. . . . . . . . . . . . . . . 54
3.4 The user can find information by browsing through the complexes
within Binding MOAD. The structures are organized by function: EC
numbers for enzymes and our own classifications for entries without
EC numbers. All protein families within a class are displayed for the
user to compare related systems and their binding affinity data. . . 55
3.5 Distribution of ligand size within the complexes in redundant and
non-redundant Binding MOAD, note the larger scale for the redun-
dant complexes. Black bars represent all complexes in Binding MOAD;
gray bars represent only the complexes with affinity data. . . . . . . 57
3.6 Plots of ligand size vs. binding affinity for the complexes in redundant
and non-redundant Binding MOAD. The data points in black squares
are from complexes with Kd data, and gray diamonds are used for
complexes with K i or IC50 data. . . . . . . . . . . . . . . . . . . . 57
3.7 (A) Distribution of the buried surface area (Å2) for cavities within
Binding MOAD as calculated with GoCAV, note the larger scale for
the redundant data. Black bars represent all complexes in Binding
MOAD; gray bars represent only the complexes with affinity data.
(B) Plots of buried surface area of the cavity (Å2) vs. ligand size.
The data points in black squares are from complexes with K d data,
and gray diamonds are used for complexes with K i or IC50 data.
Error bars for data points were available in two cases. First, if a side
chain in the active site was resolved in more than one orientation.
Second, some multimer complexes are solved with slight differences
in the independent binding sites (for instance, the atomic coordinates
of the binding sites within a dimer will not be the exactly same if
symmetry was not imposed while fitting the electron density). . . . 59
x
3.8 Histograms of the percent of surface area that is buried. (A) Percent-
age of buried MSA of the cavity and (B) Percentage of buried SASA
of the ligand. Black bars represent all complexes in Binding MOAD;
gray bars represent only the complexes with affinity data. . . . . . . 61
3.9 The largest ligands tend to have much of their surface area exposed to
solvent (low % buried). (A) Percentage of buried MSA of the cavity
and (B) Percentage of buried SASA of the ligand. The data points in
black squares are from complexes with K d data, and gray diamonds
are used for complexes with K i or IC50 data. . . . . . . . . . . . . . 62
4.1 Comparisons of (A) enzyme complexes, (B) non-enzyme complexes,
(C) high-affinity complexes and (D) low-affinity complexes are pre-
sented. High-affinity enzymes are shown in dark blue, and low-affinity
enzymes are in green. High-affinity non-enzymes are in red, and low-
affinity non-enzymes are in gold. Distribution of ligand sizes (num-
ber of non-hydrogen atoms), buried surface area of the pocket (Å2),
SlogP, and exposed surface area (Å2) are given in normalized percent
frequencies. P-values show the significance of the difference in the
medians of the distributions, as determined by a two-tailed Wilcoxon
rank-sum evaluation (insignificant differences have p>0.05). . . . . . 72
4.2 Limited correlation is seen between size and affinity in non-enzymes
(A and B). The proteins with “clusters” of points have smaller bind-
ing sites and no ligands over 40 non-hydrogen atoms. The ligands
have similar sizes and affinities for oligopeptide-binding protein (OBP),
glutamate receptor 2 (GluR2) and mannose-binding protein (MBP),
arabinose-binding protein (ABP), and estrogen receptor (ER) alpha
and beta. The only non-enzymes with a range of ligand sizes are
maltose-binding protein and the non-enzymatic site on the SH2 do-
main of pp60src tyrosine kinase (C and D, respectively). . . . . . . . 74
4.3 Many examples are available of enzyme complexes that show a strong
correlation between size and affinity of the ligands; seven are given
here (A-G). HIV-1 protease (G) demonstrates that a large collection
of ligands may show no correlation, but subsets of data may reveal
strong trends (data for the C95A and Q7K/L33I/L63I mutants). It
is interesting that even small binding sites with ligands of 40 non-
hydrogen atoms or less (B,C,D) show a linear trend with affinity;
this was not seen for non-enzymes with small binding sites. . . . . . 75
xi
4.4 Distribution of ligand efficiencies per size (-kcal/mol-atom) and per
contact (-kcal/mol-Å2), given in normalized percent frequencies. Dis-
tributions present comparisons of (A) high-affinity complexes (p<0.0001
in both cases) and (B) low-affinity complexes. High-affinity enzymes
are shown in dark blue, and low-affinity enzymes are in green. High-
affinity non-enzymes are in red, and low-affinity non-enzymes are in
gold. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.5 The binding sites (left) and the entire protein sequences (right) are
analyzed for amino acid content. Distributions are given in nor-
malized frequencies percent frequencies. Amino acids within 4Åof
the ligands are considered to comprise the binding site. Distribu-
tions of (A and B) low- and high-affinity complexes of the same class
show smaller differences than comparisons between enzymes and non-
enzymes (C and D). Amino acids are listed by hydrophobic, aromatic,
cationic, anionic, and hydrophilic nature. “X” denotes contacts with
cofactors, unnatural amino acids, and covalent modifications on the
protein. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.6 Distribution of ligand efficiencies (-kcal/mol-atom) for enzymes, given
in percent frequencies normalized for the different number of com-
plexes in each enzyme class. The distribution of transferases (EC 2,
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5.1 Plotting the affinity of the complexes versus their physical character-
istics reveals the limiting cases as well as the general trends. Mea-
surements used for affinity data are noted as IC50 (green diamonds),
Ki (red squares), or Kd (black diamonds). (A) Affinity versus size
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number of non-hydrogen atoms. The units of the ligand efficiencies
listed above the lines are -kcal/mol-atom. (B) Affinity versus the
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5.2 Close up view of the complexes with the highest ligand efficiencies.
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5.3 Binding sites of the 11 most efficient complexes. Figures show all
residues within 4Å of the small molecule ligand. The ligand is colored
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molecule ligand. The ligand is colored by atom type. Acidic residues
are colored red; basic residues are colored blue; hydrophobic residues
are colored green; and hydrophilic residues are colored white as in
figure 5.3. The NAD+ of lactate dehydrogenase is colored blue be-
cause the moiety against the ligand is positively charged. Water is
colored red and shown in small spheres. . . . . . . . . . . . . . . . . 101
5.6 Relationship between efficiency, exposure, and protein contacts for
ligands with 5-10 atoms and more than one charge site. (A) The
distribution of efficiencies is compared for systems with well buried
(black) versus more exposed sites (white); a cutoff of 2 Å2/atom
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in normalized percent frequencies. (a) Comparisons of high-affinity
complexes and (b) low-affinity complexes are presented. High-affinity
enzymes are shown in dark blue lines, and high-affinity non-enzymes
are in red lines. Low-affinity enzymes are in green lines, and low-
affinity non-enzymes are in gold lines. . . . . . . . . . . . . . . . . . 124
A.10 Examples of enzyme families that show exceptionally strong response
and limited size ranges for ligands. (a) Wild-type (Ki as black trian-
gles, IC50 as black circles) and the R292K-mutant (Ki as gray trian-
gles, IC50 as gray circles) of neuraminidase show the same strong re-
sponse to conservative changes to the ligands. (b) Sizes and Ki (black
triangles) for ligands bound to MTA/SAH Nucleosidase. (c) The data
points for the ligands bound to protocatechuate 3,4-dioxygenase can-
not be fit to a line because of the near vertical arrangement. . . . . 129
xiv
A.11 Amino acid content in enzymes and non-enzymes, given in normal-
ized percent frequencies. Amino acids are listed by hydrophobic,
aromatic, cationic, anionic, and hydrophilic. “X” denotes cofactors,
unnatural amino acids, and covalent modifications on the protein
(does not include crystallographic additives in the crystal structure). 130
B.1 Structure of nutlin inhibitor used in molecular dynamics simulation. 149
B.2 This figure shows the definition of the angles (θ and ϕ of the lid with
respect to the binding pocket. The length(l) and width(w) of the
binding pocket are shown. The residues on the surface of the binding
pocket are colored blue. . . . . . . . . . . . . . . . . . . . . . . . . 151
B.3 This figure shows the RMSD between the snapshot pose and the x-
ray pose of the nutlin inhibitor, and the openness of the lid in each
snapshot of the four simulations that reproduced the ligand pose of
the x-ray crystal structure (1RV1). Figure A is the simulation that
had the smallest RMSD, and Figures B, C and D had the second,
third and fourth smallest RMSD, respectively. Negative time from
the simulation indicates the equilibration time period. This is in-
cluded in the figure since the ligand does interact with the protein
before the start of the production run. . . . . . . . . . . . . . . . . 153
B.4 This figure is a histogram of the distance between the center of mass
of the inhibitor in the snapshot and the center of mass of the inhibitor
in the x-ray structure (1RV1), and the openness of the pocket. The
colors represent the number of structures in each bin. Bins were
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ABSTRACT
Binding MOAD (Mother of All Databases) is the largest collection of high-quality,
protein-ligand complexes. Binding MOAD contains 13,138 protein-ligand complexes
comprised of 4078 unique protein families and 6210 unique ligands. We have compiled
binding data for 4146 of the protein-ligand complexes. The creation of this database
and three studies mining the database for biophysical properties of protein-small
molecule binding are discussed in this thesis. An additional study is included in the
appendix which investigates flexibility upon small molecule binding to MDM2.
First, we present the development of GoCav, which allows us to mine properties
of the whole database. We have determined that most complexes have well buried
binding sites (70-85%), which fits the idea that a large degree of contact between the
ligand and protein is significant in molecular recognition.
Secondly, we investigate the differences in biophysical properties of binding to
enzymes versus non-enzymes. Differences in the sizes of weak versus tight ligands in-
dicate that the addition of complementary functional groups may improve the affin-
ity of an enzyme inhibitor, but the process may not be as fruitful for ligands of
non-enzymes. Non-enzymes were found to have greater ligand efficiencies than en-
zymes, which supports the feasibility of non-enzymes as druggable targets. This has
significant ramifications for target selection in drug design. Most importantly, the
differences in ligand efficiencies appear to come from the pockets which yield different
amino acid compositions, despite similar overall distributions of amino acids.
We then investigate the biophysical properties of the most efficient protein-ligand
complexes. All highly efficient small molecules contain one or more charge and are
xx
found in binding sites with at least one charge, challenging previous thoughts that
hydrophobic properties of ligands lead to the better binding. Lastly, it is known that
affinity for complexes rarely exceeds -15 kcal/mol, and we suggest that ligands do not




Proteins utilize the binding of small molecules to perform a wide range of biological
functions. Common functions include protein processing, cell signaling, responding
to environmental conditions, regulating and performing metabolism. Due to their
great diversity of structure and function, proteins bind a vast array of small-molecule
ligands. The precise biochemical and physical properties which significantly impact
protein-ligand binding are of some debate. However, it is important to understand
the contribution of these properties because structure based drug design relies on this
information to develop small molecules which are able to bind to a particular target
and create a desirable physiological response.
This dissertation utilizes a large database of high-quality, x-ray crystal structures
of protein-ligand complexes, annotated with binding data, to determine what prop-
erties are important for small molecule binding. The creation of the database is
discussed first. Three studies regarding the mining of the database are then pre-
sented. The first study details characteristics of protein-ligand binding as a whole in
the database. The second provides insights into particular aspects of binding that are
important to particular classes and families of proteins. The third study shows the
biophysical characteristics of the complexes that exhibit the “most efficient” binding.
These studies are based on a large database of static crystal structures, so to round
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out these studies, the appendix presents molecular dynamics simulations to examine
ligand binding to the MDM2 protein.
1.1 Protein Ligand Binding
Over time, theories have changed on how small molecules interact with a binding
site of a protein. In 1894, a “lock and key” model was proposed by Herman Emil
Fisher, where a protein pocket is preformed to fit a particular shape (3; 4; 5). A
similar concept was suggested by Linus Pauling who indicated that active sites were
preformed to fit the transition state of a reaction, rather than the substrate or lig-
and (6; 7). This theory was later updated by Daniel Koshland. He introduced an
induced-fit model, where a protein would change to adapt to bind a small molecule
(8). However, more recent evidence suggests that proteins exists in an ensemble
of structures, including ones that resemble the bound state of the protein, and upon
binding of the small molecule, the population distribution will shift to favor the bound
state (9; 10; 11; 12; 13).
Of utmost importance to researchers is how tightly a small molecule binds to a
protein. The free energy of binding is defined by, entropy (∆H) and enthalpy (∆S),
in the following relationship: ∆Gbinding = ∆Hbinding - T∆Sbinding = -RTln(KA), where
KA is the equilibrium constant of the binding between protein and ligand. The pre-
cise contribution of enthalpy and entropy into the calculation of the free energy of
binding (∆G) is dependent on the protein and small molecule under investigation.
Several factors are involved in determining both the enthalpy and the entropy in-
volved in protein-ligand binding (14; 4), but these values are inherently difficult to
calculate accurately. First, it is based on determining a small difference between two
very large numbers, the energies of the complex and the energies of the protein and
ligand alone interacting with solvent. Secondly, the entropic contributions are diffi-
cult to estimate because the conformational space available to both protein and small
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molecule is potentially large. Lastly, many different factors must be considered: van
der Waals interactions, electrostatic interactions, (de)solvation, and flexibility of both
the protein and small molecule ligand (14). Here, we aim to circumvent these limi-
tations by using our large database of protein crystal structures solved with bound
small molecules to determine what types of contacts lead to the best binding. We
will also look at the ability of different classes and families of proteins to investigate
any possible differences in their ability to bind small molecules.
1.1.1 van der Waals Interactions and Electrostatic Interactions
One of the most significant contributions to the binding affinity has been thought
to be van der Waals interactions (15). These are low-energy interactions created by
the London Dispersion forces arising from placing atoms in contact with each other.
The shape complementarity of the binding pocket to the small molecule allows for
optimal contacts, in agreement with the “lock and key” model (16). Most small
molecules bound to proteins are well buried to maximize the amount of contact being
made. Liang et al. found that binding sites are buried cavities or have one or two
small exposed areas and that binding pockets tend to be the largest pockets in the
protein (17).
On the other hand, electrostatic interactions have much stronger enthalpic contri-
butions and include hydrogen bonds, contacts to metals, and salt bridges. Hydrogen
bonds form between highly electronegative atoms (generally O or N) and a hydrogen
bound to another highly electronegative atom. These bonds generally contribute 3-7
kcal/mol to the enthalpy (18). However, the precise contribution depends upon the
geometry of the hydrogen bond (4). Hydrogen bonding interactions are also made
with water, leading to a large desolvation penalty for both the ligand and binding
site; therefore, it is believed they generally do not contribute much to the free energy
of binding, since it is the difference between the standard free energy unbound in
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water and the standard free energy of the complex (4). For example, Lafont et al.
tried to gain a greater free energy of binding by adding a functional group to an
HIV protease inhibitor to make an extra hydrogen bond between the ligand and the
protein. Although a gain in enthalpy was achieved, it was completely compensated
by entropic loss induced by both desolvation of the polar group and forcing that polar
group into a particular conformation (19). Salt bridges are made between positively
and negatively charged functional groups, and are the strongest non-covalent inter-
actions that can be made. However, the desolvation penalty of removing water from
a charged group is also quite large (20).
There has been contradictory evidence as to which types of interactions play the
most significant roles even in the strongest known natural protein-ligand complexes,
specifically in the binding of biotin to streptavidin, the tightest known natural com-
plex. In 1993, Miyamoto and Kollman used free energy perturbation calculations
on biotin-streptavidin and N-L-acetyltryptophanamide-α-chymotrypsin to show that
the increased binding affinity for the biotin-streptavidin system can be accounted
for by van der Waals contacts made in the biotin-streptavidin complex where the
pocket in streptavidin is preformed as in the traditional lock and key theory (21).
However, newer work using combined quantum mechanics/molecular mechanics and
monte carlo computational techniques on hydrogen-bonding residues in streptavidin
have indicated that networks of hydrogen bonds are responsible for the strong binding
in the biotin-streptavidin complex (22). The importance of the network of hydro-
gen bonds was also confirmed using isothermal calorimetry, which showed an 11-fold
greater contribution to the free energy of binding of two coupled residues involved in
hydrogen bonding than the contribution of each of the two residues individually (23).
A common metric to evaluate how well a small molecule binds is “ligand effi-
ciency”. This metric is defined as the binding affinity per number of non-hydrogen
atoms (24; 25; 26). It was first introduced by Kuntz et al. in 1999 (27). Kuntz ana-
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lyzed 159 complexes and scaled the affinities by the number of non-hydrogen atoms
present in a ligand as a metric of size-independent affinity. They showed that for each
non-hydrogen atom the most to be gained is ˜-1.5 kcal/mol of binding affinity (27).
This maximum was consistent with their theoretical predictions based on van der
Waals and hydrophobic interactions (27). The hydrophobic effect will be discussed
further below.
Although electrostatics have previously been proposed to have little effect on the
free energy of binding, Bruce Tidor has been working to optimize charge complemen-
tarity to improve binding free energy (28; 29; 30). He has developed an analytical
solution to the Poisson equation to model the electrostatics of a binding site, and an
analytical method of optimizing the charge profile of a ligand, taking into account
the desolvation penalty, to match the calculated electrostatics of the binding site
(28; 29; 30). His group was able to predict a position to improve the charge com-
plementarity of a small molecule bound to chorismate mutase. They suggested that
this improvement would lead to a 2-3 kcal/mol benefit to the free energy of bind-
ing (31). However, this was not confirmed experimentally. The effects of hydrogen
bonds and electrostatics have been shown to be dependent on distance, short-range
hydrogen bonds of less than 2.5 Å have been shown to lead to binding affinities of
greater than 15 kcal/mol (32; 33; 34). This contradicts the previous idea of a dimin-
ished role of electrostatics in small molecule binding. In chapter five of this thesis,
we present results based on distances of charge-charge interactions and their impact
on the efficiency with which small molecules bind.
1.1.2 Desolvation and Solvation
The binding of small molecules to proteins occurs in an aqueous environment,
so water plays a significant role in the binding. Water must be removed from the
binding site as well as the ligand (4). If water molecules are found in the binding
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site, they are generally partially occupied and are able to move in and out of the
pocket. Desolvation can be either favorable or detrimental to small-molecule binding.
Desolvating a charged functional group is unfavorable to binding (35), whereas the
“hydrophobic effect” results in desolvation being favorable to binding.
The “hydrophobic effect” was first proposed in 1945 by Frank and Evans and is
a positive influence on the free energy of binding (36). The placement of a non-polar
molecule in water is an energetically unfavorable process (37). The hydrogen-bonding
network of water becomes disrupted locally around the non-polar molecule. Therefore,
burial of non-polar groups within the protein is seen to have a positive effect as water
is able to rearrange back to its favorable interactions with itself (38). It has been
shown that reorganization of the solvent can attribute anywhere from 25 to 100%
of the enthalpy gained in small-molecule binding (39). It has also been shown that
the enthalpic contribution of the hydrophobic effect is proportional to the amount of
buried non-polar surface area (38).
1.1.3 Ligand and Protein Flexibility
The formation of van der Waals interactions and the “hydrophobic effect” have
been seen to have favorable impact on the free energy of binding, while the impact
of electrostatics is dependent on the precise protein-ligand complex. There are other
factors working against protein-ligand binding. The loss of flexibility of the small
molecule and the protein by forcing them into a particular conformation is a loss of
entropy and thus a penalty in the free energy of binding. The loss of rotation in
side chains upon small molecule binding has been estimated to be ˜0.88 kcal/mol per
residue (40; 4; 41). It is also important to note, that in some cases some protein
residues will increase in flexibility, such is the case in Topoisomerase 1 (42). Also,
NMR studies have shown that backbone flexibility can increase upon ligand binding
to the mouse urinary protein (43). Additionally, Yang et al. found that in a set
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of 63 complexes from the Protein Data Bank 29 % of the atoms in the binding site
became more flexible than the corresponding free structure, using the B-factors as a
metric of flexibility (44). While, not all structures had atoms that displayed increased
flexibility, 75 percent of the structures had at least some portion of the molecule that
had some increase in their B-factors (44). To ensure the B-factors are comparable
between systems, the structures used in the study were solved by the same group
and had resolutions less than 2.5 Å and R-values less than 0.245, with the exception
of two structures (44). A recent study by Yang et al. has noted the importance of
small molecule reorganization in the prediction of binding affinity using a wide range
of scoring functions (45). Different orientations of the small molecule binding in the
binding site is observed in the case of camphene, adamantine, and thiocamphor bound
to cytochrome P450cam (46).
1.2 Surface Area Calculations
In this thesis we utilize GoCav to calculate the surface area. GoCAv was devel-
oped along with this thesis work in order to calculate the buried surface area of a
small molecule based on its location in an x-ray crystal structure. It also can handle
binding sites that are exposed, an area in which previous methods have been unable
to calculate surface areas accurately. Other programs that have been developed for
this are POCKET(47), SURFNET(48), CAST(17), PASS (49), and NACCESS(50).
1.2.1 POCKET
POCKET was developed by Levitt and Banaszak in 1992. This program identifies
pockets by scanning a grid on the x, y, and z-axis to find where a probe of a certain
radius does not touch any protein atoms. The surfaces are then determined using
a variant of the marching cube algorithm, in which a surface cube is determined by
the surrounding cubes. The shape of the surface is determined by a set of triangles
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associated with the cubes (47). This program will find all pockets in the protein
regardless of size, but does not specifically provide the specific pocket of the desired
ligand, although it may be one of the pockets found.
1.2.2 SURFNET
SURFNET was developed by Laskowski in 1995. SURFNET generates the surface
by adding a Gaussian density function about the center of each atom. At a specific
contour level, the atomic spheres are generated and spheres are placed in between
atoms to find gap regions. The binding pockets are then considered the largest of the
gap areas. This also may not find highly exposed binding pockets, since it needs two
protein surfaces to determine the gap areas (48).
1.2.3 CAST
CAST was developed by Liang et al. in 1998. It uses Veronoi tessellations to
map out the surface of the binding site. The tessellations are formed from triangles
(tetrahedral in 3-dimensions) created by using the atoms of the protein as vertices.
Triangles that do not contain any other atoms are considered cavities. This program
also cannot find exposed binding sites as the number of triangles will go to infinity
for exposed binding pockets (17).
1.2.4 PASS
PASS was developed in 2000 by Brady et al. In this algorithm probes are placed
on the surface of the protein using triplets of protein atoms, then searches for points
where a probe sphere can lie tangential to all three atoms. Any probes that are ex-
posed to the solvent are then removed. This process is continued by placing another
layer of spheres on the surface of the spheres placed in the first iteration. The al-
gorithm ends when no probes can be removed. Clusters of four or more probes are
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kept. PASS does not calculate the surface area and will not identify exposed binding
sites, since if the probes are exposed to the surface they are automatically removed
and no more probes spheres are placed in that area (49).
1.2.5 NACCESS
NACCESS was developed by Hubbard and Thornton in 1993 (50). It calculates
the solvent accessible surface area based on Lee and Richard’s method developed in
1971 (51). This method uses intersections of atomic spheres with their van der Waals
radii to create the surface of the protein. Planes are drawn through the intersections
and the remaining convex arcs are obtained as the van der Waals surface. The solvent
accessible area is created by augmenting the atomic radii with a probe radius. This
program does not locate a binding site and merely calculates the surface area of any
atom included in the calculation (50).
1.3 Protein-Ligand Databases
Given the discussion regarding the thermodynamics of protein-ligand binding, it is
important to investigate a wide range of proteins bound to a variety of small molecules.
It is not surprising that different proteins will have different contributions to the free
energy of binding. A large database of these interactions is necessary because we
aim to make generalized statements regarding a wide range of diverse complexes.
The best source of protein structures is available from the Protein Data Bank, where
greater than 60000 structures are deposited (52; 53). It is also important to have
structural coordinates of complexes correlated to the experimental binding affinity.
Other databases of protein-ligand interactions with binding data have been created
prior to this work, namely Ligand-Protein Database (LPDB)(54), BindingDB(55)
(although it does not contain coordinates it has a large number of binding affinities
reported with links to some protein crystal structures in the PDB), Protein Ligand
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Database (PLD), and PDB Bind(56; 57). However, all have their deficiencies with
respect to combining binding affinity and atomic coordinates. The next section dis-
cusses these databases in more detail. Other databases, such as MSDsite(58) and
Relibase+(59; 60) only have protein-ligand complexes, and do not have affinities.
1.3.1 LPDB
The Ligand-Protein Database (LPDB), created in 2001, has 195 complexes with
binding data. LPDB also provides computer generated docking decoys to help re-
searchers in developing more accurate scoring functions. LPDB has been analyzed
to address redundancy of the protein structures. The 195 complexes consist of 51
unique proteins in 21 protein classes (54). LPDB was created using complexes found
in training sets of previously used scoring functions and searching for those complexes
in the Protein Data Bank (54).
1.3.2 Binding DB
Binding Database (Binding DB), also created in 2001, contains very high-quality
thermodynamic data for 722 proteins. Binding DB also accepts the deposition of Ki
data, and the number of entries has grown significantly to 62,134 binding reactions
(http://www.bindingdb.org/bind/stat.jsp) and continues to grow. Most of the data
is now inhibition constants. Binding DB’s strength lies in the volumes of information
given on experimental conditions used in determining binding information, including
raw data in some cases. Most of the ligands do not have a pdb structure, but at least
one structure of the protein bound to some ligand exists (55).
1.3.2.1 PLD
The Protein Ligand Database (PLD) by John Mitchell in 2003 is a small database
of protein-ligand complexes (61). All of the entries are annotated with calculated
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binding energy using the knowledge-based method BLEEP. 357 entries are annotated
with experimental binding data. While ligand similarity scores have been calculated,
they are not available (61).
1.3.3 PDBBind
PDBbind, created in 2004, contains binding data on 3214 complexes, with 2084
unique ligands, collected from the PDB (56; 57). PDBBind was curated in a very
similar fashion as our database, but has some key differences. PDBBind focuses
on complexes with only one ligand in the crystal structure (56; 57). PDBbind also
excludes any complex binding a simple cofactor such as ATP. Our database does not
discriminate against molecules such as ATP, since it is also a small molecule that binds
to a defined binding pocket in proteins. PDBBind has no threshold value for quality
of the electron density(the largest crystal structure resolution is 4.7 Å). PDBbind
only provides structures of complexes for which it has binding data (56; 57). To meet
our specific needs, we have created our own database, Binding MOAD (Mother of All
Databases) (62).
1.4 MDM2
The majority of the thesis will discuss the creation of Binding MOAD to answer the
questions as to what biochemical properties lead to high-affinity binding. However, we
do not take in to account system flexibility. Therefore, we present a study regarding
the highly flexible MDM2 protein and investigate the flexibility of the protein using
molecular dynamics upon binding of a small molecule. The next session discusses the
importance of MDM2 and the details of the flexible binding site.
The p53 tumor suppressor, also known as the guardian of the genome, is vital
in cell cycle regulation, DNA repair, and apoptosis (63; 64; 65). Mutations in p53
are seen in approximately half of all human cancers (66). Where p53 is in wild-type
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form, it is inhibited by over-expression(67; 68) or amplification(69) of murine double
minute 2 oncoprotein (MDM2; also referred to as HDM2 in human). Reactivation of
p53 through inhibition of the p53-MDM2 interaction has been shown to be a novel ap-
proach for initiating or enhancing cancer cell death (70; 71). A better understanding
of MDM2 dynamics is important for the design of more selective and potent inhibitors
of the MDM2-p53 interaction.
A crystal structure containing residues 25 to 109 of MDM2 and residues 17 to 29
of p53, was solved in 1999 (1YCR) (72). This showed two approximately similar sub-
domains, which come together to form a binding cleft for p53. Three side-chains of
p53 (Phe19, Trp23, and Leu26) fill the relatively deep hydrophobic pocket of MDM2.
This crystal structure has been the basis of several dynamics studies (73; 74; 75; 76),
in all cases the authors compared the MDM2-p53 complex to apo-MDM2, which was
generated by removing the peptide.
Barrett et al. utilized CONCOORD(77), a non-Newtonian method of ensemble
generation to examine protein motion in creation of their program Dynamite (73).
They found that the principle mode of apo-MDM2 was a bilobal flexing, or breathing,
of the protein; this motion was greatly reduced in the p53 bound complex. Previous
work in the Carlson lab has utilized MD simulations to develop receptor-based phar-
macophore models. The models were used to identify five small-molecule inhibitors of
the MDM2-p53 interaction (78; 76). Espinoza-Fonseca and Trujillo-Ferrara presented
two 35-ns molecular dynamics (MD) simulations; again demonstrating that the apo-
MDM2 had a highly flexible and narrow cleft (75). Whereas with p53 bound, the
cleft was more stable and wider. They also reported important side-chain motions
in residues Leu57, Tyr67, His96, and Tyr100 which were present in apo MDM2 but
not MDM2-p53, and they suggested that these motions are involved in the molecular
recognition of p53 and other ligands (75).
The deep, well-defined binding cleft shown from in the crystal structure of MDM2-
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p53, suggested that the MDM2 cleft would be a suitable target for small molecule in-
hibitors. To date, several small molecule inhibitors of the MDM2-p53 interaction have
been reported (reviewed in (79; 80; 81)). The crystal structure of MDM2 was solved
with both a member of the nutlin class (1RV1)(82) and from the 1,4,-benzodiazepine-
2,5-diones (1T4E) (83). Several other structures have been solved with a variety of
small molecules, in all, there are ten structures solved bound to a ligand.
The sequence of MDM2 residues 16-24 is highly conserved in mammals (84). NMR
studies show that these residues form a “lid” which stabilizes MDM2 in the absence
of p53 (84; 85). When the lid is closed, it shields the hydrophobic binding cleft of
MDM2. Ile19 occupies the same space as Pro27 of bound p53, and makes interactions
with His96, Arg97, and Tyr100 (85). However, the lid is easily displaced 3-4 Å to
deepen the binding cleft and then peptide or inhibitor completely binds (84; 86; 85).
In the appendix, we present work in progress to examine the role of the lid and the
flexibility of the system during ligand binding.
1.5 Conclusion
The precise biophysical characteristics that determine the affinity with which a
small molecule binds to a protein is highly variable. Many believe that the primary
interactions favorable to binding are van der Waals contacts and desolvation due
to the “hydrophobic effect”. However, electrostatics-such as hydrogen bonding and
charge complementarity-have been shown to also have a favorable impact, despite the
higher desolvation penalty and the fact that these interactions are also made with
water. Although flexibility and conformational entropy play roles in the free energy
of binding, it is very difficult to account for in calculations. Since we are using a large
database of protein-small molecule complexes from static x-ray crystal structures,
this thesis is rounded out by a molecular dynamics investigation of the highly flexible
protein MDM2.
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In the first chapter, we discuss the creation and curation of Binding MOAD
(Mother Of All Databases). The second chapter discusses the development of GoCav
for calculating surface areas and provides some general trends regarding the complexes
in Binding MOAD. The third chapter breaks down the database into families and
notes differences in the physical properties of the protein-ligand complexes, namely
enzymes versus non-enzymes, as well as tightly bound ligands versus weakly bound
ligands. The fourth chapter investigates the complexes that have the most efficient
binding, based on an affinity per atom or per buried surface area metric. The ap-
pendix provides preliminary results regarding the binding of a specific small molecule
to the human MDM2 protein, to investigate the role of flexibility on a protein-small
molecule complex.
This thesis work has far reaching implications for computational biology and theo-
retical biophysics. In several reviews of methods of structure-based drug design, each
points out the need for databases which provide structural data of protein-ligand
complexes as well as binding affinity in order to provide training sets and tests sets
for scoring functions. These reviews cite Binding MOAD and databases like it as valu-
able resources for improving docking and scoring algorithms (87; 88; 89; 90; 91; 92).
Since publishing Binding MOAD, many researchers have acknowledged the usefulness
of Binding MOAD, but have created similar databases that have additional informa-
tion regarding the ligand and/or binding site, and/or have provided binding affini-
ties for complexes which do not have structures deposited (93; 94; 95; 96; 97; 98).
These databases are publically available: AffinDB(93), sc-PDB(94), SuperSite(95),
PDBCal(96), PLID(97), and PSMDB(98). Others have also acknowledged Binding
MOAD, yet have created datasets to meet their specific research aims(99; 100; 101).
Potential uses of Binding MOAD have been suggested to be of benefit in two projects.
First, it can be used to augment the DUD dataset, which is a dataset of decoy lig-
ands (102), and as a link from the cheminformatic toolkit developed by Rosania et
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al. (103). Additionally, Binding MOAD has been noted to be unique in its inclusion
of ligands bound to heme containing proteins (104).
Binding MOAD has also had some implications in research that is ongoing in
investigations of binding sites. Park and Kim utilized the ideas of “invalid” ligands,
developed in Binding MOAD to create a dataset of ligand binding sites from the
PDB. They utilized this dataset to link structure to function by creating a network
model of similar binding sites (105). Daily and Gray also used this idea to create a
dataset in their investigation of conformational changes in allosteric proteins (106).
Binding MOAD was directly used in four studies. A subset of Binding MOAD
has been used to investigate the specificity of binding of FAD and NAD (107).
Binding MOAD was used in conjunction with AffinDB, PDBBind, and PLD to de-
velop a training set to evaluate a model for predicting the affinity of enzyme-ligand
interactions(108). Binding MOAD was also utilized to locate the binding affinites
of specific molecules used in their study of Fluorine containing compounds bound to
proteins (109), and yet another study used it to find a small chelating compound that
binds to an antibody with high-affinity (110). Lastly, the development of Binding
MOAD has helped lead to the formation of the Community Structure Activity Re-
source (CSAR) center, which is the only NIH funded center designed to gather data
to improve scoring of protein ligand complexes for structure based drug design.
The investigations of binding sites as a whole, as well as enzymes versus non-
enzymes is beginning to influence how we look at binding sites. In a recent review of
drug discovery for protein-protein interactions, our research has provided a limit to
the size of protein-ligand binding sites compared to protein-protein interfaces (111).
The study of enzyme binding sites versus non-enzyme binding sites has helped to
shape our knowledge of enzyme binding sites (112). It has also provided data that
indicates the necessity for different strategies for improving binding to enzymes and
non-enzymes, as well as data that point to non-enzymes being more “druggable”.
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This has potential to effect the choice of protein targets in the drug industry, since
they may be inclined to use a more druggable target to increase their chance of
success. Our investigation is beginning to change how the community looks at ligand
efficiencies and suggests that it cannot be applied strictly when investigating multiple
systems (113). This has potential implications in how we think about designing small
molecules for different types of proteins.
The study of the most efficient ligands implies that short electrostatic interactions
of very small molecules are responsible for the most efficient small molecules. This
may indicate the desolvation penalty of highly charged molecules is not as large as
previously thought. We also suggest that affinities better than -15 kcal/mol may be
difficult to attain because there is no evolutionary driving force to allow this selection.
When ligands have such high affinities, their bound lifetimes are on the order of days
to weeks. Many proteins degrade before these ligand are able to dissociate, and may
explain the limit of -15 - -19 kcal/mol. The fact that short electrostatic interactions
define the boundary of ligand efficiency challenges previous ideas of the biophysics
of small molecule binding, where hydrophobic and van der Waals are the dominant
interactions which lead to improved binding.
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CHAPTER II
Binding MOAD (Mother of All Databases)
2.1 Introduction
Binding datasets for protein-ligand complexes were first used in computational
chemistry to develop scoring functions for ligand docking and de novo design of en-
zyme inhibitors. The earliest relevant dataset was only 45 complexes(114) and more
recent sets are 200-800.(54; 55; 56) Some sets have been made available online, chang-
ing their nature from a flat list of data in a paper to a dynamic and searchable tool
for the scientific community. The largest and most useful datasets are outlined below.
The strengths of each are noted and the comparative strengths of Binding MOAD are
highlighted. Our aim is to make Binding MOAD the largest possible collection of high-
quality, protein-ligand complexes available from the Protein Data Bank (PDB)(115)
and augment that set with the inclusion of binding data. When initially introduced
in 2005, Binding MOAD contained 5331 protein-ligand complexes, of which bind-
ing data was collected for 1375 (26%) of the protein-ligand complexes. As the PDB
grew, we have updated the dataset three times. Currently BindingMOAD contains
13,138 structures, with binding data available for 4203 (32%) of these structures.




The Ligand-Protein Database (LPDB) has 195 complexes with binding data.(54)
LPDB also provides computer generated docking decoys to help researchers in de-
veloping more accurate scoring functions. We do not plan to add decoys to Binding
MOAD, but our dataset is an order of magnitude larger. LPDB has been analyzed
to address redundancy of the protein structures. The 195 complexes consist of 51
unique proteins in 21 protein classes.(54)
2.1.2 Binding DB
In one of the first papers announcing the Binding Database (Binding DB), it was
reported to contain very high-quality thermodynamic data for 400 binding reactions
(90 for biopolymers).(55) Binding DB has recently started to accept the deposition
of Ki data, and the number of entries has grown significantly to >60,000 binding
reactions (http://www.bindingdb.org/bind/stat.jsp). Most of the data is now inhi-
bition constants for biopolymer binding. Binding DB’s strength lies in the volumes
of information given on experimental conditions used in determining binding infor-
mation, including raw data in some cases. Though we do not provide isothermal
titration calorimetry details like Binding DB, our dataset is larger and we supply
structural data from the PDB. The complexes in Binding DB are not cross-linked to
their structural data.
2.1.3 PDBbind
PDBbind was created by Shaomeng Wang and coworkers.(56) It contains binding
data on 2665 complexes with resolution 2.5 Å (459 structures> 2.5 Å are also provided
as a secondary set). PDBbind does not address redundancy, but does note that
approximately 200 different types of proteins are present. This set was curated in
a similar fashion as Binding MOAD but focuses on complexes with only one ligand
18
in a pocket. PDBbind also excludes any complex binding a simple cofactor such as
ATP. Binding MOAD is larger because we do not ignore cofactors or protein-cofactor-
ligand complexes. We also provide information on the structures when we do not have
binding data because they are still a valuable resource in database mining. PDBbind
only provides structures of complexes for which it has binding data.
PDBbind and Binding MOAD were developed independently at the University of
Michigan, Ann Arbor. When we learned of our similar research efforts, we found that
our goals were synergistic. The research projects around PDBbind focus on devel-
oping scoring functions and searching ligand substructures. Our focus with Binding
MOAD is more on protein binding sites and protein flexibility. In sharing binding
data between our groups, we found a disagreement of only 1%, which highlights the
high accuracy and quality of binding data collected in both groups. Disagreements
were simple typos that were easily corrected by consulting the reference again. This
arrangement allows both groups to double check all of the data, basically eliminat-
ing the errors inherent in hand-processed data. This high level of quality control is
unheard of for datasets of this size.
2.1.4 Other Online, Protein-Ligand Databases Without Binding Data
Of course, various improvements are constantly being added to the PDB to provide
additional information and viewers to aid understanding protein-ligand complexes.(116;
117) However, several other online resources deserve discussion. These databases do
not present binding data for the protein-ligand complexes in the PDB, but they do
provide useful search tools, various analyses, and viewers of PDB complexes.
Relibase+ and MSDsite are similar datasets that specifically focus on protein-
ligand complexes. In 2002, Relibase+ contained 15,454 PDB entries, 50,514 individual
ligand sites, and 4530 unique ligands.(59; 60) MSDsite is the newest resource in
the MSD suite of web-based tools from the European Bioinformatics Institute.(58)
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However, the description of ligands in both datasets is unusual for our application.
We have taken great care to make extensive lists of molecules to exclude as ligands
in Binding MOAD. Metal cations like magnesium, inorganic salts such as sulfate,
and common crystal additives like polyethylene glycol are not counted as ligands in
Binding MOAD, but they are ligands in Relibase+ and MSDsite. They even count
modified amino acids in the protein chain as ligands. The strengths of Relibase+
and MSDsite are that they provide powerful search tools for mining their datasets
for interaction patterns. A benefit to the description of ligands in Relibase+ and
MSDsite is that it allows a user to investigate a protein’s interactions with a feature
like a modified residue, a structural zinc ion, or an inorganic reactive center in the
active site. These groups are simply considered to be part of the protein in Binding
MOAD because of its focus on substrates, organic cofactors, and inhibitors. Such an
investigation is not possible with Binding MOAD at this time.
PDBsum and MMDB do not focus on protein-ligand interactions, but they provide
resources that are very useful for those interests. PDBsum is an online resource from
Laskowski and Thornton(118; 119; 120) that provides analyses for all structures in
the PDB (not just protein-ligand structures). PDBsum provides chemical, enzymatic,
and genomic information about the entry, and it provides viewers to analyze protein-
ligand interactions. The viewers display secondary structure, ligand interactions, and
cavities. MMDB is Entrez’s 3D-structure database.(121) Its focus is protein data, but
several resources for comparing related sequence and structure have direct relevance
for ligand binding.
2.1.5 Redundancy in Protein-Ligand Databases
Binding databases available to-date usually do not address the issue of redun-
dancy. Many protein complexes have more than one bound structure. Many small
datasets contain several examples of HIV protease, dihydrofolate reductase, thrombin,
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trypsin, lysozyme, etc. To address this issue in Binding MOAD, we have analyzed
for redundancy and grouped proteins by 90% sequence identity. Of 13,138 complexes
in Binding MOAD, there are 4078 unique protein families when clustered at 90%
identity. In our nonredundant version of Binding MOAD, each protein family is
represented by the structure of the tightest binder. Of the 4078 complexes in the
nonredundant set, we have obtained binding data for 1176. (In cases where binding
data was not available, best resolution and other factors were used to choose repre-
sentatives of the protein families). As we mine this database for general biophysical
properties, our results for redundant and nonredundant Binding MOAD can be com-
pared to measure the influence of bias in the structures available in the PDB. Also,
inverse docking techniques, where a single ligand molecule is screened against a set
of many proteins, will require a nonredundant set of protein complexes.(122; 123)
2.2 Methods
2.2.1 Top-Down Approach
Older protein-ligand databases were originally created by reading through the
literature and compiling lists of appropriate complexes and their binding affinities.
This sort of bottom up approach relies on finding good information in a relatively
random fashion. We chose a top down approach to create Binding MOAD so that
it contained every protein-ligand complex with a 3D structure. We started with the
entire PDB,(115) removed inappropriate structures, and used the remaining struc-
tures to guide our literature searches in a systematic fashion. Since almost all protein
structures are annotated with the authors’ names and the appropriate reference, a
starting point for the literature search is straightforward.
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2.2.2 Paring Down the PDB
Perl scripts were written to determine whether each protein structure was an
appropriate entry for Binding MOAD (Figure 2.1). Our scripts originally took ad-
vantage of the STAR parsers(124) from the Research Collaboratory for Structural
Bioinformatics (RCSB) and the new mmCIF format from the uniformity project.
The mmCIF files have gone through additional checks to correct sequence and EC
errors that may exist in the legacy PDB files.(125) By using the mmCIF files, we plan
to keep abreast of the newest improvements in data from the RCSB, making our re-
source more timely, accurate, and valuable. Since the uniformity project has not been
continued, we now use the remediated PDB files, and have modified our scripts to
parse these files using the Bioperl PDB parser. Our technique is similar to that used
by Rognan and coworkers to create sc-PDB, a set of protein binding sites for inverse
docking.(123) The major difference is that we did not use a keyword search to identify
complexes. Our group and others have found that keyword searches miss complexes
that can be identified through analyzing the individual structures. Starting with
the entire PDB (22,660 structures on 8/19/2003), we eliminated theoretical models,
NMR structures, and structures with poor resolution (> 2.5 Å). Large macromolecu-
lar complexes between proteins and nucleic acids were removed. However, we wanted
to keep any metabolic enzymes that process nucleic acids, so structures with chains
of four nucleic acids or less were kept in Binding MOAD. Short chains of 10 amino
acids or less were counted as peptide ligands. Short-chain ligands were identified in
the SEQRES section of the PDB format ({ pdbx poly .seq scheme} data items in
mmCIF format). Small molecule ligands were identified in the HET and FORMUL
(in PDB format) sections ({ chem comp} in mmCIF) or in ATOM and HETATM (in
PDB format) ({ atom site} in mmCIF). Initial filtering of the database utilized the
mmCIF files from the uniformity project, however, currently we utilize the remediated
PDB files.
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Figure 2.1: Criteria to judge all PDB structures for entry into Binding MOAD. The
scripts evaluate each structure - one at a time - against all criteria, but
this step-by-step diagram is given to show the impact of each criterion.
The numbers shown are taken from the first public release of Binding
MOAD.
Covalently linked ligands were identified by calculating the minimum distance
between the protein and each ligand. Minimum distances greater than 2.4 Å were
defined as noncovalent. Values between 2.1-2.4 Å were examined visually to determine
covalency. Distances less than 2.1 Å were considered covalent unless the short contact
was to a metal ion (we considered many common catalytic metals to be part of the
protein during this analysis). All short contacts to metals were examined visually.
This was crucial in the case of zinc-containing enzymes where a zinc-ligand distance
< 2.1 Å is not necessarily a covalent bond.(126) HET groups within 2 Å of another
HET were identified as multipart ligands (unless they had partial occupancy and
were actually two ligands occupying the same space). If any group of a multipart
ligand was covalently linked to the protein, all components are identified as a covalent
modification. This was important in the case of sugar chains on glycosylated proteins.
Proteins with covalent modifications can still be part of the database if they have
another acceptable ligand. If all ligands are covalent or inappropriate (see Table 2.1),
the crystal structure is rejected.
2.2.3 Extensive Hand Curation of the Data
The literature citations for all final structures were read to confirm the validity
of the ligands and find binding data. Our preference for affinity data is K d over K i
over IC50. Table 2.1 shows the great care that was taken to ensure that entries in
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Table 2.1: Definition of Unusual HET Groups
Classification Type of HET (Examples)
111 Suspect
ligands
Sugars (glucose, galactose, fructose, xylose, sucrose, β-D-
xylopyranose, trehalose)
Small organic molecules (phenol, benzene, toluene, t-butyl alco-
hol)
Membrane components (phosphatidylethanolamine, palmitic
acid, decanoic acid)




Chemical groups (amino group, ethyl group, butyl group,
methoxy, methyl amine)
Inorganic centers of transition state or product mimics (aluminum
fluorides, beryllium fluorides, boronic acids)
Modifications to amino acids (oxygens of oxidized CYS, phos-
phate group on TYR)
511 Rejected
ligands
Unknown or dummy groups (UNK, DUM, unknown nucleic acid,
fragment of)
Salts and buffers (Na+, K+, CI−, PO−34 , CHAPS, TRIS, tetram-
ethyl ammonium ion)
Solvents (DMSO, hexane, acetone, hydrogen peroxide)
Crystal additives and detergents (polyethylene glycol,
oxtoxynol-10, dodecyl sulfate, methyl paraben, 2,3 propanediol, pen-
taethylene glycol, cibacron blue)
Metal complexes that associate to the protein surface and are used
for phase resolution (terpyridine platinum, bis bipyridine imidazole
osmium)
Metal ions that are part of the protein (Mg+2, Zn+2, Mn+2, Fe+2,
Fe+3)
Catalytic centers that are part of the protein (4Fe-4S cluster, Ni-
Fe active center)
Heme groups (heme D, bateriochlorophyll, cobatamin, protopor-
phyrin IX)
For brevity, not all compounds are listed.
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Binding MOAD contain only appropriate protein-ligand structures. Short protein-
ligand distances and suspect ligands were flagged for visual inspection in a more
careful hand-check stage. Suspect ligands are crystal additives that are valid only
in some cases. Partial ligands are molecules that cannot be a ligand on their own
but are often a component of multipart ligands. Any HET with 3 heavy atoms
is automatically part of this list. The covalency check identifies if these HET are
modifications to the protein or a ligand.
The reason for our choice to reject or suspect various HETs in Table 2.1 is obvious
in many cases. The reader may notice that β-D-N-acetylglucosamine (GlcNac, NAG
in the PDB) is not on the suspect lists. We found that GlcNac was never used as a
crystal additive. It was either part of a ligand or a covalent modification that was
readily identified by our scripts.
Modifications to amino acids are on the partial ligand list because they can be
part of the protein or part of a peptide ligand. Complexes containing heme groups
were rejected because the covalent association of ligands to the central metals made
it difficult for us to properly identify the true ligands. In many cases, it was a small
molecule (oxygen, carbon dioxide). Of course, this neglects P450s which are very
important in medicinal chemistry, toxicology, and pharmacology.(127) We plan to
add P450s to Binding MOAD in the future to make it more useful.
2.2.4 Grouping the Proteins to Address Redundancy in the Data
It is desirable to group proteins by related structure and function so that users can
compare related systems. Enzyme classification (EC) numbers are used to broadly
group entries into classes with similar chemical functionality. Within these classes,
proteins are grouped into homologous protein families based on sequence.
The EC numbers and protein sequences are pulled from the mmCIF files of all ap-
propriate structures. To compare the sequences in Binding MOAD, we use BLASTp
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v2.2.7.(128) Defaults are used (E = 10, BLOSOM62 matrix, gap cost = 11, gap
extend cost = 1). To create protein families, we use a cutoff of 90% sequence iden-
tity like HOMSTRAD,(129) but our grouping of proteins is slightly different than
the clustering used for grouping similar sequences at the PDB.(130) The routine is
presented in Figure 2.2:
Figure 2.2: Currently, 4078 protein families exist over all EC classes. Our routine
for grouping proteins by EC number and 90% sequence identity is shown
schematically below. The dashed arrows represent a protein with two EC
numbers being added to two EC classes. The bold arrows show how a
protein with no EC number is added to an EC class by sequence identity.
The bold arrows represent a protein that is nearly identical to the dashed
protein, so it is added to the same two classes. The gray arrow notes that
the homologous protein families are compared in the end, and entries
found multiple in families are corrected.
1. Use BLASTp to compare each protein chain of each entry to all other chains.
2. All protein sequences are initially grouped into classes by the EC numbers. If
a protein has more than one EC number, it is a member of more than one EC
class (dashed arrows in Figure 2.2).
3. Structures that do not have an EC number are checked against the existing
EC classes. If the sequence is 90% identical to any protein in an EC class, the
sequence is added to that class. These entries can be added to more than one
class (see bold arrows in Figure 2.2).
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4. Any structures that do not have matches in the EC classes are initially grouped
into a nonenzyme class. The nonenzyme class can contain enzymes that lack
EC numbers or proteins that bind ligands but do not catalyze a reaction.
5. Homologous protein families in each EC class are created using the comparison
matrix generated from step 1. At this stage, two entries (A and B in a class)
are grouped together into a homologous family if one of the sequences in A is
90% identical to one of the sequences in B. With 90% sequence identity being
so strict for clustering, we always found that any additional chains in entries A
and B were also 90% sequence identical.
6. In some cases, every entry in an EC class may be at least 90% identical to all
other entries. In those cases, the entire EC class is grouped into one homologous
protein family. In the nonenzyme class, there are many, different homologous
protein families because of the greater structural diversity.
7. At this point, the homologous families within all EC classes are compared to
identify any potential errors.
(a) For proteins with more than one EC number, we find nearly identical
protein families in more than one EC class. Only one of the families is
retained and placed in the most appropriate EC class.
(b) If an error was made in the EC number of an entry, it will initially be
placed into the wrong EC class, but it will have little similarity to the
other entries in that class. The misplaced entry will have high similarity
to the entries in another protein family in the correct EC class (e.g., HIV
protease was given many different EC numbers for historical reasons, but
the entries must be grouped together). The incorrectly labeled entry is
moved to the proper class/family. At this time, a missing or incorrect
EC number in Binding MOAD can only be corrected if the entry can be
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identified by its similarity to a homologous protein family in the proper
EC class.
8. The best entry in a protein family is the structure with the tightest binder.
In cases where a family has no entry with binding data, complexes of ligand-
protein or ligand-cofactor-protein are chosen over protein-cofactor complexes.
The priority for choosing a representative of the protein family is:
(a) Tightest binder (when binding data available)
(b) Best resolution (complexes with ligands preferred over complexes with just
cofactors)
(c) Wild-type over structures with site mutations
(d) Most recent deposition date
(e) When all criteria are the same, the representative is chosen based on com-
ments in the crystallography paper.
2.2.5 Annual Updates
We conduct updates annually to incorporate more structures into Binding MOAD
as they become available in the PDB. Our 2004 update began in August. The update
procedure is:
1. Use the PDB’s list of obsolete entries to identify any existing structures in
Binding MOAD that should be removed.
2. Download a new set of mmCIF files. The previous version will be compared
to identify all new structures that have been added to the PDB since the last
version of Binding MOAD was created.
3. Identify good protein-ligand complexes in the new structures using our current
scripts.
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4. Any new HETs must be classified as suitable ligands or added to the suspect,
partial, or reject lists.
5. The literature portion of the updates should be faster because the number
of complexes will be significantly smaller than the existing set and almost all
references will be available as online PDF files.
6. Sequences will be added to existing classes and protein families, but regrouping
all sequences from scratch may be necessary to periodically confirm our protein
classes and families.
7. Each new structure will be compared with the leader of its homologous protein
family to determine if the new structure is a better representative of the family.
2.3 Results and Discussion
The creation of Binding MOAD has been the compilation of many years of work
and has had several people assist with the project. I am directly responsible for
writing the perl program used to filter the Protein Data Bank. The description of
the filtering of the PDB and the generation of the data in binding MOAD has been
placed in Appendix C. I was also responsible for intitiating the use of the list of
ligands that are to be considered “suspect” ligands and to be investigated by hand.
Upon going through each ‘HET’ group by hand to determine whether it is a valid
or suspect ligand, another class of ligands was determined, the “partial” ligand list
from Table 2.1. I was also involved with the decision of how to handle metals when
determining whether a ligand was covalent.
The undertaking to go through the thousands of literature citations to pull out
binding affinity values was shared among several people, with the majority falling
on my shoulders. In the first two updates, the papers were viewed in ’.pdf’ format
in Adobe Acrobat Reader. In order to make the process more manageable, I used
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keywords to search the paper, such as ‘ki’, ‘kd’, ‘ka’, ‘ic50’, ‘affinity’, ‘bind(ing)’,
‘constant’, ‘association’, ‘dissociation’, ‘inhibitor’, and ‘inhibition’. These keywords
as well as other combinations were also used to build a dictionary of terms that was
used in BUDA, which is discussed further later in the chapter.
After determining the complete set of Binding MOAD, the entries were grouped
by family, with enzymes annotated with the EC number. I used several common key-
words for entries that were not provided EC numbers to sort them into the categories
listed in Table 2.2.
After examining the PDB contents in our latest updated, January 1st, 2009 (55,072
entries), a total of 13,138 valid protein-ligand complexes was obtained. Table 2.2
provides detailed information about the functional roles of the proteins contained in
Binding MOAD. Our distribution of structures is a little different than that of sc-
PDB(123) due to slightly different selection criteria. Three-fourths of the proteins
are enzymes, with hydrolases and transferases having the most representatives.
Binding MOAD contains 6213 unique, valid ligands within the 13,138 complexes.
Cofactors, inhibitors, and substrates are all considered ligands in Binding MOAD.
Figure 2.3 provides the distribution of valid ligands by size. The ligands range from
4-176 heavy atoms. The average molecular weight of the ligands in Binding MOAD
is 455 g/mol; an example of the average ligand is ATP which has molecular weight
of 507 g/mol. Figure 2.3 shows that the number of significantly larger ligands drops
off quickly. The largest ligands are peptide, nucleic acid, and sugar chains.
2.3.1 Clustering Binding MOAD into Homologous Protein Families
The protein sequences of the entries in Binding MOAD were grouped into homol-
ogous protein families. When the set is clustered at 100% sequence identity, 7247
unique protein sequences were identified. As one would expect when the criterion
for sequence identity is relaxed, fewer protein families are found and the size of the
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Table 2.2: Functional classification of current entries in Binding MOAD
Proteins identified with EC numbersa Entriesb
1.-.-.- (OXIDOREDUCTASE) 2168 (16.5%)
2.-.-.- (TRANSFERASE) 2927 (22.3%)
3.-.-.- (HYDROLASE) 3641 (27.7%)
4.-.-.- (LYASE) 723 (5.5%)
5.-.-.- (ISOMERASE) 463 (3.5%)
6.-.-.- (LIGASE) 331 (2.5%)
Total enzymes 10253 (78.0%)
Proteins without EC numbers Entries
Binding (lectin, streptavidin, agglutinins, etc.) 593 (4.5%)
Signalling, cell cycle, apoptosis 450 (3.4%)
Folding (chaperones, etc.) 67 (0.5%)
Immune (antibodies, immunoglobulins, cytokines, etc.) 294 (2.2%)
Mobility/structural (actin, myosin, etc.) 94 (0.7%)
Toxin/Viral 87 (0.7%)
Transcription, translation, replication proteins 320 (2.4%)
Transport (amino acid transporters, electron transport, etc.) 414 (3.2%)
Enzymes without EC numbers (eg., isopenicillin N synthase) 83 (0.6%)
Other 483 (3.7%)
Total proteins without EC numbers 2885 (22.0%)
aEnzyme counts include entries without EC numbers that could be identified through keywords
or enzyme names. Some were also identified by 90% sequence identity to entries with EC numbers.
bNumber of entries and their percentage of all 11,368 entries in Binding MOAD
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Figure 2.3: Distribution of the current 6213 unique ligands by molecular weight. The
average ligand in Binding MOAD is 455 g/mol. The largest are small
chains of sugars, amino acids, and nucleic acids.
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protein families increases (Table 2.3). Clustering at 90% sequence identity (our pref-
erence) produces 4078 homologous protein families with the largest family containing
278 complexes. The largest families are for systems that have been well studied
for molecular recognition between proteins and ligands (e.g., trypsin, thrombin, HIV
protease, lysozyme, dihydrofolate reductase, etc.). In Figure 2.4, a histogram of the
homologous protein families shows that most of the families have only a few entries.
This reflects the emphasis in structural biology to identify new structures and folds,
rather than solve many structures of the same protein. Generally, families contain
multiple complexes when mutagenesis studies have been performed or various ligands
have been co-crystallized.
Table 2.3: Characteristics of Binding MOAD When Grouped Into Families by Se-
quence Identity
Clustering Criterion Number of homologous Size of the largest family
protein families (second largest family is also noted)
100% Sequence identity 7247 124 complexes1 (52)2
90% Sequence identity 4078 278 complexes3 (165)1
75% Sequence identity 3823 272 complexes3 (182)1




2.3.2 Nonredundant Binding MOAD
To create a nonredundant version of the dataset, we had to choose unique repre-
sentatives for each protein family. As outlined in the Methods, we made every effort
to identify the tightest binder to represent each family. For the dataset clustered at
90% sequence identity, 2107 of the 4078 families contained only one complex, and
so the choice for the representative was obvious. The remaining families contained
multiple complexes. In the 2008 update of Binding MOAD, for 724 of the families,
the representative was easily identified by binding data. Resolution was the deciding
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Figure 2.4: Histogram of the homologous protein families shows that most families
have only a few complexes. There is a near-exponential decrease in the
number of larger and larger families. This trend is basically the same for
clustering at 100% sequence identity (blue), 90% (red), 75% (yellow), and
50% (gray).
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factor for 335 of the families (either because there was no binding data or the binding
affinity was the same for more than one ligand). Of the remaining families, 46 were
chosen based on complexes with ligands being preferred to complexes with only cofac-
tors, 13 were chosen by wild-type over mutated protein, 24 by most recent deposition
date, and 48 by other criteria (R factor, comments about ligands in the paper, etc.).
In the current version, the new structures were checked against the previous leader
to determine the leader.
The nonredundant version of Binding MOAD contains 4078 unique proteins. After
choosing the complexes for the nonredundant set as outlined above, this set contains
binding data for 1176 of the unique structures.
2.3.3 Binding-Affinity Data
The binding-affinity data contained within Binding MOAD ranges 13 orders of
magnitude, from low fM to high mM values (see Figure 2.5). The dataset contains
mostly K d and Ki values. There are 1167 entries have IC50 data, ranging 21 pM -
125 mM. For the 1365 entries with K d data, values range 77 fM - 900 mM. The 1671
entries with K i data have the largest range of binding affinity, 11 fM - 400 mM.
One of our primary goals is to obtain binding data for all entries in the full set of
Binding MOAD (all 13,138 complexes). At this time, only 4203 complexes (30%) in
Binding MOAD are augmented with binding data. Though this is much larger than
other datasets with a few hundred binding affinities,(54; 55; 114) we were disappointed
to find that so few of the structure papers notes binding-affinity data. A survey of
the literature by Wang and coworkers found a similar rate of binding data included
in the crystallography papers.(56)
Of course, some of our complexes inherently lack binding data; protein-cofactor
structures do not have K d, K i, or IC50 data for us to report. K M is the more
appropriate binding data for most cofactor-protein complexes, and we have started to
35
collect that information for our complexes. Protein-cofactor structures should be part
of the dataset because they can be very important in studying molecular recognition
and drug design. For example, patterns in ATP recognition can be extracted from
ATP-binding domains to explain enzymatic regulation or develop inhibitors.(131; 132)
Figure 2.5: The distribution of binding-affinity data within Binding MOAD. Data is
available as K d (red), K i (blue), or IC50 (yellow). For this histogram,
binding data were converted to free energies by -RT ln (data). Though
not strictly appropriate for many K i or IC50, this simply provides a com-
parison for the reader.
2.3.4 Database Growth and Updates
As mentioned above, we are committed to the growth and quality of Binding
MOAD. Since its introduction in 2004, Binding MOAD has regularly expanded its
collection with new data. Originally with 5331 crystal structures of protein-ligand
complexes, it has increased by almost 1500 each year, growing to 6638 in 2005 and
then 8250 in 2006, reaching 9836 entries in 2007, 11,368 in 2008, and 13,138 with the
latest update. This steady growth mirrors the growth of the PDB (Binding MOAD
contains approximately one-fourth of the PDB). The primary literature for each crys-
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tal structure is read in order to verify the ligand and to extract any affinity data
for the ligand. Thus, adding new data to Binding MOAD involves reading tremen-
dous number of journal articles for manual annotation and validation of appropriate
ligands.
To facilitate the literature-checking process, a natural language processing (NLP)
based workflow tool called Binding Unstructured Data Analysis (BUDA) has been
developed. The NLP portion of BUDA is built upon the General Architecture for
Text Engineering (GATE) framework(133). It identifies key sentences and phrases
in papers and uses a weighted scoring algorithm to rank the likelihood that the key
sentences and phrases contain binding data. The workflow portion of BUDA is used to
interact with the researcher to organize the data for the annotation process. From the
workflow interface, the curators can sort the articles by their weighted scores, review
the annotated texts and highlighted sentences, and update the data into Binding
MOAD.
2.3.4.1 Platform
Binding MOAD is built on proven technologies. The Binding MOAD database is
based on the Java 2 Platform, Enterprise Edition (J2EE), using an open-source JBoss
Application Server, Enterprise JavaBeans (EJB), and a MySQL database backend.
These tools provide a standards-compliant, easy-to-use website that unifies the pre-
sentation of structural, chemical, and binding data in one simple format.
2.3.4.2 Improving User Experience
Having a flexible infrastructure, allows for changes in the web-site presentation.
Efforts are made to make the data as easily accessible as possible. We have removed
the need for users to login, and data is now freely accessible to private companies, non-
profits, and foreign institutions. Additional features have been added. A screenshot
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of the modified layout for a datapage in Binding MOAD is shown in Figure 2.6.
Figure 2.6: Screenshot of the data page for 3ERK, showing the additional ligand data
and the connectivity to proteins with similar structure and function.
2.3.4.3 Viewer
A new 3D protein viewer, EolasViewer, is available to view the ligand in the
protein pocket. The new viewer is built using the Eolus platform from Metamatics
and it replaces the previously used GoCavViewer. A screenshot of the viewer is shown
in Figure 2.7 The new viewer is still capable of selecting and viewing the ligand pocket
using both ball-stick and surface representations. EolasViewer incorporates significant
improvements in the areas of performance, visual quality, and back-end flexibility for
future application development efforts.
By taking advantage of rendering algorithms and OpenGL Shader Language (GLSL),
Eolus provides the new viewer with new representation styles. The surface represen-
tation has been expanded to a fully transparent polygon surface. The proteins are
rendered as ribbons by default, and the entire protein (instead of only the ligand
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pocket atoms) can now be rendered either as ribbon or ball-stick. Finally, many ad-
vanced features are planned for future versions of this tool. Eolus is a platform for
structual biology being developed in conjunction with this and other tools.
Like its predecessor, the new Eolus-based viewer is built using a Java framework
and we are deploying it as a WebStart application. Eolus uses Jogl (Java Bindings for
OpenGL) to fully utilize the 3d acceleration features available in nearly all modern
computers. These two technologies, Java WebStart and OpenGL, provide nearly
hands-free deployment of the software, together with state-of-the-art performance
and visual quality.
Figure 2.7: EolasViewer for 3ERK. The SB4 ligand is shown in ball in stick inside the
pocket. The surfaces shown are the ligand surface in blue, the binding
site in red and the solvent-exposed regions of the binding site are in green.
(Top) The protein backbone is shown as a gray ribbon, and in the close-up
(Bottom), the backbone is colored by B-factors.
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2.4 Conclusion
As stated above, we have developed and continue to expand Binding MOAD, in
the future we wish to contain more binding-affinity data (including the addition of
K M for cofactors). We have also committed to annual updates of the dataset to keep
pace with the growth in the PDB. Binding MOAD has over eleven thousand, hand-
curated, protein-crystal structures that contain biologically relevant ligands. Binding
affinity data is available for almost one-third of the entries. Part of the value of
Binding MOAD is in its careful curating and in its size and wealth of data. This
has been only achievable because of the efforts invested to maintain the continual
growth. Binding MOAD has plans for even greater improvement. We are planning
to add similarity-based searches for the ligands. Furthermore, while we have been
able to use text-mining tools to speed up our annotation process, we are looking to
make these tools available online to allow users to mine text for additional types of
data. We are now using NLP to aid in our searching. Such NLP based text mining
approaches can be readily applied to other bioinformatic projects. This technology
can be used to extract a wide variety of data - not just binding information - from
the huge body of literature available today. NLP is proving to be a valuable tool in
aiding the curation of Binding MOAD. It has significantly sped up the process of the
annual updates of adding data.
We have made the dataset available online at http://www.BindingMOAD.org.
This web-accessible resource makes our information freely available to other research
groups at non-profit organizations (annual licenses are available to the private sec-
tor). Data from our perl scripts and our hand curation include PDB id, EC class,
homologous protein family, binding-affinity data, and classification of each ligand in
the entry (valid versus invalid). The datapage for each complex in Binding MOAD
provides this information to the user. Our scripts also note the reason any PDB
structure was excluded (resolution > 2.5 Å, no appropriate ligand, etc.). If a user
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tries to access a PDB entry that is not part of Binding MOAD, a datapage provides
the reason for its exclusion from the dataset.
We are choosing to make the structures available as biological units rather than
PDB files. The biological units provide the proper multimer for biological activity.
For instance, only the proper dimer is provided when multiple dimers occupy a unit
cell, or the proper tetramer is provided from symmetry operations of a unit cell
containing only the monomer. This will provide users with the structures that are
most related to biological activity and therefore the most appropriate for study.
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CHAPTER III
Exploring Protein-Ligand Recognition with
Binding MOAD
3.1 Introduction
A growing trend in computational biology is the development of large datasets
to provide the scientific community with various information on protein-ligand struc-
tures. Of course, the definitive online resource for structural data of these complexes
is the Protein Data Bank (PDB) (53). It is constantly being improved through the
addition of online tools and links to complementary datasets (134). Most recently,
Ligand Depot was created by the curators of the PDB to facilitate searching the HET
groups via chemical substructures and text-based searches (117). There are many
other examples of databases and websites that analyze and augment protein-ligand
complexes from the PDB. The following discussion is by no means an exhaustive
listing of such derivatives of the PDB.
Our own contribution in this area is Binding MOAD (Mother of All Databases)
(62). Our goal for Binding MOAD is to create the largest resource of high-quality
protein-ligand complexes and augment those structures with binding affinity data
and online analytical tools. We took a top-down approach to create Binding MOAD.
Starting with the entire PDB, we selected only crystal structures of high resolution
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(= 2.5). We ensured that Binding MOAD contained only appropriate protein-ligand
structures through extensive hand curation. Structures were required to contain at
least one valid, non-covalently bound ligand. Chains of 4 nucleic acids or less and
10 amino acids or less were treated as ligands. In our original creation of the 2003
version of Binding MOAD, we eliminated any structure with a heme group because of
the difficulty in distinguishing non-covalently bound ligands. With the August 2004
update, all heme-containing proteins have been examined by hand and appropriate
structures are now part of Binding MOAD. The 2004 version of Binding MOAD
contains 6821 complexes. We read over 6000 crystallography papers to confirm the
validity of the protein-ligand complexes and to gather binding affinity data. As a
result of this process, we have binding data for 1793 (27%) of the complexes. The
2008 version now contains 13,138 complexes with binding affinity for 4203 (32%).
We wanted to mine Binding MOAD to provide general patterns of molecular
recognition to the scientific community. How exposed binding sites are across all
protein-ligand complexes? To answer this, we needed a resource that could properly
treat any binding site – regardless of size, shape, degree of solvent exposure, the
inclusion of bridging water molecules, or the occurrence of side chains with multiple
resolved orientations (partial atom occupancy). For this, we have developed GoCAV
and the GoCAVviewer to calculate and display molecular surfaces for the ligands and
for the protein cavities.
A number of online tools are already available to view atomic coordinates, sec-
ondary structure, and cavities. We are not presenting GoCAV as a breakthrough to
supercede these programs. We simply feel that GoCAV and the GoCAVviewer are
complementary alternatives to these other excellent resources, and by incorporating
the viewer into our website (www.BindingMOAD.org), we have a means to share the
data from this study with the scientific community. The discussion below highlights
some of the most useful online resources created by other research groups for an-
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alyzing and viewing protein-ligand complexes. Generally, these databases describe
a ligand as any molecule that is not one of the common 20 amino acids or 8 com-
mon nucleic acids. They make no distinction between valid and invalid ligands like
crystallographic additives or covalent modifications to the protein.
PDBsum is the most comprehensive resource. It provides data on the entire
collection of structures from the PDB (120; 135; 118; 119). Chemical, enzymatic,
and genomic information is available for all PDB structures, even if they are not
proteins and even if they do not contain ligands. One of the most powerful features
of PDBsum for understanding the molecular recognition of ligands is its analysis of
macromolecule-ligand interactions. The information is provided via 2D pictures and
several 3D viewers. Most relevant to this work is the fact that PDBsum provides
analysis of potential cavities using an updated version of SURFNET (48).
CASTp is an online database that uses rigorous analytical techniques to analyze
all proteins in the PDB for interior cavity voids and surface pockets (136). Using
the program CAST (17), it calculates the volumes and surface areas of the sites,
and it also determines the size of the openings in solvent-exposed pockets. It is not
limited to proteins with bound ligands, so it has the benefit of identifying previously
unknown binding sites, but it also identifies many small surface pockets that do not
bind ligands. The online viewer displays the residues that make up the cavities and
pockets, but it does not show the bound ligands. This makes it difficult to understand
the molecular recognition that controls binding in that site.
MSDsite (58) provides information on ligand interactions with any macromolecule,
not just proteins. MSDsite provides various analyses of the macromolecular environ-
ment surrounding ligands. The dataset can be mined by matching patterns based
on the ligand or on the binding-site environment. PDB-Ligand (137) is a new re-
source that is very similar to MSDsite, but strictly focuses on analyses of protein
residues and nucleic acids within 6.5 Å of a HET group. Relibase (59; 138) is a
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resource that specifically focuses on the protein-ligand complexes in the PDB. It al-
lows for text-based and sequence-based searching of the PDB. SMILES strings can
be used to search ligand substructures. It also provides graphics tools to examine the
structures. Relibase+ (60) is a newer version that allows for additional 2D and 3D
similarity searches. NCBI’s Entrez resource for 3D structures is the Molecular Model-
ing DataBase (MMDB) (121). MMDB is based on pregenerated relationships, found
by comparing each PDB entry with various structure and sequence databases. Their
viewer can be used to compare any individual PDB entry to its structural homologs.
This reveals their similar tertiary structure and can be used to examine common
binding motifs of bound ligands. So though the focus of MMDB is the comparison of
folds and domains, it can provide valuable information on protein-ligand recognition.
Each of the four online databases mentioned above has very useful features, but as
mentioned above, they make no distinction of which HET groups are proper ligands.
Two additional datasets, PDBbind and sc-PDB, are similar to Binding MOAD
and also focus on valid ligands. These databases do not provide viewers to exam-
ine protein-ligand complementarity, but the atomic coordinates of the proteins and
ligands are available for download and can be examined offline. PDBbind is a large
set of protein-ligand complexes from the PDB, focusing on binary structures with a
single ligand in a protein binding site (56). PDBbind also provides binding affinity
data obtained from reading the crystallography papers. As of its latest update in
January 2004, it contains binding data on 1622 complexes (a subset of 900 complexes
makes up the “refined” set) (57). PDBbind provides graphical interfaces, similar to
those used with Ligand Depot, to view the ligands and perform substructure searches
to find related systems. The other database, sc-PDB (123), was created in a fashion
similar to Binding MOAD and PDBbind, but it does not provide binding data. The
set of structures is used for “inverse screening,” a procedure where a ligand is docked
to a series of binding sites to determine its appropriate target. sc-PDB is a set of
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5634 protein binding sites and 7109 ligands at the time of writing this paper [personal
communication, Esther Kellenberger, Universit Louis Pasteur, placeCityStrasbourg].
The online interface to the dataset allows for text-based searches of much of the in-
formation within the PDB files (PDB ID, HET group name, authors, EC numbers,
deposition date, resolution, etc.). The data can also be accessed by information based
on other resources like Swiss-Prot (139) data and NCBI taxonomy notation (140).
3.2 Methods
Rather than simple PDB files, “corrected biounit files” were used for all protein-
ligand complexes. Biounit files are available from the PDB, and they represent the
appropriate multimer for biological activity. For instance, if only a monomer appears
in the unit cell, but a trimer is the appropriate biounit, the other two monomers
are generated through symmetry operations. We found that HET groups and water
molecules frequently were not properly treated in the PDB’s biounit files. They
were not propagated where necessary, and they were not removed in cases where
their corresponding protein was deleted from the unit cell. We corrected all biounit
files by propagating the water and ligands as necessary using the program PyMOL
(141). We also removed any molecules that were more than 10 Å away from the
protein. Covalent links were checked to avoid truncating sugar chains and other post-
transcriptional modifications that were longer than 10 Å. These corrected biounit files
are the structures that are available for download on the Binding MOAD website.
It is straightforward to calculate the surface of an enclosed binding site (142; 143),
but many interesting ligands are bound in open clefts. Molecular surface area (MSA)
is calculated by ”rolling a solvent probe” on the van der Waals (vdw) surface of the
atoms. With an exposed binding site, the probe escapes and maps out the entire
protein surface. Ho and Marshall suggested that some cutoff distance to the ligand
might be a reasonable way to determine the boundary of an open site (144). We were
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not able to find code to do this, so we wrote GoCAV to accomplish the task and
provide a consistent treatment for any type of binding site in Binding MOAD.
GoCAV, uses an “enlarged ligand surface” (ELS) to create a boundary for the
binding site (Figure 3.1). It calculates MSAs using a grid-based method. Voronoi
tessellations are more accurate than grids for enclosed sites (145; 146; 143), but
the method does not work as well on surfaces (147; 148). We use a very fine, 0.2-
Å grid (0.008 Å3 cubes) to minimize the errors as much as possible. Codes have
been developed by other groups that calculate surfaces and cavities (for example,
POCKET (47), SURFNET (48), CAST (17), PASS (49), and an unnamed grid-
based technique by Schneider and coworkers (149)). Many of these have the benefit
of finding pockets without needing bound ligands to guide them, which means they
can identify new binding sites (a definite advantage over GoCAV). However, in the
process of analyzing/identifying all possible cavities, some of these codes produce
pockets that are not true binding sites. Some have poorly defined boundaries that do
not encapsulate all of a bound ligand. Some do not identify all types of pockets, and
others tend to create large networks of interconnected cavity spaces over the surface of
the protein. For our purposes with Binding MOAD, we needed a code which focuses
on defining a cavity within the local vicinity of a bound ligand.
To create the ELS, we extended the ligand’s vdw radii by 2.8 Å (the equivalent of
one layer of water as the exterior boundary for an open binding site). We wanted to
define a boundary for open binding sites, but not hinder the calculation of enclosed
binding sites that incorporate bridging water molecules. To verify our description
of the ELS, we examined several binding sites with bridging water molecules (see
Figure 3.2). Appropriate boundaries of these binding sites were identified with the
ELS radius of 2.8 Å. The MSA for ligands are straightforward to calculate and were
also part of the GoCAV output.
The overwhelming majority of Binding MOAD’s structures do not contain hydro-
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Figure 3.1: Determining the boundary of an open cavity using ELS. (Left) A ligand
molecule (black) is bound in an open protein cleft (gray). The dashed
line is the ELS, determined by adding 2.8 Å to the radii. A probe rolls
over the vdw surfaces of the protein atoms and the inward-facing surface
of the ELS. The resulting surface of the cavity is shown as a bold, black
line. The solvent-exposed portion of the cavity surface is defined as the
section of bold, black line that is defined only by the ELS in the opening
of the binding site.
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Figure 3.2: The use of an ELS does not create inappropriate boundaries for open or
closed cavities that contain bridging water molecules. Examples are given
for completely buried cavities (1ECM and 1KDK) and solvent-exposed
pockets (1AZ8 and 1GFY). (left) Binding site and ligand surfaces cal-
culated with GoCAV, employing an ELS cutoff. (right) The resulting
surfaces when the noted bridging water molecules within the cavity are
included in the calculation as additional protein atoms. The ligand sur-
face is blue, and the binding site surface is red and gray. The red regions
are buried, and the gray region denotes the solvent-exposed or ELS sur-
face of the cavity. Protein atoms are not shown for clarity. This figure
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gen atoms, so we needed to use united-atom radii in our analyses. Our chosen radii
were based on averaged OPLS united-atom vdw parameters: C=1.925 Å, N=1.655
Å, O=1.52 Å, S=1.81 Å, P=1.87 Å (150). (We estimated radii for other less-typical
atoms as 2.0 Å.) OPLS parameters were carefully developed to reproduce thermody-
namic properties in condensed phases. We are confident in the choice of OPLS radii
because of their good agreement with Li and Nussinov’s radii set which was deter-
mined in an entirely different fashion (151). Li and Nussinov derived radii through
contact distance distributions in a set of 1405 protein crystal structures (C=1.92 Å,
N=1.66 Å, O=1.51 Å, S= 1.92 Å). Though we do not present the data here, a user
can use a second set of radii in GoCAV. We made the Fleming and Richards’ radii
(147) (C=1.9 Å, N=1.5 Å, O =1.4 Å, S=1.85 Å) an available option because they
are well established and many groups support smaller radii. Gerstein and coworkers
determined similar, smaller radii using contact distance distributions from crystal
structures of small organic molecules (C=1.88 Å, N=1.64 Å, O=1.44 Å, S= 1.77 Å)
(152).
Invalid ligands are not included in the calculations unless they are a covalent mod-
ification of the protein or a structural element like a catalytic/structural zinc ion or a
heme (these are treated as additional protein atoms). When mining a large dataset,
the code must properly treat unusual cases. GoCAV was created with several “filters”
to analyze structures before performing the surface calculations. With these filters,
GoCAV was able to properly process >98% of the structures in Binding MOAD. In
the case of ligands with warnings (too many or too few atoms), those complexes were
not included in this study (even when GoCAV was able to calculate their surfaces).
Unusual protein-ligand complexes include the following situations: 1) Side chains
within a binding site can be solved in multiple orientations (as denoted by partial oc-
cupancy). In these cases, GoCAV automatically calculates the surfaces twice, with the
side chain in either orientation. Appropriate combinations are generated if more than
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one side chain in the binding site requires this treatment. All solutions are presented
in our analysis, providing averaged data points with error bars for those complexes.
2) Some sugar-binding proteins actually contain both enantiomers of the sugar in
the binding site, superimposed with 50%-50% occupancy. Again, GoCAV recognizes
the two solutions inherent in the structure and does two independent calculations,
each with a single enantiomer. Both ligands are presented independently in our plots
and histograms (no error bars because they are not the same ligand). 3) When two
separate ligands are accommodated in a large binding site (such as a cofactor and
an inhibitor bound in close proximity), GoCAV actually does three calculations: a)
both ligands are treated as one large molecule, b) the first ligand is treated as part
of the protein while the surfaces around the second ligand are calculated, and c) the
second ligand is part of the protein while the first ligand is calculated independently.
The later two calculations, where each ligand is treated independently, are the values
included in the plots and histograms in this study.
To verify that the patterns calculated with GoCAV are appropriate and compa-
rable to other standard techniques, we have also calculated the solvent accessible
surface area (SASA) of the ligands with the program NACCESS (50). (SASA of the
ligand should be roughly comparable to the MSA of the cavity.) NACCESS is based
on Lee and Richard’s analytical method (51) as opposed to our grid-based approach.
It uses radii based on Chothia’s (153) but with more subtypes for carbon, nitrogen,
and oxygen with slightly different radii (carbons range 1.76-2.0 Å, nitrogens range
1.5-1.65 , oxygens are 1.35 or 1.4 Å, S=1.85 Å, P=1.9 Å, Fe=1.47 Å). NACCESS
provides SASA on a “per residue” basis. If the ligand is completely buried, the SASA
calculated with NACCESS is zero. The SASA of each ligand in each complex was
calculated in the presence and absence of the protein (again, we included any other
appropriate ligands as part of the protein environment). We calculated the buried sur-
face area of the ligand as SASA(no protein)-SASA(with protein) and percent buried
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surface area as 100*(1-SASA(with protein)/SASA(no protein)). NACCESS is not
able to treat the unusual cases that we describe above for GoCAV. Those systems are
not included in the NACCESS plots and histograms.
3.3 Results and Discussion
3.3.1 Binding MOAD
Several features of Binding MOAD make it particularly useful for examining the
degree of solvent exposure of all protein-ligand binding sites. First, the dataset has
been carefully curated to identify valid and invalid ligands in each structure. Only the
valid ligands are included in our analysis. Without this analysis, any broad mining of
the structures would reflect real binding patterns skewed by the less relevant patterns
seen for crystallographic additives. (We have also excluded any ligands with warnings
of too many or too few atoms from the analysis, though they are part of the MOAD
dataset.)
Second, the dataset has been analyzed for redundancy. The proteins have been
grouped into families by 90% sequence identity. The non-redundant set of structures
from Binding MOAD contains only one complex from each protein family. The rep-
resentative for the family is the tightest binder when binding data is known. In cases
where there is no binding data for any of the complexes in the family, the represen-
tative is chosen based on best resolution and other structural considerations (62).
This allows us to present the data without some of the inherent bias of structures
deposited within the PDB.
3.3.2 Sharing the data on the Binding MOAD website
Each entry’s datapage on the Binding MOAD website is organized to help users
identify related protein systems and compare binding data, see Figure 3.3. Entries
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are cross-linked by function (classes for both enzymes and non-enzymes), sequence
identity, and ligand content. All HET groups in the complex are identified as valid
or invalid, and warnings are provided when too few or too many ligand atoms appear
in the PDB entry (unresolved atoms or multiple resolved orientations for parts of the
ligand, respectively). Binding data is provided when available. Text-based searches
can be used to identify entries based on PDB id, EC number, protein name, 3-
letter HET codes, and authors. Wildcards are permitted. The results can be limited
to a user-defined range of crystallographic resolution. The user can also limit the
search to the 1793 structures in Binding MOAD with available binding data, the
2223 structures of the non-redundant Binding MOAD dataset (where each protein
family is only represented once), or the 630 structures in the non-redundant set that
have binding data. There is also a browse feature to allow users to page through
functional classes of structures. When a user clicks the “class” link on a datapage
(seen in Figure 3.3), they are taken to the browse page for that functional class where
all protein families within the class are shown and ligand/binding information also
provided (Figure 3.4).
Clicking the blue and red thumbnail on a datapage, see Figure 3.3, launches a
version of the GoCAVviewer that interactively displays the atomic coordinates and
the surfaces calculated with GoCAV. The binding-site surfaces and the ligand surfaces
calculated with GoCAV are grid points, so the “raw” surfaces look like LEGO building
blocks. A smooth surface is created by a graphics trick, applying a Gaussian filter to
the image. The GoCAVviewer is written entirely in standards compliant Java, and
the code will work on any operating system that provides an implementation of the
standard Java Runtime Environment and Java3D API. GoCAVviewer is interactive,
allowing the user to rotate, zoom, or translate the structures in real time. The cavity
surfaces are transparent and near-by protein atoms can be displayed, so the user can
look at the complex in detail. At this time, the most critical issue is speeding up the
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Figure 3.3: The datapage for the HIV-1 protease complex 1MTR. The page starts
with the general information from the PDB file. The ligand HET codes are
single-click searches that pull up all other structures with that ligand. All
ligands are listed as valid or invalid, and binding affinity data is provided
when available. Warnings are provided when the number of atoms in
the structure do not match the formula section of the PDB file. Clicking
the thumbnail launches the GoCAVviewer. Links to the right of the
thumbnail take the user to the equivalent datapage at the PDB and to
the crystallography paper on Pubmed. Various sets of structural and
binding data are available for download. At the bottom of the page, the
structure is linked to other entries with the same functional class, and
all other members of its protein family are listed with ligand information
(over 100 HIV-1 protease structures are included in Binding MOAD and






























Figure 3.4: The user can find information by browsing through the complexes within
Binding MOAD. The structures are organized by function: EC numbers
for enzymes and our own classifications for entries without EC numbers.
All protein families within a class are displayed for the user to compare
related systems and their binding affinity data.
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viewer. We are committed to improving it, but we wanted to make the data available
to the rest of the community as soon as possible.
Tight complementarity between the protein and ligand is highlighted by the ligand
surface projecting through the cavity surface (see Figure 3.2). We have found that
these intersections only occur at positions with strong hydrogen bonding or very
specific vdw interactions. We have also configured the viewer to display a second
set of surface information calculated with bridging water molecules. It was easy to
include water molecules as additional protein atoms in a GoCAV calculation and
determine their influence on creating a surface to complement the ligand. Figure
3.2 shows how the surfaces change when bridging waters are treated as part of the
protein. The shape complementarity between the ligand and the pocket is often more
evident when waters are included.
3.3.3 Mining Binding MOAD
Figure 3.5 provides histograms of the size of the ligands in the redundant and
non-redundant Binding MOAD sets. The distribution of ligand sizes is similar in the
two sets. In Figure 3.6, the plots of size vs. affinity show the wide range of data
available in Binding MOAD. One issue that should be noted is that the “affinities”
used in our plots are a simplistic translation of the K d, K i, and IC50 data using
the formula RT*ln(data). This is not strictly correct for K i or IC50, but it is a
way to do a standardized treatment of a large dataset. The K d data in the plots is
highlighted in black because the affinities should be more reliable and better reflect
true free energies of binding. Complexes with K i and IC50 data are in gray. The
data available for download from the website is the original K d, K i, and IC50 data
from the crystallography papers.
The ranges in Figure 3.6 are approximately the same for the redundant and non-
redundant sets, but the averages for both sets are slightly different. The average
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Figure 3.5: Distribution of ligand size within the complexes in redundant and non-
redundant Binding MOAD, note the larger scale for the redundant com-
plexes. Black bars represent all complexes in Binding MOAD; gray bars
represent only the complexes with affinity data.
Figure 3.6: Plots of ligand size vs. binding affinity for the complexes in redundant
and non-redundant Binding MOAD. The data points in black squares are
from complexes with Kd data, and gray diamonds are used for complexes
with K i or IC50 data.
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binding affinity for the redundant set is -8 kcal/mol, but the average for the non-
redundant set is -9 kcal/mol. Both sets have a standard deviation of 3 kcal/mol.
The average numbers of heavy atoms for the ligands in these sets are 26 and 27,
respectively, both with a standard deviation of 14 atoms. A size range of 12-41 heavy
atoms corresponds to drug-like molecular weights of approximately 150-700. It should
be noted that these are the averages for just the complexes with binding affinity data
(all points in Figure 3.6, but only the gray bars in Figure 3.5). The average number
of heavy atoms for ligands in all of the Binding MOAD complexes is 31 (black bars
in Figure 3.5).
Figure 3.7A presents histograms of buried MSA for the binding-site cavities as
calculated by GoCAV. The distribution of buried surface area parallels the size dis-
tribution of ligands, and in Figure 3.7B, a plot of the cavity’s buried MSA vs. ligand
size shows a good correlation, simply reflecting the relationship between increasing
size of the ligand and increasing surface of the cavity it occupies. (As expected, the
distributions for buried SASA of the ligands, as calculated with NACCESS, were very
similar and also well correlated to ligand size, data not shown).
Liang et al. found that a linear correlation exists between ligand volume and
binding site volume, provided that the pockets were small (=700 Å3). Figure 3.7B
also shows that the correlation is not as tight for the larger ligands and pockets.
Others have found that binding sites tend to be the largest pockets/cavities in a
protein (154; 155; 156; 17). We have not examined other cavities within our proteins,
but we plan to compare the patterns of valid and invalid ligands in the future. One
would assume that the crystal additives on the surfaces of the protein are in shallow
pockets with little buried surface area, but covalent cofactors and structural elements
of proteins will occupy both surface and buried positions. Patterns of valid vs. invalid
ligands of both types should help current efforts in the field to identify binding sites
in apo structures. At this time, groups are focusing on the analysis of occupied vs.
58
Figure 3.7: (A) Distribution of the buried surface area (Å2) for cavities within Bind-
ing MOAD as calculated with GoCAV, note the larger scale for the re-
dundant data. Black bars represent all complexes in Binding MOAD;
gray bars represent only the complexes with affinity data. (B) Plots of
buried surface area of the cavity (Å2) vs. ligand size. The data points
in black squares are from complexes with K d data, and gray diamonds
are used for complexes with K i or IC50 data. Error bars for data points
were available in two cases. First, if a side chain in the active site was
resolved in more than one orientation. Second, some multimer complexes
are solved with slight differences in the independent binding sites (for
instance, the atomic coordinates of the binding sites within a dimer will
not be the exactly same if symmetry was not imposed while fitting the
electron density).
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unoccupied pockets and having good success (49; 154; 136; 157; 158; 159; 160; 161;
156; 17; 162; 149), but the methods could be further refined with data on the invalid
ligands identified within Binding MOAD.
Liang et al. also found that binding sites are either buried cavities or more often
pockets with one, occasionally two, exposed openings (17). In agreement with that
study, our histograms in Figure 3.8 show that most ligand-binding sites have limited
exposure to solvent; GoCAV data shows that 70% of the cavities have ≥70% of their
MSA buried, and NACCESS data shows that 85% of the ligands have ≥70% of their
SASA buried. The high degree of burial also parallels findings by Keil et al (161)
where they show that binding sites for ligands are deeper and more concave than
binding sites for protein-DNA or protein-protein associations. We found that the
largest ligands are rarely well buried. They tend to have less percent buried MSA of
the cavity and less percent buried SASA of the ligand (Figure 3.9); many of them are
short peptide or nucleic acid chains, again fitting with the findings that such binding
sites are more shallow.
3.4 Conclusions
The histograms in Figures 3.7A and 3.8 tell us that most ligands are well buried.
This fits the common paradigm that many contacts between the ligand and the protein
are a significant factor in molecular recognition. Figure 3.9 shows that largest ligands
tend to have more exposed surface area. These large ligands are typically peptide,
nucleic acid, or sugar chains, and one would expect the patterns of binding such
molecules to start to resemble the patterns of proteins binding macromolecules.
The general trends found here do not change with the choice of MSA of the pocket
vs. SASA of the ligand. Also, GoCAV and NACCESS use different methodologies and
radii, so the patterns appear to be independent of how the calculation is performed.
We do want to note that surfaces of the binding site calculated with GoCAV are
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Figure 3.8: Histograms of the percent of surface area that is buried. (A) Percentage
of buried MSA of the cavity and (B) Percentage of buried SASA of the
ligand. Black bars represent all complexes in Binding MOAD; gray bars
represent only the complexes with affinity data.
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Figure 3.9: The largest ligands tend to have much of their surface area exposed to
solvent (low % buried). (A) Percentage of buried MSA of the cavity and
(B) Percentage of buried SASA of the ligand. The data points in black
squares are from complexes with K d data, and gray diamonds are used
for complexes with K i or IC50 data.
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not completely independent of the ligand because of the use of an ELS to “bound”
the binding site. However, the probe never reaches the ELS boundary in a buried
binding site. Most of our sites are highly buried, so the majority of the cavity surface
is defined only by contacts to the protein. This typically makes the portion of the
surface defined by the ELS only a small percentage.
In closing, future efforts with Binding MOAD will allow us to compare – broadly,
for the first time – the binding affinity data to the patterns of molecular recognition
mined from the PDB. Past studies have mined subsets of the PDB with various
structural analyses of proteins and ligands (49; 154; 59; 163; 136; 157; 164; 158; 165;
159; 160; 161; 156; 142; 17; 162; 132; 166; 149; 167), but now, we will be able to
add another layer of depth to such studies. There is more to binding affinity than
just burying a ligand inside a protein, and all of the complex issues that go into
creating an effective scoring function (168) will need to be considered in our analyses.
Both shape and chemical complementarity are thought to be the basis of molecular
recognition. Our future analyses will have to consider the chemical complementarity
or what “types” of surfaces are solvent-exposed or interact with the protein. We will
also need to address the very complex issue of entropic changes upon binding.
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CHAPTER IV
Differences between high- and low-affinity
complexes of enzymes and nonenzymes
4.1 Introduction
Both enzymatic and non-enzymatic proteins can bind small molecules, but en-
zymes catalyze reactions and have a fundamentally different role from non-enzymes,
which may have an impact on their recognition of ligands. Do these two types of
binding events have the same physical characteristics? Furthermore, are there any
differences between high-affinity complexes and weaker binding events that can be
linked to their physical contacts? To answer these questions, physicochemical pat-
terns were mined from our protein-ligand database Binding MOAD (Mother of All
Databases), where MOAD is pronounced “mode” as a pun on a ligand’s mode of
binding.(62; 169)
Binding MOAD is the largest curated database of high-resolution protein-ligand
complexes from the Protein Data Bank (PDB).(115) Though it only reflects proteins
that can be crystallized, these are the exact systems where structure-based insights
will be used. The PDB is the source of all structures used for docking and scoring
development by academics. However, the data used here are significantly larger than
most sets used to develop existing scoring functions, which are typically sets of <300
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complexes of <50 unique proteins. We use 2214 structures: 1790 enzymes and 424
non-enzymes (512 unique enzymes and 176 unique non-enzymes). This study provides
an important benchmark of the current landscape available from structural biology
(incomplete and/or biased as it may be).
For this study, we have compared distributions of various properties between four
classes of protein complexes. Distribution analysis is used widely in many fields,
and it is important to stress that it does not define “absolute rules”, nor are the
data presented as such. These are general guidelines, and of course, there will be
exceptions to those trends. Distribution analysis can show that “men are taller than
women” and “women live longer than men.” Those trends are true even though some
women are 6’ tall and some men live to 100.
Empirically derived rules can be very useful in discovering and applying new prin-
ciples in chemistry. One of the most well known examples is Lipinski’s Rule of Five,
which describes the physical properties of orally-available drugs.(170; 171) These rules
provide general guidelines for size, lipophilicity, and hydrogen-bonding characteris-
tics that correlate with the likelihood that a molecule can be orally absorbed into
the body. The findings are based on distribution data of the chemical characteristics
of orally absorbed molecules going into Phase-II testing. The dataset is biased by
issues outside of pharmacokinetics such as the need for good synthesis (not just ac-
cessible chemistry, but few steps in high yield) and market considerations (completely
economic, no basis in the thermodynamics of protein-ligand binding). The rules do
not hold for natural products, actively transported molecules, molecules that require
metabolism for activation, or most antibiotics, antifungals, vitamins, and cardiac gly-
cosides. There are plenty of molecules in Lipinski space that are not drugs, and many
molecules outside that space that are. Despite these limitations and biases, the Rule
of Five is used widely in the pharmaceutical industry.
We hope that the present work will also aid drug discovery. In this study, we
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provide new patterns which describe high-affinity, protein-ligand binding and outline
differences between enzymes and non-enzymes. Of course, there will be examples that
fall outside the typical pattern, but these relationships provide a good description of
the general landscape that structural biology can provide at this time. We expect
that our understanding will grow as more structures become available through the
various protein structure initiatives.(172) These guiding principles may be useful in
designing targeted libraries for drug discovery and improving scoring functions. They
are also important to advancing our fundamental understanding of chemical biology,
protein-ligand binding, and the biophysics that dictate molecular recognition.
Non-covalent, small molecule binding is a tradeoff between the enthalpy gained by
making specific contacts between functional groups of the ligand and the protein and
entropy lost by forcing the ligand and protein into a specific conformation.(173; 174)
Since this study uses crystal structures it is difficult to fully account for the effect
caused by entropy. However, it is possible to determine the physical characteristics
of the small molecule and the protein which leads to the binding affinity.
Other studies(175; 176) have noted an inherent limitation in mining protein struc-
tures for physical characteristics of binding. When a pocket is discovered on a protein
surface, it is difficult to identify whether it is a true binding site or if it is capable of
high-affinity binding appropriate to represent drug-like binding. This study does not
suffer from these limitations; all sites have been curated to assure that they are true
binding pockets, and the high-affinity complexes are separated from those with low
affinity.
Only complexes with binding data (Kd, Ki, or IC50) were used for this study. No
complexes in MOAD are annotated with Km data, so almost all ligands are inhibitors,
agonists, or antagonists (a small number are cofactors, 5%, included only for systems
were affinity data is appropriate). We specifically focused on the contacts between
the ligand and the protein, excluding any structure with poorly defined contacts such
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as missing atoms from under-resolved density or ligands and side chains resolved in
multiple orientations. Distributions of ligand size, buried surface area (BSA), exposed
surface area (ESA), and other physical characteristics were examined for statistically
significant differences between four subsets of the complexes: high-affinity binding
to enzymes, high-affinity non-enzymes, low-affinity enzymes, and low-affinity non-
enzymes. A common metric to evaluate lead compounds is ligand efficiency.(24; 25;
27; 26) In this study, ligand efficiencies for the different classes of proteins are reported
as affinity per size (-∆Gbind divided by the number of non-hydrogen atoms) and per
the degree of contact between the ligand and the pocket (-∆Gbind/BSA).
Here, we focus on the most significant differences between molecular recognition
of tight and weak binding to enzymes and non-enzymes.
4.2 Methods
Data for this study come from the largest comprehensive database of protein-
ligand crystal structures with binding data, Binding MOAD. The latest version of
Binding MOAD was created from structures released on 12/31/2008 or earlier; it
contains 13138 complexes, comprised of 4078 unique protein families binding 6213
unique ligands. The great care taken in curating this dataset has been outlined
elsewhere,(62) but it should be noted for these purposes that ∼11,000 crystallogra-
phy papers have been examined to determine the appropriateness of every ligand
(crystallographic additives, post-translational modifications, and covalently bound
ligands are excluded from consideration). From these efforts, binding affinity data
is available for 30% of the entries, with a preference for Kd data over Ki data over
IC50 values. The affinities were converted to free energies of binding by ∆Gbind =
RTln(Kd) or simply approximated by ∆Gbind = RTln(Ki or IC50) with a temperature
of 298 K.
High-affinity binding was defined Kd, Ki, or IC50 ≤250 nM (∆Gbind ≤-9 kcal/mol),
67
which is approximately the average of all the complexes with binding data in Binding
MOAD. Enzyme complexes were defined from the Enzyme Classification number in
the PDB file. The non-enzymes were annotated by hand using keywords reported in
the remarks section of the PDB entry. Binding MOAD’s high-affinity non-enzymes
and enzymes are listed in the Supporting Information. Enzymes that had ligands that
were allosteric sites, were considered non-enzymes. For instance, the non-nucleoside
inhibitors of HIV Reverse transcriptase are bind in a non-enzymatic allosteric site,
and it was included in the non-enzyme list. All complexes and binding data are
available at the Binding MOAD website, www.BindingMOAD.org.
To calculate surface areas, BSA and ESA were calculated with GoCAV using radii
based on united-atom OPLS parameters.(169) This code reports buried molecular
surface area (MSA) of the pocket and also defines ESA of the binding site, bounded
by the 3D coordinates of the ligand.
The SlogP for the ligands was calculated using MOE,(177) based on the method
developed by Wildman and Crippen.(178) For the 2D and 3D descriptors calculated
with MOE, the idealized SDF files from the PDB were used if available; otherwise,
the coordinates of the ligand from the protein’s structure were taken. Hydrogens
were added with MOE. In an effort to identify any differences, all 2D and 3D ligand
characteristics available within MOE were compared for the four groups of complexes:
high-affinity enzyme, low-affinity enzyme, high-affinity non-enzyme and low-affinity
non-enzyme.
4.2.1 Statistical Analysis
Statistical significance was assessed with the programs SAS(179) and JMP(180).
Initial assessments used JMP to calculate all pair-wise correlations for the over 200
descriptors calculated. For the descriptors showing interesting trends, the significance
of the differences between the distributions of physical properties were determined by
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the Wilcoxon rank-sum test, which is most appropriate given the non-Gaussian dis-
tributions of the data. We also performed one-way ANOVA, two-way ANOVA, and
Tukey-Kramer HSD tests between the four classifications. Since these second series
of tests require near-normal distributions, the square-root transform was applied to
reduce the skew and bring the distributions closer to normal. For the important de-
scriptors, distribution analyses from JMP are included in the Supporting Information
(Supporting Information, Figures A.1-A.7), and each includes the mean, median,
quantiles, distribution histogram, and outlier box plot. The results of the Tukey-
Kramer HSD test are presented in Supporting Information (Supporting Information
Tables A.1-A.5).
Histograms of the distributions of ligand size were binned in increments of 5 heavy
atoms. Distributions of BSA and ESA were binned by 50 Å2. Those plotting ligand
efficiency were binned by 0.1 kcal/mol-atom for affinity per size or 10 cal/mol-Å2
for affinity per degree of contact. Distributions of SlogP were binned by 2 log units.
These bin sizes were in proportion to the size of the datasets and were consistent with
those automatically generated by JMP.
4.3 Results and Discussion
Considerable effort was made to determine direct mathematical relationships be-
tween affinity and surface area, ligand size, or other characteristics of protein-ligand
interactions, but there was no global correlation across all complexes. Recent work
by Coleman and Sharp(181) based on the PDBbind dataset(57) also found no corre-
lation between affinity and surface area or depth of the binding pocket. Inspired by
analyses of distributions of ligand efficiencies from screening data,(24) we changed our
approach and focused on distributions of the properties between subsets of protein-
ligand complexes.
Table 4.1 outlines the characteristics that differ between high-affinity and low-
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affinity binding for enzymes and non-enzymes; all emphasized differences in the
datasets have a statistical significance >99.99% (p<0.0001) based on a two-tailed,
Wilcoxon rank-sum test. Figure 4.1 shows a comparison between each of the sub-
sets of complexes, examining the distribution of ligand sizes, BSA, SlogP, and ESA.
Many of the low-affinity complexes have ∼300 Å2 of BSA, but the high-affinity com-
plexes display more contact. It has been estimated that drug-like binding sites have
∼300 Å2 of solvent-accessible surface area (SASA).(175) Our measurement for BSA
is based on MSA, and so, the slightly higher values of the high-affinity complexes are
appropriately comparable.(175)
4.3.1 Different approaches for improving inhibitors of enzymes versus
non-enzymes
For enzymes, there is a significant difference in the size of the ligands in high-
and low-affinity complexes (Figure 4.1a). High-affinity ligands are much larger (11
more non-hydrogen atoms). However, non-enzymes display very little difference in
the size of the ligands between high-affinity and low-affinity complexes (Table 4.1,
Figure 4.1b). These differences do not come from any influence of the inclusion of
cofactors in the set. The medians are nearly unchanged if they are removed from the
dataset (see Supporting Information, Table A.6).
Sizes of the ligands point to a strong difference in the complexes, particularly in
how to improve an inhibitor for enzymes versus non-enzymes. To improve the affinity
of an enzyme inhibitor, it appears fruitful to add functional groups to increase the
complementary contact between the inhibitor and the protein. In contrast, improving
ligands for non-enzymes may best involve conservative changes which maintain the
ligand’s size. Tight binders for non-enzymes are less exposed than the low-affinity
ligands, making them more sequestered from the surrounding solvent (Table 4.1).
Distributions of the calculated octanol/water partition ratios (Figure 4.1a,b) show
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Table 4.1: Characteristics of Protein-Ligand Binding for Enzymes and Non-Enzymes






















































































a. Values presented are medians for each population.
b. All differences noted in the comparisons sections have a statistical significance of
>99.99% (p<0.0001).
c. Ligand size is given in the number of non-hydrogen atoms.
d. Percent exposure is ESA/(ESA+BSA).
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Figure 4.1: Comparisons of (A) enzyme complexes, (B) non-enzyme complexes, (C)
high-affinity complexes and (D) low-affinity complexes are presented.
High-affinity enzymes are shown in dark blue, and low-affinity enzymes
are in green. High-affinity non-enzymes are in red, and low-affinity non-
enzymes are in gold. Distribution of ligand sizes (number of non-hydrogen
atoms), buried surface area of the pocket (Å2), SlogP, and exposed sur-
face area (Å2) are given in normalized percent frequencies. P-values show
the significance of the difference in the medians of the distributions, as
determined by a two-tailed Wilcoxon rank-sum evaluation (insignificant
differences have p>0.05).
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that high-affinity ligands are more hydrophobic than those with low affinity, but
there is no significant difference between enzymes and non-enzymes in this regard.
It appears that “adding grease” equally improves binding to both enzymes and non-
enzymes, consistent with a general desolvation effect.(173)
The above trends for improving inhibitors for enzymes versus non-enzymes come
from observing patterns across different proteins (inter-protein relationships), but
information to improve inhibitors for a specific target must come from observing
trends of one protein binding a variety of ligands (intra-protein binding trends). This
is a more difficult comparison to make because few proteins are crystallized with a
significant range of bound ligands. For the few that exist, we must divide them into
enzymes and non-enzymes, further reducing the sizes of the available datasets. The
findings below are qualitative in nature. Overall, our data show that enzymes appear
to have better correlations between size and affinity than non-enzymes.
In order to determine a relationship between ligand size and affinity within a
protein family (Figures 4.2 and 4.3), the complexes were grouped by 100% sequence
identity. This organization ensures that changes in affinity are the result of changes
in the ligand and not a mutation within the binding site. (For a few proteins, we were
able to combine two sets when the mutations were far from the active site and incon-
sequential.) Groups that contained ≥5 complexes were examined. For non-enzymes,
there were only a few proteins available: oligopeptide-binding protein, glutamate re-
ceptor 2, estrogen receptor alpha, estrogen receptor beta, arabinose-binding protein,
mannose-binding protein, maltose-binding protein, and src SH2-binding domain. For
most of the non-enzymes, the ligands are very similar in size and affinity. Six of
the eight proteins have a small range of ligand sizes which shows little correlation
to affinity (Figure 4.2a, b). The small range of observed ligand sizes supports the
idea that conservative changes are most appropriate for trying to improve ligands for
non-enzymes. However, the lack of a distinct trend between ligand size and affinity
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does not necessarily prove that a trend could not be observed. It is unclear if the
small range of ligands is the result of the specificity of the protein systems or whether
more diverse complexes are simply not available from the PDB.
Figure 4.2: Limited correlation is seen between size and affinity in non-enzymes (A
and B). The proteins with “clusters” of points have smaller binding sites
and no ligands over 40 non-hydrogen atoms. The ligands have similar
sizes and affinities for oligopeptide-binding protein (OBP), glutamate re-
ceptor 2 (GluR2) and mannose-binding protein (MBP), arabinose-binding
protein (ABP), and estrogen receptor (ER) alpha and beta. The only non-
enzymes with a range of ligand sizes are maltose-binding protein and the
non-enzymatic site on the SH2 domain of pp60src tyrosine kinase (C and
D, respectively).
Only maltose-binding protein (Figure 4.2c) and the non-enzymatic site on the
SH2 domain of pp60src tyrosine kinase (Figure 4.2d) have a significant range of ligand
sizes. The maltose-binding protein complexes contain sugar chains of varying length.
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Figure 4.3: Many examples are available of enzyme complexes that show a strong
correlation between size and affinity of the ligands; seven are given here
(A-G). HIV-1 protease (G) demonstrates that a large collection of ligands
may show no correlation, but subsets of data may reveal strong trends
(data for the C95A and Q7K/L33I/L63I mutants). It is interesting that
even small binding sites with ligands of 40 non-hydrogen atoms or less
(B,C,D) show a linear trend with affinity; this was not seen for non-
enzymes with small binding sites.
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Almost all bind with roughly the same affinity, and this may be explained by the
fact that the larger ligands show little difference in the BSA contact, despite the very
large range of sizes. The non-enzymatic site on the SH2 domain of pp60src tyrosine
kinase is the only non-enzyme complex showing some correlation between ligand size
and binding affinity. It is interesting that the only exception in non-enzymes is a
regulatory site on an enzyme. These linear correlations reflect a trend across several
ligands, ∆(∆Gbind/size), which is slightly different than the ligand efficiency of an
individual ligand, ∆Gbind/size. In the discussions below, we will use the term “trend”
or “correlation” when comparing across several ligands bound to the same protein,
∆(∆Gbind/size).
In the case of enzymes in MOAD, thirty-seven proteins were available with five
complexes or more. Unlike non-enzymes, over half of the families showed correlations
between size and affinity. For brevity, only seven examples of MOAD’s enzymes are
given in Figure 4.3. One of the most interesting features of the data in Figure 4.3 is
that the slopes - the overall trend for each set - significantly vary! Though a linear
correlation can be found for a good number of enzymes, the additive contributions
of more functional groups appear to be system dependent, with some contributions
being rather small. The trends range from 0.44 kcal/mol-atom for carboxypepti-
dase A (Figure 3b) to 0.09 kcal/mol-atom for FK506-binding protein (Figure 4.3f).
Most scoring functions use additive terms, and these findings underscore the diffi-
culty in developing a universal scoring function, appropriate for all protein systems.
Yang et al. have also noted these difficulties in development of their M-Score scoring
function(182).
However, for 11 enzymes, there was no correlation; the ligands had roughly compa-
rable affinity and sizes, much like the non-enzyme examples. Three enzymes showed
a very small range of ligand sizes and a large range in binding affinity (Supporting
Information). It is debatable whether these trends are exceptional examples of the
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correlation expected for enzymes or whether they indicate cases where only conser-
vative changes in sizes are allowed, as would be expected for non-enzymes. It is also
possible that they result from an unusual set of ligands from one chemical class.
Though Babaoglu and Shoichet have used fragments of inhibitors of β-lactamase
to show that ligand efficiency is not necessarily additive within a binding site,(183)
fragment-based design often couples these small building blocks in the pursuit of high-
affinity ligands.(184) From our data above, one might expect greater success for this
strategy when targeting enzymes where increasing size generally leads to increasing
affinity. A recent study by Hajduk compared fragment-based design for 14 enzymes
and four non-enzymes to show that ligand efficiency remained rather constant as
the optimal leads were increased in size.(185) The contributions were roughly addi-
tive for the best functional groups. The average trend across these systems was 0.3
kcal/mol-atom, with individual systems showing trends from approximately 0.23 to
0.51 kcal/mol-atom (reported as binding efficiency indices of 11-28 pKd units per MW
in kDa). It is encouraging that the values are comparable to the ligand efficiencies
reported in Table 4.1.
Hajduk’s trends were presented for the most efficient ligands for each protein,
emphasizing the most ideal cases of improving a ligand.(185) However, his data for
Bcl-xL, a non-enzyme with a large binding cleft, showed that many changes will not
be optimal. A detailed analysis for >2300 additional molecules showed that many had
significantly lower efficiencies. In fact, he suggests that chemical modifications that
reduce the ligand efficiency by >10% deviate too much from the ideal and indicate
that either the location or chemical nature of the modification is less desirable.
The HIV-1 protease data (Figure 4.3g) shows that there is a large scatter of
inhibitor sizes and affinities, but two subsets of data (from mutants of HIV-1 protease)
show strong linearity. This could demonstrate the same issue seen in Hajduk’s detailed
analysis of Bcl-xL.(185) The full set of data shows wide scatter and little trend, but a
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carefully chosen subset could reveal idealized trends for a particular protein system or
class of ligands from a specific synthetic series. For HIV-1 protease, the compensation
between enthalpy and entropy can be hard to control. Lafont et al. have demonstrated
that an increase in size from the KNI-10033 inhibitor to the KNI-10075 inhibitor
did not increase binding affinity despite a more favorable enthalpy from a strong
hydrogen bond.(19) The entropic penalty of changing a thio ether (two heavy atoms)
in KNI-10033 to a sulfonyl group KNI-10075 (four heavy atoms) is responsible for
the lack of change in binding affinity. That study noted that, although others have
been able to optimize certain HIV-1 protease inhibitors with respect to enthalpy, the
enthalpy-entropy compensation could make optimization of affinity impossible for
some chemical series.
An important caveat should be considered in the preceding discussion. It is pos-
sible that strong correlations between size and affinity can only be easily determined
for large binding sites. Large ligands can be truncated to provide smaller, weaker lig-
ands that bind to subsites. This would give a wide range of ligand sizes and affinities,
allowing a definite size-affinity relationship to emerge from the data. It may be more
difficult to determine a trend for a small binding site. This would still imply that
enzyme inhibitors are more likely to be improved through the addition of functional
groups, simply because the binding sites in enzymes are generally larger than those
of non-enzymes. However, if this were the case, the trend would be due to the size of
the binding site and not necessarily the protein’s basic function.
Though the size argument above is important to note, it is most likely not the cause
of the difference between enzymes and non-enzymes. Several examples of smaller
binding sites, characterized by ligands of 40 non-hydrogen atoms or less, are presented
in Figures 2 and 3. For small non-enzymes, there are no proteins which show a
correlation between size and affinity. Conversely, there are several enzymes with small




Distributions of ligand efficiencies are given in Figure 4.4. Ligand efficiency based
on contact (-∆Gbind/BSA) can be compared to established values for the desolvation
effect. The free energy of transferring a hydrophobic molecule from a hydrophobic sol-
vent into water has been estimated as 24-47 cal/mol-Å2, with the higher value being
the most widely accepted.(186; 187; 37) Honig and coworkers have noted this is lower
than the value of 72 cal/mol-Å2, derived from the surface tension of a hydrocarbon-
water interface.(37) Only 0.8% of the complexes in this study have ligand efficiencies
that exceed 72 cal/mol-Å2 (i.e., greater than Honig’s value), and many have effi-
ciencies ranging between 20-40 cal/mol-Å2. The low-affinity complexes are roughly
bounded by the 47 cal/mol-Å2 value (only 4.1% have greater efficiencies), but the
high-affinity complexes have large populations greater than that value. Although,
the complexes in Binding MOAD are not exclusively driven by hydrophobic associa-
tion, these values provide a yardstick for comparisons. However, it should be noted
that the range of values from the literature are based on SASA of small molecules in
differing environments (ligands), and our values are based on MSA of the contacts
within the pockets. While the comparison is not ideal, MSA-based values for ligands
are not prevalent in the literature, and SASA of a pocket is not equivalent to SASA
of a ligand.
For low-affinity complexes, the ligand efficiencies are basically the same for en-
zymes and non-enzymes (Table 4.1, Figure 4.4b). However, the differences are sig-
nificant in high-affinity complexes (p <0.0001 for both efficiencies). The ligand ef-
ficiencies for high-affinity, non-enzyme complexes are ∼17% greater than those of
high-affinity, enzyme complexes (Table 4.1). Non-enzymes in Figure 4.4a show a
broader distribution of efficiencies and much higher populations above 0.4 kcal/mol-
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Figure 4.4: Distribution of ligand efficiencies per size (-kcal/mol-atom) and per con-
tact (-kcal/mol-Å2), given in normalized percent frequencies. Distribu-
tions present comparisons of (A) high-affinity complexes (p<0.0001 in
both cases) and (B) low-affinity complexes. High-affinity enzymes are
shown in dark blue, and low-affinity enzymes are in green. High-affinity
non-enzymes are in red, and low-affinity non-enzymes are in gold.
atom (55% of high-affinity non-enzyme complexes vs 37% of high-affinity enzyme
complexes) and 30 cal/mol-Å2 (51% of non-enzymes vs 35% of enzymes). On average
over the high-affinity complexes, every atom and square Ångstrom of buried cavity
surface is worth more free energy in non-enzymes!
The differences in efficiencies between high-affinity enzymes and non-enzymes are
not dependent on the choice of cutoff between high- and low-affinity complexes. Even
if the full set of enzymes is compared to the full set of non-enzymes, the ligand
efficiencies are better for non-enzyme complexes. For the 1790 enzyme complexes,
the median ligand efficiencies are 0.33 kcal/mol-atom and 23 cal/mol-Å2; the median
ligand efficiencies for the 424 non-enzymes are 0.36 kcal/mol-atom and 26 cal/mol-Å2.
The same patterns for enzymes and non-enzymes are observed when redundancy
is removed (Appendix A, Table A.7, Figures A.8 and A.9). This is important because
it corrects for some biases in the dataset by using only one complex of a protein
(some proteins have hundreds of entries and are heavily represented in the PDB). The
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non-redundant dataset in Binding MOAD is obtained by grouping the proteins into
families of 90% sequence identity and representing that family by the single complex
with the highest-affinity ligand - in essence, the optimal binding event available for
that individual protein. There are 688 unique complexes in this dataset, 512 enzymes
and 176 non-enzymes. Again, the high-affinity enzymes (235 complexes) have poorer
ligand efficiency than the high-affinity non-enzymes (85 complexes). For the non-
redundant datasets, the median ligand efficiencies for high-affinity enzyme complexes
are 0.39 kcal/mol-atom and 28 cal/mol-Å2. The median ligand efficiencies for the
non-redundant, high-affinity, non-enzyme complexes are still larger at 0.44 kcal/mol-
atom and 34 cal/mol-Å2. The smaller number of complexes produces nearly identical
distributions, and although the p-value of the comparison is slightly poorer (p =
0.04), it is still significant (96%).
4.3.3 Efficiencies, evolution, and druggability
The significant differences in ligand efficiencies suggest a differentiation in the
binding sites of these two classes of proteins, based on their function. This may
reflect the different evolutionary pressures upon enzymes and non-enzymes. The
higher ligand efficiencies of non-enzymes make them, in essence, more responsive to
low concentrations of ligand molecules. This is fitting, given their roles in signaling
and regulatory control of cellular function in response to stimuli. Conversely, enzymes
are optimized to bind molecules, change them, and release them again.
Ligand efficiencies are one key factor in describing the druggability of a target.
Does this imply that non-enzymes may be more druggable? In general, higher lig-
and efficiencies mean that drug-like affinities can be obtained with smaller molecules.
Smaller molecules would tend to provide better oral absorption and fewer functional
groups for toxicity concerns.(188; 176; 189; 190) Of course, ligand efficiencies reflect
“bindability”, and it is important to recognize that there are additional properties
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that make a protein a suitable drug target. It must be essential to the disease state.
Leads must show selectivity to avoid any negative consequences of off-target binding
events. There are a myriad of ADME and pharmacokinetic properties to be consid-
ered. However, the differences in ligand efficiencies do indicate a greater likelihood to
have better drug-like properties for inhibitors, agonist, and antagonists of non-enzyme
targets.
Many non-enzymes are the subject of intense drug discovery efforts in both the
private and public sectors; for instance, hormone receptors, signaling proteins, and
transcription regulators are targets for anticancer treatment.(191; 192) Recent discus-
sions on the druggability of protein-protein interfaces note that these difficult targets
may be more amenable than originally thought.(193; 111) Small molecules have been
developed that bind to key hot-spot regions with greater efficiencies and deeper burial
than the natural partner. Furthermore, many of the non-enzymes not represented in
the PDB are membrane-bound receptors. Even though they are not included here,
it is likely that the additional information would support the hypothesis that non-
enzymes are more druggable, since they are the target of many drugs. G-protein
coupled receptors alone constitute 30% of the drugs on the market,(189) and genomic
analysis has indicated many more receptors are druggable.(194)
Our results are also in good agreement with a recent study that estimated the
druggability of 1096 non-redundant human proteins.(176) The predictions used a
statistical model trained on NMR-screening data using a small fragment library.(195)
Four of the top six classes were non-enzymes: vitamin-binding, steroid-binding, lipid-
binding, and nucleotide-binding proteins.(176) The non-enzymes that were predicted
to be the least druggable were large macromolecular complexes and are not reflected
in Binding MOAD and this study.
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4.3.4 What produces the higher ligand efficiencies in non-enzymes?
Obviously, the root cause of the disparity in ligand efficiencies between enzymes
and non-enzymes is of paramount interest. Though the ligands for non-enzymes are
smaller, the SlogP characteristics are roughly the same for high-affinity ligands of
enzymes and non-enzymes (Figure 4.1c). If the ligands are chemically similar, then
the difference in efficiencies must come from the protein pocket. The most significant
difference is the degree of exposure for ligands of non-enzymes versus enzymes. High-
affinity ligands have a median exposure of only 11% in non-enzymes, but 25% in
enzymes (note that %ESA are used instead of ESA to correct for the difference in sizes
of the ligands). Low-affinity ligands for non-enzymes are significantly more exposed
(median of 33%), even more than the low-affinity ligands for enzymes (22%). Tight
and weak inhibitors have the same degree of exposure in enzymes, but tight ligands for
non-enzymes are much more encapsulated than the weak ligands (p<0.0001). Other
2D and 3D ligand descriptors displayed no significant patterns. This comparison was
cognizant of correlations between characteristics; for instance, differences in surface
area are correlated to size and were not “double counted” as additional differences
between high-affinity ligands of enzymes vs non-enzymes.
Amino acid composition of the binding sites was examined (Figure 4.5, left col-
umn). There is little difference between the binding sites of high- and low-affinity en-
zyme complexes. The largest differences are an increase in Val content in high-affinity
enzymes and an increase in Arg in the low-affinity complexes. For enzymes, the hy-
drophobic residues (Ala through Trp) on Figure 4.5 are 47.0% of the binding sites
for high-affinity complexes, but 43.9% for low-affinity ones. This is fitting with the
aforementioned finding that the high-affinity ligands are slightly more hydrophobic.
The comparison between binding sites of high- and low-affinity non-enzyme complexes
shows more pronounced variation, but also holds the general pattern of high-affinity
complexes having more hydrophobic content. The Ala-Trp residues are 55.9% of the
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binding sites for high-affinity complexes, but 43.2% for low-affinity ones. What is
most interesting is the comparison between enzymes and non-enzymes, particularly
for the high-affinity complexes. The hydrophobic content is higher for non-enzymes
(55.9% vs 47.0%), but the reader should recall that there is no significant difference
in the SlogP of the ligands (in fact, the median value for non-enzymes is more hy-
drophilic). Why are more hydrophobic sites recognizing slightly more hydrophilic
molecules with better affinity? The answer may lie in the fact that the amino acids
making the contacts are significantly different. In high-affinity non-enzymes, Leu and
Met provide a large portion of the hydrophobic contacts, at the expense of Val and
Ile. The non-enzyme’s preference for Glu over Asp is reversed in high-affinity enzyme
complexes, yet the use of Lys and Arg is the same. Leu, Met, and Glu are larger than
their counterparts Val, Ile, and Asp. It is possible that those residues are slightly
more polarizable. (Confirmation will have to come from in-depth examinations of
fully modeled complexes, inclusive of added hydrogens, detailed atom typing, and
possibly polarizable force fields. To do this for thousands of complexes is a sizable
effort, and outside the scope of the present study.) It should be noted that differences
in the binding sites are not correlated with differences in the overall amino acid con-
tent; the reader should compare the left and right columns in Figure 4.5. Leu, Met,
Phe, Tyr, and Trp make up nearly the same percentage of residues in the protein
sequences, but not the binding sites. This selective placement of differing residues
within binding pockets may have direct relevance to analyses of hot-spot regions and
potential binding sites on proteins.(196; 197; 198)
4.3.5 Most druggable enzymes
Of course, many pharmaceutically relevant targets are enzymes. By no means is it
suggested that they are not appropriate drug targets, especially when they constitute
47% of the drugs on the market(189) and a large percentage of new targets identified
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Figure 4.5: The binding sites (left) and the entire protein sequences (right) are an-
alyzed for amino acid content. Distributions are given in normalized
frequencies percent frequencies. Amino acids within 4Åof the ligands are
considered to comprise the binding site. Distributions of (A and B) low-
and high-affinity complexes of the same class show smaller differences than
comparisons between enzymes and non-enzymes (C and D). Amino acids
are listed by hydrophobic, aromatic, cationic, anionic, and hydrophilic
nature. “X” denotes contacts with cofactors, unnatural amino acids, and
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through genomic analysis.(194) The distribution of ligand efficiencies for the enzyme
classes suggests that lyases and oxidoreductases are the most druggable enzymes,
Figure 4.6. The distribution of lyases is significantly shifted to higher efficiencies,
standing out from the other data. The better efficiencies for oxidoreductases come
from an increased population in the tail of the distribution. The median ligand
efficiencies for the 139 lyases are 0.50 kcal/mol-atom and 33 cal/mol-Å2; and the
median ligand efficiencies for the 256 oxidoreductases are 0.39 kcal/mol-atom and 26
cal/mol-Å2. The 1395 enzymes from the other four classes have median efficiencies of
0.31 kcal/mol-atom and 23 cal/mol-Å2, which are significantly lower (significance of
≥99.99% using the Wilcoxon test). It should be noted that the two enzymes which
were predicted to be most druggable in the aforementioned study were also lyases
and oxidoreductases, in that order.(176)
Recently, a new method was introduced to predict druggability of a binding site
by estimating the site’s maximum Kd based on the percent hydrophobic SASA and a
scaling factor for efficiency that is dependent on the curvature of the site.(175) The
model was trained on 8 enzymes and applied to 63 structures, comprised of complexes
of 26 enzymes and a single structure of the non-enzyme mdm2.(199) An important
goal of the study was to fit a predictive equation to assess druggability of a site
based on protein-ligand structures of orally available compounds. This feature of the
study is important to note because the contributions of various physical characteris-
tics within the model should reflect both high-affinity binding and oral bioavailability
of the ligand. The model was fit under the assumption that hydrophobic desolvation
is the major driving force of binding, so terms based on electrostatics were not in-
cluded. The model was able to properly rank the training set, noting that outliers
were compounds with strong electrostatic components, prodrugs, or ligands that are
actively transported. The model was then used to identify new, druggable structures
from the PDB. It was interesting that the two newly identified targets were both
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Figure 4.6: Distribution of ligand efficiencies (-kcal/mol-atom) for enzymes, given in
percent frequencies normalized for the different number of complexes in
each enzyme class. The distribution of transferases (EC 2, 468 com-
plexes), hydrolases (EC 3, 843 complexes), isomerases (EC 5, 60 com-
plexes), and ligase (EC 6, 17 complexes) are the same and have been
added together for this example (black line). Oxidoreductases (EC 1, pur-
ple line, 256 complexes) have larger populations in the higher efficiencies
(p<0.0001). The distribution of lyases (EC 4, blue line, 139 complexes)
is notably shifted (p<0.0001).
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enzymes. With only two new targets presented, it is not clear whether the model
preferentially identifies enzymes over non-enzymes, but a preference towards enzymes
may be expected from their model given the training and test sets used. Our data
indicate that enzymes and non-enzymes may require different models in such anal-
yses. Furthermore, many of the ligand efficiencies in our set exceed the established
values for hydrophobic association, indicating that the most efficient complexes have
additional factors which contribute to their affinity. The affinity of these complexes
may not be well described by models based solely on hydrophobic SASA.
4.4 Conclusion
We have presented a substantial mining study of Binding MOAD, the largest
public database of curated protein-ligand structures with binding data. Physical
characteristics of bound ligands were compared between enzymes and non-enzymes
as well as high-affinity and low-affinity complexes. The comparison between ligand
sizes for low-affinity versus high-affinity binding shows that divergent approaches
are likely needed to improve the affinity of enzyme inhibitors versus those for non-
enzymes. The traditional approach of adding functional groups to fill more of the
pocket may work for enzymes, but it may not be as appropriate for non-enzyme
systems. However, making ligands more hydrophobic appears to aid binding in both
enzymes and non-enzymes.
Non-enzymes have higher ligand efficiencies than enzymes, which may be a re-
flection of their biological roles. This is also encouraging when considering the drug-
gability of non-enzymes. In the pharmaceutical industry, ligand efficiencies have
become a metric for evaluating hits from screening campaigns and even candidate
compounds.(25) Our results would caution against applying a rigid standard across
all protein targets. At the very least, a cutoff based on ligand efficiency should dif-
fer between enzymes and non-enzymes. Ideally, cutoffs would differ between protein
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families and only be considered as one of several guidelines in a selection process.
Binding MOAD provides strong support of several mathematical models cited
above,(199; 185; 176) particularly those of Hajduk and coworkers. Our results have
implications for the development of scoring functions for docking and predicting drug-
gability of a binding site.(200; 201; 202; 203) The differences between non-enzymes
and enzymes, as well as the differences across enzymatic systems, underscore the chal-
lenges of developing universal functions that perform well across all systems. Modest
improvement might be achieved by developing separate functions for enzymes and




Charge-charge interactions appear to dictate the
maximum ligand efficiencies available for
protein-ligand binding
5.1 Introduction
Protein-ligand binding is a delicate balance between the loss of entropy resulting
from complexation and the enthalpy gained by forming favorable contacts with the
protein (4; 19). The precise contribution of these contacts is a source of debate
and has provided a significant obstacle in the ability to predict how small molecules
will bind (204; 182; 205). The interplay between entropy and enthalpy is difficult
to determine since they are influenced by several factors. For entropy, binding two
entities results in a loss of six degrees of freedom, a change in the internal flexibility
of the protein and ligand must be taken into account, and the reorganization of water
around the ligand and within the binding site has significant implications. In the case
of enthalpy, several types of contacts can be made to varying degrees in the binding
site (4). Current thinking is that van der Waals forces are the most significant factor
for binding due to tight packing between the small molecule and protein (16; 4).
Hydrogen-bonding and electrostatic interactions are thought to contribute more to
the specificity of binding (4). Since these interactions are also present with water and
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counter ions, they are thought to have a smaller impact on affinity (4).
Highlighting the different interpretations regarding the drive for efficient binding,
there has been contradictory evidence as to which types of interactions play the
most significant roles in the binding of biotin to streptavidin, the tightest known
natural complex. In 1993, Miyamoto and Kollman used free energy perturbation
on biotin•streptavidin and N-L-acetyltryptophanamide•α-chymotrypsin to show that
the increased binding affinity for the biotin-streptavidin system can be accounted for
by van der Waals contacts made in the biotin•streptavidin complex where the pocket
in streptavidin is preformed as in the traditional lock-and-key theory (21). However,
newer work has shown that networks of hydrogen bonds are responsible for the strong
binding in the biotin•streptavidin complex (22).
A common metric to evaluate a small molecule’s ability to bind is “ligand effi-
ciency”. This metric is defined as binding affinity per number of non-hydrogen atoms
(24; 25; 26). It was first introduced by Kuntz et al. in 1999 (27), where they an-
alyzed 159 tightest-binding complexes and the relationship between the number of
heavy (non-hydrogen) atoms present in a ligand and its affinity. They showed that
each heavy atom can provide at most -1.5 kcal/mol of binding affinity (27). This
maximum was consistent with their predictions of the maximum affinity obtainable
by van der Waals and hydrophobic interactions (27). Though many of the most ef-
ficient ligands were metals and small ions, electrostatics was given little attention.
Even in recent investigations this class has been ignored because they are not “drug-
like” and most scientists prefer to focus on drug-like molecules for ligand efficiency
(206; 207; 208).
In this study, we investigated which properties lead to an optimal efficiency. To
study general patterns with regard to binding affinity and efficiency, it is necessary to
use a large set of protein-ligand complexes for which a structure has been solved and
an experimentally-derived binding constant (Kd, Ki, or IC50) has been determined.
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We used the largest dataset available, Binding MOAD(62; 169), to explore the re-
lationship between structure and binding affinity, extending Kuntz’s examination to
include all available binding events in the Protein Data Bank (115). By looking at
the most efficient ligands and the characteristics of their binding pockets, we reveal
which interactions are most important to provide the highest binding affinity and
efficiency. This study explores all binding events with the goal of examining funda-
mental biophysical properties, rather than focusing solely on properties of drug-like
chemical space.
5.2 Methods
Structural properties were derived from the complexes in our protein-ligand database
Binding MOAD (Mother of All Databases) (62; 169). Binding MOAD is the largest
database of high-resolution protein-ligand complexes annotated with binding data
from the PDB(115) (13,138 complexes comprised of 4078 unique protein families,
binding 6213 unique ligands). We have compiled binding affinity data for 32% of
the entries (4203 complexes), with a preference for Kd data over Ki data over IC50
data. The free energy of binding was determined directly from Kd values by ∆Gbind =
-RT×ln(Kd), and in the case Kd was not available, we approximated the free energy
of binding using ∆Gbind = -RT×ln(Ki or IC50). All structures and affinity data are
freely available at http://www.BindingMOAD.org.
Only complexes with binding data were used for this study. Coordinates were
taken from the biological unit files provided by the PDB, which display the functional
form of the protein. These files were processed to remove artifacts. We specifically
focused on the size of the ligand and its contact surface with the protein, so any
structure with poorly defined contacts were not considered. Therefore, we excluded
structures with partially occupied or missing atoms from under-resolved ligands or
side chains, as well as structures with too many atoms from ligands or side chains
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resolved in multiple orientations. A ligand was determined to have too many or two
few atoms if the number of atoms in the formula did not match the number of atoms
in the coordinate section of the pdb file. The total number of structures used in this
study was 2794.
Ligand efficiency is the free energy of binding divided by the number of non-
hydrogen atoms in the ligand (24; 25; 27; 26). Hence, a ligand with 10 atoms is twice
as efficient as a ligand with 20 atoms if they bind with the same affinity. In this study,
ligand efficiencies are reported as affinity per size (-∆Gbind/atoms) and per degree of
contact between the ligand and the pocket (-∆Gbind/BSA).
Surface areas were calculated using OPLS-based radii(150) with our code GoCAV
which reports buried molecular surface area (BSA) of the pocket (169). Variation
in BSA occurs when several examples of ligand binding occur in the biological unit
(i.e., slightly different interactions for three ligands in the three binding sites of a
homotrimer). This variation is represented by error bars on the graph of BSA. The
exposed surface area (ESA) is also computed from the total surface area minus the
BSA.
To estimate the electrostatic interactions of the ligand and the pocket with respect
to efficiency, we calculated the minimum distance of each charge of the ligand to the
charged residues of the pocket, including any metal atoms that may be present in the
binding site. We then averaged the minimum distance over all the charge sites on
the ligand. The charge sites were determined by calculating the pKa of each atom in
Pipeline Pilot(209) with the pKa calculator at a pH of 7.0.
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5.3 Results and Discussion
5.3.1 Maximum and average ligand efficiencies
If van der Waals terms are the definitive contribution, then we may expect to see a
correlation between affinity and contact surface area between the protein and ligand.
However, no correlation is seen between affinity and size or conatcet area(Figure 5.1A
& 5.1B).
Our dataset is significantly larger than that of Kuntz et al. (27), and we find
a slightly higher maximal efficiency for ligands of -1.75 kcal/mol-heavy atom. This
“hard” limit is set by several systems, but an alternative “soft” limit is -0.79 kcal/mol-
heavy atom, which is the upper bound of 95% of the data in Figure 5.1. The soft limit
is established by a significant number of Kd measurements. Given the significant drop
in efficiency between the two limits, it is extremely rare to find exceptional ligands
and suggests that the -0.79 kcal/mol is a sufficient limit for most uses.
The average and median efficiencies of our dataset are -0.38 kcal/mol-atom and -
0.33 kcal/mol-heavy atom, respectively. These averages are in agreement with average
values for ligand efficiency of -0.37 kcal/mol-heavy atom for enzymes (median = 0.33
kcal/mol-atom) and -0.42 kcal/mol-heavy atom for non-enzymes (median = -0.36
kcal/mol-heavy atom), as reported in our previous work (210). Accurate benchmarks
for ligand efficiencies are very important because these values define physical limits of
ligand binding. Furthermore, ligand efficiencies are often used to evaluate HTS data
or to eliminate lead compounds during a drug development cycle (24; 25; 26; 211).
Anecdotally, the best ligand efficiencies from HTS data approach -0.6 kcal/mol-atom
(26; 211). Pushing for leads with ligand efficiencies near -0.3 or -0.4 kcal/mol-atom
from a simple combinatorial library may be too restrictive for some systems as this
is near the average for all good structures, as noted above (25). However, ligand
efficiencies of candidate compounds must often be higher to allow for changes during
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Figure 5.1: Plotting the affinity of the complexes versus their physical characteristics
reveals the limiting cases as well as the general trends. Measurements used
for affinity data are noted as IC50 (green diamonds), Ki (red squares), or
Kd (black diamonds). (A) Affinity versus size of the ligand. Affinity is
given in -kcal/mol and size is given as the number of non-hydrogen atoms.
The units of the ligand efficiencies listed above the lines are -kcal/mol-
atom. (B) Affinity versus the buried surface area of the binding site, in
Å2. The units of the ligand efficiencies listed above the lines are -cal/mol-
Å2. The “hard limits” of ligand efficiency are denoted with black lines
and values; the “soft limits” which bound 95% of the data are denoted
with solid blue lines and values; the average ligand efficiencies are given
with orange lines and values. The dashed blue line denotes how few of
































































further drug development (211; 212).
We can also define ligand efficiency in terms of BSA of the binding site. Others
have proposed metrics for ligand efficiency based on free energy of binding per surface
area of the ligand, but these have been based on pharmacokinetic considerations and
are not equivalent to contact surface area between the ligand and its protein target
(24; 25; 26). Recently Nissink, has proposed that the maximal ligand efficiency should
be proportional to protein-ligand contact area and volume (206). That work further
suggests a modified measure of ligand efficiency based on affinity/N3.0, to estimate
the area to volume ration of a ligand (206). This metric is also useful for reducing
the dependency of a traditional ligand efficiency based on affinity/N, where N is the
number of heavy atoms (206).
Estimates based only on the ligand ignore a large portion of the interaction with
the protein. Instead, we have chosen to measure the contacts directly. In our descrip-
tion based on the BSA of the binding site, the average efficiency is 27 cal/mol-Å2.
Houk and coworkers coupled structure and affinity data for a moderate set of over
1000 host-guest, 175 antibody-antigen, and 176 enzyme-inhibitor complexes to pro-
pose that affinity is proportional to BSA of the ligand (213; 214). Their data implies
a relationship, equivalent to 7 cal/mol-Å2 (reported as approximately 1 log Ka for
every 90 Å2 of buried surface). This average is approximately one-fourth of our av-
erage, but Houk’s trend is for surface area of the ligand and ours is for molecular
BSA of the binding site. Other reported values of the relationship of surface area
versus free energy for transferring a hydrophobic solvent into water range from 24 to
47 cal/mol-Å2 (186; 187), which is in excellent agreement with the range between our
average and soft-limit efficiencies.
In Figure 5.1B, the “hard limit” for efficiency is 120 cal/mol-Å2 and the soft
limit that bounds 95% of the data is 51 cal/mol-Å2. We were surprised to find that
the maximum efficiency with respect to BSA was in exact agreement with limits
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proposed for macromolecular binding (215). In a follow-up work examining protein-
protein, protein-RNA, and protein-DNA complexes, Brooijmans et al. established
the same limit of 120 cal/mol for every Å2 of BSA (215). Macromolecular recognition
generally involves large, flat regions of a protein surface (216), but despite that large
contact surface, macromolecules do not inherently bind with higher affinities than
small molecule ligands (215). Keil et al. have shown that binding sites for ligands
are deeper and more concave than binding sites for protein-DNA or protein-protein
associations, implying a good degree of burial for small molecules despite their smaller
size (161). It is rather remarkable that the 120 cal/mol-Å2 limit of binding efficiency
appears to be universal across all varieties of binding interfaces on proteins.
5.3.2 Electrostatic Interactions Define Maximal Efficiency
Structures which define the limit of ligand efficiency all share a single distinct char-
acteristic: every system involves a charged ligand, in contact with a charged protein
residue or a metal ion cofactor. In fact, many of the ligands with the best efficiencies
have two or three charge centers, and they are complemented in their binding sites
by several charged side chains and/or dicationic ions. Figure 5.2 shows the systems
with the maximum efficiencies, annotated with their PDB codes. The highest effi-
ciency is seen for a phosphonoacetohydroxamate compound with a -3 charge that is
sandwiched between two dications in yeast enolase (PDB code 1els Figure 5.3) (217).
The crystal structure shows several unusually tight contacts in the chelation (2.1 Å)
which create very small contact surfaces. Not only is the small molecule bound by
two magnesium ions, there are two charged aspartates, two glutamates, two lysines,
an arginine, and a histidine (that potentially could be charged) in the vicinity.
Other high efficiency complexes include a charged benzylamine coordinated to
an acidic side chain in trypsin (1tnh) (218), a dicationic histamine complexed by
four acidic side chains in tick histamine-binding protein (1qft) (219), nitric oxide
97
synthase binding +1-charged isothioureas (4nos, 1ed4, 1d1w, and 9nse - the natural
substrate for this enzyme is arginine, which has a positively-charged side chain and
a zwitterionic core) (220; 221), a zwitterionic cystine complexed by four charged side
chains in the cystine transporter (1xt8) (222), a +2-charged 1,4-diaminobutane in
the putrescine receptor (1a99) (223), and an anionic acetohydroxamic acid inhibitor
sandwiched between two Ni+2 in urease (4ubp) (224). Each of these binding sites can
be viewed in Figure 5.3. Even though some of these structures contain metal ions
and may be considered partially covalent by some, each structure in Binding MOAD
has been verified to be non-covalently bound, according to the primary citation listed
in the PDB for the structure (62).
Figure 5.2: Close up view of the complexes with the highest ligand efficiencies. (A)
Affinity (kcal/mol) compared to size as in Figure 5.1A. (B) Affinity com-
pared to BSA as in Figure 5.1B. Complexes are labeled with their PDB
codes.
Examining the structures that are at the maximum limit of efficiency per BSA
shows three structures in common with efficiency per non-hydrogen atom (1els, 1qft,
and 1xt8). We note that all but one of the additional systems in Figure 5.2B contain
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Figure 5.3: Binding sites of the 11 most efficient complexes. Figures show all residues
within 4Å of the small molecule ligand. The ligand is colored by atom
type. The water is colored red and shown in small spheres. Metal ions are
shown in larger blue spheres. Acidic residues (Asp, and Glu) are colored
red; basic residues (His, Lys, Arg) are colored blue; hydrophobic residues
(Ala, Ile, Leu, Met, Phe, Pro, Val) are colored green; hydrophilic residues
(Cys, Gly, Asn, Gln, Ser, Thr) are colored white; and Tyr and Trp are
colored either green or white depending on the interaction made with the
ligand. The heme is colored with C=light blue and the Iron=brown.



































































Figure 5.4: Figure 5.3 continued.
a charged ligand, see Figure 5.5. Three are lactate dehydrogenase bound to singly-
charged, azol-based carboxylic acids (1t24, 1t25, and 1t26) (225). Other complexes
include 1lah (an ornithine with three charge sites bound to the lysine-argninine-
ornithine-binding protein) (226) and 1y20 and 1pb8 (the glutamate NMDA recep-
tor binding a zwitterion and D-serine, respectively) (227; 228). The only structure
without a charged ligand is ribose bound to D-ribose-binding protein (1drj) (229).
Although the ligand is not charged, the binding site in this structure contains four
charged residues (plus two asparagines and a glutamine) each making hydrogen bonds
with the ribose (Figure 5.5E).
Based on the known size dependence of ligand efficiency, it is not surprising that
the best ligands are small. However, the ten most efficient complexes in 5.6 are still the
ten most efficient when scaled to counter small-size artifacts as suggested by Reynolds
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Figure 5.5: Binding sites of highly efficient complexes (affinity per buried cavity sur-
face area). Figures show all residues within 4 Å of the small molecule lig-
and. The ligand is colored by atom type. Acidic residues are colored red;
basic residues are colored blue; hydrophobic residues are colored green;
and hydrophilic residues are colored white as in figure 5.3. The NAD+
of lactate dehydrogenase is colored blue because the moiety against the
ligand is positively charged. Water is colored red and shown in small
spheres.
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et al. (208). Also, it is important to note that not all small charged molecules in
charged binding sites are highly efficient. If we focus on all highly charged ligands
that contain 5-10 heavy atoms, we see that there are several small molecules that have
more modest efficiencies (-0.40 kcal/mol-atom or poorer). Note that we are using a
rather high cutoff to define less efficient binding as drugs often have efficiencies this
high (a 1-nM ligand with ≥31 non-hydrogen atoms has ≥400 MW and an efficiency
of -0.4 kcal/mol-atom or less). Higher efficiency cutoffs have been recommended for
small molecules (207).
To determine why these ligands are less efficient, we examined all ligands with
5-10 non-hydrogen atoms and more than one charged site (63 complexes, of which
9 have efficiencies of -0.4 kcal/mol or weaker). We used two metrics to determine a
complementary fit between the ligand and protein. First, the average distance be-
tween charged groups of the protein and those of the ligand was used to calculate
the degree of complementarity in a way that is independent of the number of charge
sites in the ligands and pockets. Second, we calculated the exposed surface area and
normalized for the number of non-hydrogen atoms (ESA/size). Figure 5.6 presents
the relationship of efficiency to those metrics. There is a very significant difference
(two-sided Wilcoxon p-value = 0.005) in the efficiencies of complexes that are well
buried (ESA/size < 2 Å2/atom) versus those that are more exposed, Figure 5.6A.
The median efficiency of well-buried ligands is -0.83 kcal/mol-atom versus a median
efficiency of -0.57 kcal/mol-atom for those with ESA/size > 2 Å2/atom (mean ef-
ficiencies are -0.81 versus -0.60 kcal/mol-atom, respectively). Furthermore, if those
efficiencies are compared to the average distance between charged groups (Figure
5.6B), it appears that longer distances severely limit the maximum efficiency possible
for the system. This is in keeping with Nissink’s proposal that maximal efficiency
should be proportional to contacts normalized for ligand size (206).
It should be noted that there are five systems that are not included in Figure
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5.6 because they do not fit our definition of multiply charged. Though each has two
titratable, all include an amine that is tightly coordinated to a metal cofactor, making
it neutral. These systems have very short average contact distances, but very poor
ligand efficiencies. The binding event must include a change in ionization, which
is unfavorable and leads to reduced binding. To avoid confusion, these have been
excluded.
For every increase of 1 Å in the average contact distance, the maximum efficiency
drops by 0.7 kcal/mol-atom. Perhaps a more appropriate view is that a ligand’s
maximum efficiency is reduced by 0.1 kcal/mol-atom for a misfit as small as 0.14
Å in the average contacts between its charged groups and the protein’s. Such sig-
nificant gains/losses for such small spatial changes in the charges may explain why
synthetic modifications to ligands that alter polarization and charge distribution can
be so effective. The importance of charge interactions may support the ideas of op-
timizing charge complementarity that has been developed by Tidor and co-workers
(28; 30; 230). They developed an analytical solution the Poisson-Boltzmann equation
to model the electrostatics of the binding site and an analytical method of optimizing
the charge profile of the ligand to match the calculated electrostatics of the binding
site while also accounting for the desolvation penalty (28; 30; 230).
The importance of charge complementarity in ligand binding can be supported by
other biological binding events. The ability of salt bridges to improve the stability
of protein-protein interactions in protein folding or protein-protein binding may be
supportive (231). Networks of salt bridges have been shown to stabilize proteins,
although the majority of individual salt bridges have been shown to be destabilizing
in proteins (232; 231). In a statistical study of 94 proteins from the PDB, Musafia et
al. found that one-third of all residues participating in salt-bridges were involved in
‘complex’ salt bridges, which they defined as ones involving three or more amino acids
(233). Olson et al., were able to stabilize α-helical peptides by engineering multiple
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Figure 5.6: Relationship between efficiency, exposure, and protein contacts for ligands
with 5-10 atoms and more than one charge site. (A) The distribution of
efficiencies is compared for systems with well buried (black) versus more
exposed sites (white); a cutoff of 2 Å2/atom is used to define the two sets.
(B) Efficiencies are compared to the average contact distance between
charged groups (black circles denote systems with ESA/size < 2 Å2/atom,
and white circles are ESA/size> 2 Å2/atom). The line highlights the drop
in maximal efficiency as the contacts become less favorable: roughly 0.7
kcal/mol-atom for every 1 Å increase in the average contact distance. The
gray background notes systems with more modest efficiencies. The error
bar indicates the standard deviation of the average of two affinity values
reported in the literatures (1; 2).
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Table 5.1: Properties of small charged ligands, all ligands are between five and ten
heavy atoms. Efficiency is affinity/size.









1a99 PUT 7.74 1.290 0.12 2.76
1ahy MAE 4.56 0.570 0.41 3.45
1amk PGA 5.84 0.649 3.16 3.53
1b74 DGN 1.77 0.177 8.36 4.10
1cea ACA 6.74 0.749 10.41 3.22
1czc GUA 3.84 0.426 0.27 2.79
1cze SIN 3.56 0.445 0.49 3.62
1ebg PHA 14.71 1.63 0 2.34
1egh PGA 7.74 0.860 0.93 3.13
1el5 DMG 2.39 0.341 0.07 3.43
1ftj GLU 8.27 0.827 0.13 3.20
1ii5 GLU 8.99 0.894 1.52 3.47
1kc7 PPR 7.50 0.750 7.46 3.75
1kv5 PGA 5.74 0.637 3.54 3.67
1lah ORN 10.22 1.14 0.10 3.19
1m1b SPV 6.33 0.633 0.085 3.38
1o4m MLA 1.90 0.271 9.85 2.69
1o4n OXD 1.90 0.317 7.93 3.96
1pb8 DSN 7.00 1.000 0 2.74
1pot SPD 7.47 0.747 0.02 2.96
1poy SPD 7.47 0.747 0.03 2.54
1qds PGA 5.87 0.652 3.47 3.61
1s89 PGA 7.11 0.790 1.27 3.17
1s8a PGA 5.43 0.600 0.93 3.15
1ssq CYS 8.15 1.16 2.43 2.66
1tok MAE 3.35 0.419 0.23 3.30
1txf GLU 9.84 0.984 0.56 3.17
1usk LEU 8.69 0.966 0.01 3.38
1wdn GLN 9.51 0.951 0.17 2.77
1xt8 CYS 9.51 1.36 0.07 2.75
1y1m AC5 2.47 0.274 1.62 3.04
1y1z 192 4.19 0.523 0.14 2.71
1y20 1AC 7.23 1.03 0.02 2.67
1z16 LEU 7.66 0.851 0.02 3.36
1z17 ILE 8.21 0.913 0 3.37
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Table 5.2: Table 5.1 Continued









1z18 VAL 7.33 0.917 0.01 3.38
1zha PEP 10.05 1.01 1.27 3.09
2aay GPJ 3.76 0.376 0.10 2.69
2dua OXL 3.67 0.611 5.56 2.60
2fpz 270 5.38 0.538 3.68 3.75
2gga GPJ 3.02 0.302 0.10 3.09
2ggd GPJ 5.16 0.516 0.08 2.98
2iqd LPA 6.24 0.780 8.21 3.11
2o1c PPV 6.41 0.713 8.71 3.21
2pt9 2MH 6.05 0.757 0.45 2.99
2pyy GLU 9.10 0.910 0.22 3.02
2qrl OGA 5.43 0.543 10.63 3.17
2rk7 OXL 5.50 0.917 6.01 2.13
2rke SAT 5.55 0.693 2.86 3.68
2v2c PGA 4.63 0.515 3.45 3.61
2v2h PGA 5.12 0.569 3.12 3.91
2v7x MET 6.48 0.720 0.002 3.18
2ypi PGA 6.55 0.728 3.38 3.79
2ze3 AKG 4.14 0.414 3.04 3.45
2zlz GLU 3.64 0.364 7.98 3.37
3bm5 CYS 4.02 0.574 1.88 2.92
3bra AEF 3.67 0.367 10.80 2.76
3bu1 HSM 11.07 1.38 1.60 2.73
3bxe 13P 7.44 0.744 3.08 3.69
3epa PUT 4.48 0.748 0.55 2.71
3epb PUT 5.43 0.906 0.33 2.93
3jdw ORN 4.89 0.543 1.30 3.76
3kiv ACA 6.38 0.709 12.50 2.67
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salt bridges, and found that the amount of stability obtained was cooperative (234).
Networks of salt bridges were also found to be stabilizing by Kumar and Nussinov us-
ing continuum electrostatics to computationally determine the difference in energy of
salt bridges compared to their hydrophobic isosteres, where the partial charges on the
residue were set to zero (235). They found that the stability for most salt bridges was
determined largely by the desolvation penalty; however, the networked salt bridges
were an exception to this phenomenon. In all cases, the networked salt bridge was
found to be stabilizing, despite a large desolvation penalty (235). These networked
salt bridges are homologous to our charged ligands complemented by multiple charged
residues in their binding sites.
Furthermore, Having a higher charge has been noted to be beneficial in metal ion
binding to DNA/RNA. In these cases the dicationic Mg2+ is the preferred counter
ion, compared to Na+, for binding to and stabilizing the phosphate backbone of the
nucleic acid (236).
Coulombic forces are the strongest non-bonded interactions that can be made, and
it may not be surprising that highly efficient molecules utilize the strongest forces per
atom. However, it is surprising that the free energy of binding is high since the
desolvation penalty for charged molecules is insignificant (20). Since these also bind
with relatively high affinity, the penalty must not be as large as previously thought.
In support of the idea that the desolvation penalty is less, almost all of the structures
contain water in the binding sites (Figures 5.3 and 5.5), so not all of the water are
displaced.
A possible reason the desolvation penalty may be lower than initially thought is
that water cannot completely solvate the charges. Many of the systems have lig-
ands and pockets with charges that are closely spaced - too close for water to pack
around each charge independently. It has been shown that the multiply charged
phosphate backbone of DNA, which puts charges close together, leads to “frustrated
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water” around the DNA. The restructuring of water was determined to dominate the
interaction of polyols with DNA (237).
The limits of efficiency may be set by closely packed charged molecules because
we are approaching covalent bonding. Zhang and Houk investigated 1017 enzymes-
transition state complexes as well as 160 enzyme/inhibitor complexes. They found
that transition states, which tend to have covalent or partially covalent bonds to the
protein, had affinities of Ka= 10
16M−1, while the inhibitors only bound with Ka=
109M−1. Additionally, they proposed that any enzyme proficiencies and affinities of
greater than 1011 M−1 (˜15 kcal/mol) would exhibit covalent or partial covalent bond-
ing (34; 213). At heavy atom distances less than 2.5 Å, low barrier hydrogen bonds
exhibit at least a partial covalent nature, and provide stability of 10-20 kcal/mol
(238; 239). Additionally, metals have the ability to exhibit coordinate-covalent bond-
ing to ligands (240). In a few highly efficient complexes, we observe distances less
than 2.5 Å between atoms capable of hydrogen bonding, and some cases have metals
involved in coordinating the ligand. We should note that we do not believe these
systems to be overly influenced by partial bonding characteristics because all are re-
versibly bound, many with affinities in the µM and nM range. furthermore, in the
NOS system (4nos, 1ed4, 1d1w, and 9nse) where the small molecule is near a heme,
the distances to the iron are greater than 4 Å. Also, investigation of the available
electron densities does not indicate partial bonding between the heme and ligand.
5.3.3 Maximum affinity of ligands
What defines the maximum binding affinity of ligands? Kuntz et al. found that
binding affinity plateaus after ˜15 atoms and little improvement is seen for larger
ligands (27). No ligand has a binding affinity of -20 kcal/mol or better. In fact, it
is rare to exceed -15 kcal/mol (0.1% of the complexes in Figure 5.1). Kuntz and
coworkers suggested that other biological factors may be the cause of the limit; for
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instance, molecules with too high of a binding affinity can exhibit clearance problems
in the body (27). Nature would tend to disfavor such molecules.
Kuntz notes that affinities better than -15 kcal/mol are so tight that a ligand will
most likely never dissociate before the protein is degraded. If we assume that kon is
the rate of diffusion of ˜106M−1s−1, then an affinity of -15 kcal/mol (Kd ≈ 10 pM)
would correspond to an average bound lifetime of ˜1 day, which is well within the
lifetime of most proteins (241), but at -16 or -18 kcal/mol, the lifetimes would be
approximately 6 and 187 days, respectively. However, we do not agree that clearance
issues limit binding because protein binding predates complex organisms. Instead,
we hypothesize that once a ligand is bound for the lifetime of a protein, there is no
evolutionary pressure to coax ligands and proteins to associate more tightly.
Reynolds et al. have also discussed the plateau at -15 kcal/mol (208). They
noted that as size increased, the maximal efficiency would decrease. They suggested
the reason for the drop in efficiency was that larger ligands would need to optimize a
larger number of contacts with the protein that would lead to structural compromises
and thus a reduced affinity (208). We acknowledge that our data could also support
this proposal because significant drops in efficiency can come from rather minor misfits
in charge complementarity.
Several other factors may also contribute to the -15 kcal/mol limit to binding.
First, assays which are used to determine binding constants have inherent limitations
when measuring high affinity. We do not believe that this is the cause of the limit.
If it was the cause, the distribution of binding affinities would drop off rapidly as
one approaches the limit, which is not the case. The distributions in MOAD folow
a near-normal distribution with centered at ≈9 kcal/mol. Second, our study has the
limitation of examining only proteins and ligands that can be crystallized. Given
that higher affinity complexes are generally hydrophobic than lower affinity com-
plexes (210), solubility issues may limit the crystallization process. Therefore, these
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structures could be under represented in our dataset. Third, most of the high affinity
complexes are man-made compounds. In the drug design process, once one obtains a
small molecule that binds well enough, there is no need to synthesize tighter binding
small molecules. In fact ADME/Tox issues may discourage pursuing molecules in
this range. Lastly, some affinities of greater than -15 kcal/mol may be incorrectly
considered covalent (34; 213). We may see a limit because Binding MOAD does not
contain covalently bound ligands.
5.4 Conclusions
The difficulty in determining which interactions dominate the contribution to
the free energy of binding has limited the ability of researchers to predict a priori
which small molecules will bind to a target and how tightly. Previously, it had been
suggested that van der Waals and hydrophobic interactions were the driving force for
small molecule binding (4; 27). Our study and other recent studies have pointed to the
importance of electrostatics in driving these interactions (28; 230; 235; 30; 233; 234).
We have looked at the most efficient protein-ligand complexes and have noted that in
all of these complexes the small molecules have at least one charge-charge interaction,
and several of them have multiple charge interactions. We highlight the importance
of not only matching the shape of the binding pocket, but also complementing the
charge profile of the active site.
Although desolvation of charged molecules is a barrier to binding, it appears that
the small size and close proximity of charges leads to water’s inability to fully solvate
the ligand and its binding site. Desolvation of the charged pocket may not be as
difficult to overcome, and many of the systems examined here retain some water in
their sites.
Lastly, we suggest that the ≈15 kcal/mol limit of binding may be due to the fact
that there is no evolutionary pressure to create tighter binding small molecules once
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We have created and utilized Binding MOAD to investigate the biophysical prop-
erties with which proteins bind to ligands. We have also committed to annual updates
of the dataset to keep pace with the growth in the PDB. Binding MOAD has over
thirteen thousand, hand-curated, protein-crystal structures that contain biologically
relevant ligands. Binding affinity data is available for almost one-third of the entries.
In the future, we wish to contain more binding-affinity data (including the addition
of K M for cofactors). Part of the value of Binding MOAD is in its careful curating
and in its size and wealth of data.
Binding MOAD has plans for even greater improvement. We will add similarity-
based searches for the ligands. Furthermore, we have been able to use text-mining
tools to speed up our annotation process, and we are looking to make these tools,
such as BUDA, which was developed in conjunction with Torrey Path, available
online. This will allow users to mine text for additional types of data. Natural
language processing (NLP) is proving to be a valuable tool in aiding the curation
of Binding MOAD. It has significantly sped up the process of the annual updates
of adding data. Such NLP-based, text-mining approaches can be readily applied to
other bioinformatic projects. This technology can be used to extract a wide variety
of data - not just binding information - from the huge body of literature available
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today.
From chapter three we find that most ligands are well buried. This fits the common
paradigm that many contacts between the ligand and the protein are a significant
factor in the specificity of molecular recognition. Since most of our sites are highly
buried, the majority of the cavity surface is defined only by contacts to the protein.
This typically makes the portion of the surface defined by the enlarged ligand surface
(ELS) only a small percentage. Figure 3.9 shows that the largest ligands tend to have
more exposed surface area. These large ligands are typically peptide, nucleic acid, or
sugar chains, and one would expect the patterns of binding such molecules to start
to resemble the patterns of proteins binding macromolecules, such as other proteins
or DNA.
Future efforts with Binding MOAD will allow us to compare broadly the binding
affinity data to the patterns of molecular recognition mined from the PDB. Past
studies have mined subsets of the PDB with various structural analyses of proteins and
ligands (49; 154; 59; 163; 136; 157; 164; 158; 165; 159; 160; 161; 156; 142; 17; 162; 132;
166; 149; 167), but now, we will be able to add another layer of depth to such studies.
There is more to binding affinity than just burying a ligand inside a protein, and all
of the complex issues that go into creating an effective scoring function (168) will
need to be considered in future analyses. Both shape and chemical complementarity
are thought to be the basis of molecular recognition. Our future analyses will have
to consider the chemical complementarity or what “types” of surfaces are solvent-
exposed or interact with the protein, in order to understand how to improve the
enthalpy of binding. We will also need to address the very complex issue of entropic
changes upon binding.
In chapter four of the thesis, physical characteristics of bound ligands in Binding
MOAD were compared between enzymes and non-enzymes as well as high-affinity and
low-affinity complexes. The comparison between ligand sizes for low-affinity versus
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high-affinity binding shows that divergent approaches are likely needed to improve the
affinity of enzyme inhibitors versus those for non-enzymes. The traditional approach
of adding functional groups to fill more of the pocket may work for enzymes, but it
may not be as appropriate for non-enzyme systems. However, making ligands more
hydrophobic appears to aid binding in both enzymes and non-enzymes.
Non-enzymes have higher ligand efficiencies than enzymes, which may be a reflec-
tion of their biological roles. This is also encouraging when considering the druggabil-
ity of non-enzymes. The differences in efficiencies between enzymes and non-enzymes
could not be attributed to the small molecules or the protein alone. Therefore, future
investigations would require one to look at the specific contacts between the protein
and ligand or entropic considerations.
In the pharmaceutical industry, ligand efficiencies have become a metric for evalu-
ating hits from screening campaigns and even candidate compounds.(25) Our results
would caution against applying a rigid standard across all protein targets, since each
individual protein family showed different ligand efficiencies. At the very least, a
cutoff based on ligand efficiency should differ between enzymes and non-enzymes.
Ideally, cutoffs would differ between protein families and only be considered as one
of several guidelines in a selection process.
We have also noted that Binding MOAD provides strong support of several math-
ematical models cited above,(199; 185; 176) particularly those of Hajduk and cowork-
ers. Our results have implications for the development of scoring functions for docking
and predicting druggability of a binding site.(200; 201; 202; 203) The differences be-
tween non-enzymes and enzymes, as well as the differences across enzymatic systems,
underscore the challenges of developing universal functions that perform well across
all systems. Modest improvement might be achieved by developing separate functions
for enzymes and non-enzymes, with even greater improvement expected for functions
trained on specific protein families.
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In chapter five, we have looked at the most efficient protein-ligand complexes in
Binding MOAD and have noted that in all of these complexes the small molecules
have at least one charge-charge interaction, and several of them have multiple charge
interactions. We highlight the importance of not only matching the shape of the
binding pocket, but also complementing the charge profile of the active site.
Although desolvation of charged molecules is a barrier to binding, it appears that
the small size and close proximity of charges leads to water’s inability to fully solvate
the ligand and its binding site. Desolvation of the charged pocket may not be as
difficult to overcome, and many of the systems examined here retain some water in
their sites. Future work to help understand water’s role may be to use isothermal
calorimetry to provide entropic and enthalpic contributions to the free energy of
binding. Additionally, we may be able to use quantum mechanics and molecular
mechanics to investigate the energy of solvation for these highly electrostatic ligands
and binding sites and how it compares to the free energy of solvation of other highly
electrostatic ligands and binding sites which do not bind with high efficiency.
It is also important to note that all of our results are developed from structures
that can be crystallized. Since our dataset is significantly large, we believe our results
to be applicable. However, it will be important in the future to compare the types
of small molecules and proteins in Binding MOAD to the entire space of drug-like
small molecules and protein binding sites, to see if this is true representation of
all complexes. Although no crystal structures are available for all protein-ligand
complexes, it would still be possible to compare the chemical properties of the small
molecule and the amino acid compositions of the proteins. This will be a daunting





Supplemental Information for Chapter 4
A.1 Distributions, box plots, and distribution analysis
see Figures A.1-A.7
Figure A.1: This figure shows the relevant statistical figures regarding the distribution
of size (a heavy) in heavy atoms for the four classifications.
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Figure A.2: This figure shows the relevant statistical figures regarding the distribution
of BSA (Å2) for the four classifications.
Figure A.3: This figure shows the relevant statistical figures regarding the distribution
of ESA (Å2) for the four classifications.
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Figure A.4: This figure shows the relevant statistical figures regarding the distribution
of sqrt(ESA)(Å) for the four classifications.
Figure A.5: This figure shows the relevant statistical figures regarding the distribution
of size ligand efficiency (kcal/mol-atom) for the four classifications.
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Figure A.6: This figure shows the relevant statistical figures regarding the distribution
of BSA ligand efficiency (cal/mol-Å2) for the four classifications.
Figure A.7: This figure shows the relevant statistical figures regarding the distribution
of SlogP for the four classifications.
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A.2 Tukey-Kramer HSD analysis
The datasets do not have normal, Gaussian distributions, so we used square-root
transformations to reduce the skew of the data. With the modification, the Tukey-
Kramer HSD test could be used to examine the means (medians were compared in
the p-values). The large population of the dataset also increased the significance of
this statistical test. The Tukey-Kramer HSD test was performed in SAS with an
exceptionally tight confidence value of 0.0001.
First, high-affinity enzymes are significantly larger than high-affinity non-enzymes
and low-affinity enzymes; however, the non-enzymes are not significantly different
(Table A.1). Since the size distributions are not normal we also analyzed the square-
root transform of the size to shift the right-skewed distribution to a more normal
distribution (Figure A.1). The same trend held when the Tukey-Kramer HSD test
for this variable is performed (Table A.1).
Secondly, in the paper we noted that the high-affinity non-enzymes were signif-
icantly less exposed than the high-affinity enzymes according to the Wilcoxon test.
This is confirmed with the Tukey test. The ESA distribution was not normal, and a
square root transform was used to transform the ESA to a more normal distribution
as well to perform the test (Figures A.2 and A.3). The Tukey grouping confirms
the significance of the difference in the degree of exposure between high-affinity non-
enzymes and high-affinity non-enzymes.
Third, high-affinity non-enzymes are more efficient than high-affinity non-enzymes.
This can also be seen in the Tukey grouping for the two efficiency variables (Tables
A.3 and A.4).
Lastly, we noted that the high-affinity complexes were more hydrophobic, accord-
ing to an increase in SlogP. The high-affinity complexes group in the same group,
while the low-affinity complexes group in separate groups, with the exception of the




Table A.1: This table shows the Tukey-Kramer HSD for size in number of heavy
atoms (sqrt(size)) over the four classifications. Classes indicated with the
same letter are not significantly different at the 99.99% confidence level.
Classification Tukey Grouping Means
High-Affinity Enzymes A 32.898 (5.61754)
High-Affinity Non-Enzymes B 27.558 (5.09263)
Low-Affinity Non-Enzymes B C 26.889 (4.93237)
Low-Affinity Enzymes C 22.613 (4.59402)
Table A.2: This table shows the Tukey-Kramer HSD for sqrt(ESA) over the four
classifications. Classes indicated with the same letter are not significantly
different at the 99.99% confidence level.
Classification Tukey Grouping Means
High-Affinity Enzymes A 11.7061 Å
High-Affinity Non-Enzymes B 8.3495 Å
Low-Affinity Non-Enzymes A 11.4802 Å
Low-Affinity Enzymes B 9.5732 Å
Table A.3: This table shows the Tukey-Kramer HSD for size ligand efficiency over
the four classifications. Classes indicated with the same letter are not
significantly different at the 99.99% confidence level.
Classification Tukey Grouping Means
High-Affinity Enzymes B 0.40555 kcal/mol-atom
High-Affinity Non-Enzymes A 0.49497 kcal/mol-atom
Low-Affinity Non-Enzymes B 0.35009 kcal/mol-atom
Low-Affinity Enzymes B 0.35191 kcal/mol-atom
A.3 Properties after removal of Cofactors
see Table A.6
A.4 Patterns obtained from the non-redundant dataset
See Table A.7 and Figures A.8 and A.9
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Figure A.8: For the non-redundant complexes: distribution of ligand sizes (number
of non-hydrogen atoms) and buried surface area of the pocket (BSA in
Å2) are given in normalized percent frequencies. (a) Comparisons of
high-affinity complexes, (b) low-affinity complexes, (c) enzymes, and (d)
non-enzymes are presented. High-affinity enzymes are shown in dark
blue lines, and low-affinity enzymes are in green lines. High-affinity non-
enzymes are in red, and low-affinity non-enzymes are in gold.
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Figure A.9: For the non-redundant complexes: distribution of ligand efficiencies per
size (-kcal/mol-atom) and per contact (-kcal/mol-Å2) are given in nor-
malized percent frequencies. (a) Comparisons of high-affinity complexes
and (b) low-affinity complexes are presented. High-affinity enzymes are
shown in dark blue lines, and high-affinity non-enzymes are in red lines.
Low-affinity enzymes are in green lines, and low-affinity non-enzymes are
in gold lines.
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Table A.4: This table shows the Tukey-Kramer HSD for BSA ligand efficiency over
the four classifications. Classes indicated with the same letter are not
significantly different at the 99.99% confidence level.
Classification Tukey Grouping Means
High-Affinity Enzymes B 29 cal/mol-Å2
High-Affinity Non-Enzymes A 35 cal/mol-Å2
Low-Affinity Non- Enzymes B C 26 cal/mol-Å2
Low-Affinity Enzymes C 23 cal/mol-Å2
Table A.5: This table shows the Tukey-Kramer HSD for SlogP over the four clas-
sifications. Classes indicated with the same letter are not significantly
different at the 99.99% confidence level.
Classification Tukey Grouping Means
High-Affinity Enzymes A 1.7338
High-Affinity Non-Enzymes A B 0.8631
Low-Affinity Non-Enzymes C -2.1065
Low-Affinity Enzymes B -0.3392
A.5 Patterns obtained from complexes with Kd data
See Table A.8
A.6 Three enzymes with a large range in affinities for a small
range of ligand sizes
In three cases – neuramidase, MTA/SAH nucleosidase, and protocatechuate 3,4-
dioxygenase – we found enzymes that had a very small range of ligand sizes and a large
range in binding affinity, Figure A.10. It is unclear whether the strong overall trends
of 0.62 kcal/mol-atom for neuramidase and 0.71 kcal/mol-atom for MTA/SAH nucle-
osidase are exceptional examples of the correlations expected for enzymes or whether
they indicate that only conservative changes in sizes are allowed for these systems, as
we suggested for non-enzymes. We have presented protocatechuate 3,4-dioxygenase
in Figure S10c to show the only example obtained for an enzyme with overwhelm-
ingly strong influence from small changes, much like arabinose-binding protein in the
125
Table A.6: Median Characteristics of Enzyme and Non-Enzyme Complexes in the
Redundant Set with All Cofactors Removed from Consideration (includes
Kd, Ki, and IC50 values for affinity). The values are nearly unchanged from
































































a. Ligand size is given in the number of non-hydrogen atoms.
b. Percent exposure is ESA/(ESA+BSA) for each individual ligand.
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Table A.7: Median Characteristics of Protein-Ligand Binding in Enzymes and Non-



















































































a. Proteins are grouped by 90% sequence identity and represented by the complex
with the highest affinity ligand
b. All differences noted in the comparisons sections have a statistical significance of
>96% (p<0.04).
c. Ligand size is given in the number of non-hydrogen atoms.
d. Percent exposure is ESA/(ESA+BSA).
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Table A.8: Median Characteristics of Enzyme and Non-Enzyme Complexes in the


















































































a. All points comparing the averages have a statistical significance of 99.1% or better.
b. Ligand size is given as the number of non-hydrogen atoms.
c. Percent exposure is ESA/(ESA+BSA).
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non-enzymes Figure A.10b. All the ligands for protocatechuate 3,4-dioxygenase have
10 or 11 non-hydrogen atoms, and it appears to be an example of a small, restricted
binding site.
see Figure A.10
Figure A.10: Examples of enzyme families that show exceptionally strong response
and limited size ranges for ligands. (a) Wild-type (Ki as black trian-
gles, IC50 as black circles) and the R292K-mutant (Ki as gray triangles,
IC50 as gray circles) of neuraminidase show the same strong response to
conservative changes to the ligands. (b) Sizes and Ki (black triangles)
for ligands bound to MTA/SAH Nucleosidase. (c) The data points for
the ligands bound to protocatechuate 3,4-dioxygenase cannot be fit to
a line because of the near vertical arrangement.
A.7 Total amino acid content in enzymes and non-enzymes
The differences in binding sites of enzymes and non-enzymes (Figure 4.6) are not
due to inherent differences in the amino acid composition of the proteins.
see Figuer A.11
A.8 Classes of proteins that make up the high-affinity com-
plexes
It should be noted that the number of enzymes and non-enzymes in the non-
redundant dataset are slightly larger than the lists below. This is because a protein
may be represented more than once if it comes from different species that have less
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Figure A.11: Amino acid content in enzymes and non-enzymes, given in normalized
percent frequencies. Amino acids are listed by hydrophobic, aromatic,
cationic, anionic, and hydrophilic. “X” denotes cofactors, unnatural
amino acids, and covalent modifications on the protein (does not include
crystallographic additives in the crystal structure).
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than 90% sequence identity. Any enzyme listed in the non-enzyme list is an example
of allosteric binding. Though we made every effort to locate these examples, it is
possible that some are contained in the enzyme set, rather than the non-enzyme set,
because of the EC notation inherent to the Binding MOAD dataset.
HIGH-AFFINITY COMPLEXES OF ENZYMES ARE COMPRISED OF:
1. ALDOSE REDUCTASE
2. 1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE
3. 2-DEHYDRO-3-DEOXYPHOSPHOOCTONATE ALDOLASE
4. 3-HYDROXYACYL-COA DEHYDROGENASE TYPE II
5. 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE
6. 5’-DEOXY-5’-METHYLTHIOADENOSINE PHOSPHORYLASE
7. A/G-SPECIFIC ADENINE GLYCOSYLASE
8. ACETOLACTATE SYNTHASE, MITOCHONDRIAL
9. ACETYLCHOLINESTERASE











20. ANGIOTENSIN CONVERTING ENZYME
21. ARGINASE
22. ASPARTATE CARBAMOYLTRANSFERASE CATALYTIC CHAIN
23. B. ANTHRAX LETHAL FACTOR






30. BIFUNCTIONAL DIHYDROFOLATE REDUCTASE-THYMIDYLATE SYN-
THASE
31. BIFUNCTIONAL PURINE BIOSYNTHESIS PROTEIN PURH
32. CAMP-DEPENDENT PROTEIN KINASE
33. CAMP-SPECIFIC 3’,5’-CYCLIC PHOSPHODIESTERASE 4B
34. CAMP-SPECIFIC 3’,5’-CYCLIC PHOSPHODIESTERASE 4D
35. CARBONIC ANHYDRASE I
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44. CELL DIVISION PROTEIN KINASE 2
45. CGMP-INHIBITED 3’,5’-CYCLIC PHOSPHODIESTERASE 3B





51. COAGULATION FACTOR VII
52. COAGULATION FACTOR X











63. DIPEPTIDYL PEPTIDASE IV




68. ENOYL-[ACYL-CARRIER PROTEIN] REDUCTASE
69. EPIDERMAL GROWTH FACTOR RECEPTOR KINASE





75. FERREDOXIN: NADP+ REDUCTASE
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76. FIBROBLAST COLLAGENASE






83. G25K GTP-BINDING PROTEIN
84. GLUCOAMYLASE
85. GLUCOSE-6-PHOSPHATE ISOMERASE
86. GLUTATHIONE S-TRANSFERASE (ISOENZYME 3-3)
87. GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE
88. GLYCOGEN SYNTHASE KINASE-3 BETA
89. GUANINE PHOSPHORIBOSYLTRANSFERASE
90. H-2 CLASS I HISTOCOMPATIBILITY ANTIGEN, K-B ALPHA CHAIN
91. HEAT SHOCK PROTEIN 90
92. HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA POLYMERASE
93. HEPATOCYTE GROWTH FACTOR RECEPTOR





98. HUMAN BETA2 TRYPTASE
99. HYPOTHETICAL PROTEIN DPP4
100. HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE
101. IMP-1 METALLO BETA-LACTAMASE
102. INDOLE-3-GLYCEROL PHOSPHATE SYNTHASE
103. INDUCIBLE NITRIC OXIDE SYNTHASE
104. INOSINE-5’-MONOPHOSPHATE DEHYDROGENASE





109. LIVER GLYCOGEN PHOSPHORYLASE
110. MATRILYSIN
111. MATRIPTASE




115. MITOGEN-ACTIVATED PROTEIN KINASE 10
116. MITOGEN-ACTIVATED PROTEIN KINASE 14
117. MMP-13
118. MTA/SAH NUCLEOSIDASE







126. NITRIC-OXIDE SYNTHASE, BRAIN
127. NRH DEHYDROGENASE [QUINONE] 2
128. ORNITHINE TRANSCARBAMOYLASE
129. OROTIDINE 5’-PHOSPHATE DECARBOXYLASE
130. PEPTIDE DEFORMYLASE 1
131. PEPTIDYL-PROLYL CIS-TRANS ISOMERASE A
132. PHENAZINE BIOSYNTHESIS PROTEIN PHZD
133. PHENOL 2-HYDROXYLASE COMPONENT B
134. PHOSPHOLIPASE A2
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135. PHOSPHOLIPASE C DELTA-1





141. PROTEIN KINASE B
142. PROTEIN KINASE C, THETA TYPE
143. PROTEIN KINASE CK2, ALPHA SUBUNIT
144. PROTEINASE *A (COMPONENT OF THE EXTRACELLULAR FILTRATE
PRONASE)
145. PROTEIN-TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1
146. PROTO-ONCOGENE SERINE/THREONINE-PROTEIN KINASE PIM-1
147. PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL
148. PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC KINASE DO-
MAIN
149. PURH (BIFUNCTIONAL PURINE BIOSYNTHESIS PROTEIN)
150. PURINE NUCLEOSIDE PHOSPHORYLASE
151. PYRUVATE DEHYDROGENASE E1 COMPONENT
152. RAP1A
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153. RAS-RELATED PROTEIN RAL-A
154. RENIN
155. RESPIRATORY NITRATE REDUCTASE 1
156. RETINOL DEHYDRATASE
157. REVERSE TRANSCRIPTASE P66 SUBUNIT
158. RIBONUCLEASE, PANCREATIC
159. RIBULOSE BISPHOSPHATE CARBOXYLASE/OXYGENASE
160. ROUS SARCOMA VIRUS PROTEASE
161. SACCHAROPEPSIN
162. SALICYLIC ACID-BINDING PROTEIN 2
163. SARCOPLASMIC/ENDOPLASMIC RETICULUM CALCIUM ATPASE 1
164. SCYTALONE DEHYDRATASE
165. SECRETED ASPARTIC PROTEINASE
166. SERINE/THREONINE PROTEIN PHOSPHATASE 1 GAMMA (CATALYTIC
SUBUNIT)
167. SERINE THREONINE-PROTEIN KINASE 6
168. SERINE/THREONINE PROTEIN PHOSPHATASE PP1-GAMMA
















184. TYPE 1 17 BETA-HYDROXYSTEROID DEHYDROGENASE
185. TYROSINE-PROTEIN KINASE ITK/TSK
186. TYROSINE-PROTEIN KINASE JAK2
187. TYROSINE-PROTEIN KINASE ZAP-70
188. TYROSYL-TRNA SYNTHETASE
189. UBIQUINOL-CYTOCHROME-C REDUCTASE COMPLEX CORE, MITO-
CHONDRIAL
190. UBIQUITIN-PROTEIN LIGASE E3 MDM2
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191. URACIL-DNA GLYCOSYLASE
192. URIDINE PHOSPHORYLASE, PUTATIVE
193. UROKINASE-TYPE PLASMINOGEN ACTIVATOR
194. WEE1-LIKE PROTEIN KINASE
195. XYLOSE ISOMERASE (GLUCOSE ISOMERASE)
HIGH-AFFINITY COMPLEXES OF NON-ENZYMES ARE COMPRISED
OF:
1. ACETYLCHOLINE-BINDING PROTEIN
2. ANDROGEN RECEPTOR LIGAND BINDING DOMAIN
3. ARABINOSE BINDING PROTEIN
4. ARTIFICIAL NUCLEOTIDE BINDING PROTEIN (ANBP)
5. AUXIN-BINDING PROTEIN 1
6. AVIDIN-RELATED PROTEIN AVR4
7. BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 7 ML-IAP
8. CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR
9. CELLULAR RETINOL BINDING PROTEIN II
10. CIRCULARLY PERMUTED CORE-STREPTAVIDIN E51/A46
11. CRABP-II
12. C-TERMINAL BINDING PROTEIN 3 (CTBP/BARS: A DUAL-FUNCTION
PROTEIN INVOLVED IN TRANSCRIPTION COREPRESSION AND GOLGI
MEMBRANE FISSION)
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17. DUAL ADAPTOR OF PHOSPHOTYROSINE AND 3-PHOSPHOINOSITIDES
18. ESTROGEN RECEPTOR ALPHA
19. ESTROGEN RECEPTOR BETA
20. EUKARYOTIC TRANSLATION INITIATION FACTOR 4E
21. FATTY ACID-BINDING PROTEIN, BRAIN
22. FEMALE-SPECIFIC HISTAMINE BINDING PROTEIN 2
23. FIMH PROTEIN
24. FMN-BINDING PROTEIN
25. GLUTAMATE RECEPTOR 2
26. GLUTAMATE RECEPTOR, IONOTROPIC KAINATE 1
27. GLUTAMATE RECEPTOR, IONOTROPIC KAINATE 2
28. GLYCOGEN PHOSPHORYLASE (ALLOSTERIC BINDING SITE)
29. HISTIDINE-BINDING PROTEIN COMPLEXED WITH L-HISTIDINE
30. HIV-1 REVERSE TRANSCRIPTASE (NON-NUCLEOSIDE INHIBITORS)
31. HPV11 REGULATORY PROTEIN E2
32. HUMAN NUCLEAR CAP-BINDING-COMPLEX
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33. IMPORTIN ALPHA-2 SUBUNIT
34. INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR TYPE 1
35. INTEGRIN ALPHA-L (LFA-1)
36. KINESIN-LIKE PROTEIN KIF11 KINESIN-MOTOR DOMAIN
37. KINESIN-RELATED MOTOR PROTEIN EG5
38. L-*ARABINOSE-BINDING PROTEIN
39. LEUCINE-SPECIFIC BINDING PROTEIN
40. LYSINE, ARGININE, ORNITHINE-BINDING PROTEIN (AMINO ACID TRANS-
PORT)
41. MALTOSE-BINDING PERIPLASMIC PROTEIN
42. NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN
43. NUCLEAR RECEPTOR (STEROIDOGENIC FACTOR-1 LIGAND BIND-
ING DOMAIN)
44. NUCLEAR RECEPTOR ROR-BETA
45. OSMOPROTECTION PROTEIN (PROX)
46. PERIPLASMIC OLIGO-PEPTIDE BINDING PROTEIN
47. PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA LIG-
AND BINDING DOMAIN
48. PEROXISOMAL TARGETING SIGNAL 1 RECEPTOR
49. PROGESTERONE RECEPTOR
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50. PUTATIVE AMINO-ACID TRANSPORTER PERIPLASMIC SOLUTE-BINDING
PROTEIN
51. RAB PROTEINS GERANYLGERANYLTRANSFERASE COMPONENT A 1
52. RETINOBLASTOMA PROTEIN
53. RETINOIC ACID RECEPTOR BETA
54. RETINOIC ACID RECEPTOR RXR-ALPHA
55. RETINOL BINDING PROTEIN
56. SEX HORMONE-BINDING GLOBULIN
57. TETRACYCLINE REPRESSOR
58. THYROID HORMONE RECEPTOR BETA-1
59. TRANSCRIPTION ELONGATION PROTEIN NUSA
60. TRANSTHYRETIN
61. TYROSINE-PROTEIN KINASE BTK
62. TYROSINE-PROTEIN KINASE TRANSFORMING PROTEIN SRC
63. VITAMIN D NUCLEAR RECEPTOR
64. VITAMIN D3 RECEPTOR
65. ANTIBODIES
(a) 28B4 FAB (CATALYTIC)
(b) 29G11 FAB
(c) 4-4-20 (IG*G2A=KAPPA=) FAB FRAGMENT
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(d) DIELS ALDER CATALYTIC ANTIBODY FAB
(e) ANTI-TESTOSTERONE FAB
(f) BLUE FLUORESCENT ANTIBODY (19G2)
(g) CATALYTIC ANTIBODY FAB 15A9
(h) CATALYTIC ANTIBODY FAB 34E4
(i) CHIMERIC 48G7 FAB
(j) ANTI-MORPINE FAB 9B1
(k) HLA CLASS I HISTOCOMPATIBILITY ANTIGEN WITH FAB




(p) CATALYTIC IMMUNOGLOBULIN MS6-164
(q) MONOCLONAL ANTIBODY FV4155
(r) TAB2
(s) CHA255 IMMUNOGLOBULIN
(t) IGG2B (KAPPA) FAB





The p53 tumor suppressor, also known as the guardian of the genome, is vital
in cell cycle regulation, DNA repair, and apoptosis (63; 64; 65). Mutations in p53
are seen in approximately half of all human cancers (66). Where p53 is in wild-type
form, it is inhibited by over-expression(67; 68) or amplification(69) of murine double
minute 2 oncoprotein (MDM2; also referred to as HDM2 in human). Reactivation of
p53 through inhibition of the p53-MDM2 interaction has been shown to be a novel ap-
proach for initiating or enhancing cancer cell death (70; 71). A better understanding
of MDM2 dynamics is important for the design of more selective and potent inhibitors
of the MDM2-p53 interaction.
A crystal structure containing residues 25 to 109 of MDM2, and residues 17 to
29 of p53, was solved in 1999 (1YCR) (72). This showed two approximately similar
sub-domains, which come together to form a binding cleft for p53. Three side-chains
of p53 (Phe19, Trp23, and Leu26) fill the relatively deep hydrophobic pocket. This
crystal structure has been the basis of several dynamics studies (73; 74; 75; 76). In all
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cases, the authors compared the MDM2-p53 complex to that of apo-MDM2, which
was generated by removing the peptide from the structure prior to the dynamics
simulation.
Barrett et al. utilized CONCOORD (77), a non-Newtonian method of ensemble
generation to examine protein motion (73). They found that the principle mode
of apo-MDM2 was a bilobal flexing, or breathing, of the protein; this motion was
greatly reduced in the p53 bound complex. Previous work in our lab has utilized
MD simulations to develop receptor based pharmacophore models. The models were
used to identify five small-molecule inhibitors of the MDM2-p53 interaction (78; 76).
Espinoza-Fonseca and Trujillo-Ferrara presented two 35-ns molecular dynamics (MD)
simulations; again they demonstrated that the apo-MDM2 had a highly flexible and
narrow cleft (75). Conversely, when the p53 peptide was bound, the cleft was more
stable and wider. They also reported important side-chain motions in residues Leu57,
Tyr67, His96, and Tyr100 which were present in apo MDM2 but not MDM2-p53, and
suggested that these motions are involved in the molecular recognition of p53 and
other ligands (75). A recent molecular study of the X. laevis by Espinoza-Fonseca
and Garcia-Machorro has indicated that aromatic-aromatic interactions are involved
in the interaction of p53 and MDM2 (242).
The deep, well-defined binding cleft shown in the crystal structure of MDM2-p53,
suggested that the MDM2 cleft would be a suitable target for small molecule inhibitors
(243). To date, several small molecule inhibitors of the MDM2-p53 interaction have
been reported and the subject of recent reviews (79; 80; 81)). Through structure-
based design, a nano-molar inhibitor of MDM2 (Ki = 3 nM) has been discovered
(244). The crystal structure of MDM2 has been solved with both a member of the
nutlin class (1RV1)(82) and a 1,4,-benzodiazepine-2,5-diones (1T4E) (83). A total of
ten structures of MDM2 are found in the Protein Data Bank (115), all with a small
molecule bound, and all missing the N-terminal “lid” residues.
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The sequence of MDM2 residues 16-24 is highly conserved in mammals (84). NMR
studies show that these residues form a lid which stabilizes MDM2 in the absence of
p53 (84; 86; 85). When the lid is closed, it shields the hydrophobic binding cleft of
MDM2. Ile19 occupies the same space as Pro27 of the bound p53 peptide, and makes
interactions with His96, Arg97, and Tyr100 (85). The lid unfortunately is not well-
defined in the apo-NMR structure, 1Z1M, but this was the first and only structure
including it when we began this study (85). NMR studies on MDM2 residues 17-
125 indicate the apo-MDM2 structure exists in two states, with the dominant state
being closed, and the minor state open (245). There is also evidence that the lid is
phosphorylated on Ser18 (86). When the lid is phosphorylated it binds the pocket
and inhibits p53 association (86). The unphosphorylated lid is easily displaced by
p53, as well as small molecule and peptidic inhibitors (84). It is thought that the
two sub-domains then swing apart by 3-4 Å to deepen the binding cleft, allowing
the peptide or inhibitor to completely bind (84; 86; 85). In this study, we present
the preliminary results of molecular dynamics simulations of the full-length apo N-
terminal of MDM2 and the nutlin inhibitor from the x-ray crystal structure, which
has an IC50 of 0.14 µM (82). The structure of the nutlin is show in Figure B.1.
B.2 Methods
An NMR ensemble of the apo N-terminal, p53 binding region of MDM2 is avail-
able (1Z1M) (85). This ensemble consists of 24 structures and provided the starting
conformations for the protein in each set of Langevin dynamics simulations. The
NMR structure was from a more complete construct (residues 2-118) than that used
for the available x-ray structures. However, residues 2-6 had no assignments and were
assumed to be disordered (85). Therefore, the N-terminal residues 1-6, Met1, Val2,
Arg3, Ser4, Arg5, and Gln6, were built in with PyMOL (141). The resulting protein
represents the entire p53-binding region, including the binding site lid.
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Figure B.1: Structure of nutlin inhibitor used in molecular dynamics simulation.
The crystal structure of a nutlin small molecule with MDM2 (1RV1)(82) was
overlaid on each structure from the NMR ensemble. The MDM2 protein was removed
from 1RV1, leaving just the nutlin in the binding cleft of the NMR structure. To
attempt to recreate a binding event, the nutlin was then translated to two positions
where the inhibitor RMSD values from the x-ray structure were 13.0 and 16.8 Å,
but the original orientation of the ligand was preserved. From these conformations,
two positions other were obtained by rotating the ligand 180 degrees on itself after
translation, yielding nutlin RMSD values of 15.7 and 19.3 Å respectively.
Hydrogen atoms were placed by using the LEaP (246) module in AMBER (247).
FF03(248) was used together with parameters for the nutlin were obtained using
the antechamber module and GAFF(249) with AM1-BCC charges (250). Langevin
dynamics were performed, with a collision frequency of 1 ps−1, and a timestep of
1 fs. No nonbonded cutoff was applied. Aqueous solvation was modeled implicitly
with a modified generalized Born model (251). The system was minimized, and then
gradually heated to 300K. All heavy atoms were harmonically restrained, with the
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force decreasing from 2 to 0.1 kcal/mol-Å2 in four steps, for a total of 80 ps. Then
just the backbone atoms were harmonically restrained at 0.1 kcal/mol-Å2 for 50 ps.
The last step of equilibration was 100 ps of unrestrained Langevin dynamics at 300K.
All production simulations were unrestrained at 300K for 1 ns.
The ptraj module in AMBER was used to generate snapshot structures every 1
ps from each simulation. These structures were overlaid using a Gaussian-weighted
alignment tool (252). This superimposed the core of the protein, without the highly
flexible N- and C-terminus tails skewing the alignment. The MMTSB toolset(253)
was used to calculate the RMSD of the flexible residues in the binding site: Leu63,
Tyr73, His96, and Tyr100. It was also used to calculate the RMSD of the nutlin
ligand in each structure to the position of the ligand in the crystal structure. The
center of mass of the nutlin ligand was also calculated and compared to the center of
mass in the crystal structure.
The dynamics of the cleft were estimated by using NACCESS(50) to calculate the
solvent accessible surface area of the residues lining the binding pocket, while ignoring
the ligand (colored in blue in Figure B.2). The width (w) of the binding site is the
length of the vector between the Cα of Leu63 and the Cα of Tyr100. The length (l)
of the binding site is the length of the vector between the Cα of Gln24 at the base of
the lid and the Cα of Tyr73 at the other end of the binding cleft (see Figure B.2).
The dynamics of the cleft with respect to the binding site are determined by two
angles, the angle of the lid with respect to the cleft and the shear angle with respect to
the plane of the binding cleft. The (ϕ) angle is formed between the lid vector formed
by the Cα of Gln22 and the Cα of Thr16 or the center of mass of the lid residues
(residues 16-24). For our discussion we use the center of mass of the lid residues since
it is most representative of the lid. The shear of the binding site (θ) is the angle
projected by the lid vector on the plane of the binding site formed by the width and
length vectors. See Figure B.2 for more details. A completely closed lid will have ϕ
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Figure B.2: This figure shows the definition of the angles (θ and ϕ of the lid with
respect to the binding pocket. The length(l) and width(w) of the binding
pocket are shown. The residues on the surface of the binding pocket are
colored blue.
= 0 and θ = 0. The distance from this point is then defined by d =
√
(ϕ2 + θ2) and
will be used as a direct measure of openness.
B.3 Result and Discussion
B.3.1 Lid Dynamics
Initial comparisons of the RMSD of the ligand in the snapshots compared to
the RMSD of the ligand in the x-ray structure indicate four simulations were able
to reproduce the binding of the inhibitor into the binding site (RMSD< 3 Å). One
additional structure reproduced the fit but only stayed in the bound conformation
for a short period of time at the end of equilibration. It is left off of Figure B.3,
since the inhibitor is not in the bound conformation during nearly the entirety of the
production run. The dynamics of the lid in each of the simulations that reproduce
the pose varies. In the simulation which obtained the ligand pose closest to the small
molecule in the x-ray, the lid opens very wide, which allows the small molecule to
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enter the pocket (Figure B.3A). This is the only structure to reproduce the crystal
structure, but also have the lid open. The other three cases display of variety of lid
dynamics. In fact, during the second trajectory the small molecule gets caught in
the N-terminal residues and is brought close to the pocket by these residues (Figure
B.3C). In the third simulation the lid is just open enough to allow the ligand to enter
the binding site, and then closes down on the ligand and binding site. In the fourth
system the lid opens during equilibration then comes closes on part of the pocket
when the small molecule binds.
The lid has been shown previously to have large fluctuations upon small molecule
binding. In an NMR study by Showalter et al. the apo- form of MDM2 was shown to
predominantly favor a closed lid state, while the state with 13-residues of p53 bound
was only found in the open lid conformation (245). Coordinates for this structure
were not deposited in the PDB for comparison. However, the bound state does not
appear to be open in the four simulations that represent the nutlin binding mode. In
the third best simulation, that represents the bound state of the ligand, the lid has
closed on the small molecule. Figure B.4 further demonstrates this since the majority
of structures with a center of mass near the ligand in the crystal structure have a
relatively closed lid. Additionally, all snapshots where the ligand is unbound (> 40 Å
from the x-ray pose) have a lid that is open, which contradicts the NMR findings, but
since there are so few snapshots that are unbound, compared to bound, it may be an
artifact of the ligand in the simulation, which on occasion interacts with unstructured
N-terminal residues, influencing the lid.
What also can be seen in Figure B.4 is that many of the snapshots have a small
molecule within 5 Å of the crystal structure ligand, but only four simulations were
able to reproduce the binding mode of the crystal structure. This indicates that
more sampling may be necessary in these simulations to allow the ligand to adopt
the appropriate conformation. In addition, since the lid is shown to bind in the
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Figure B.3: This figure shows the RMSD between the snapshot pose and the x-ray
pose of the nutlin inhibitor, and the openness of the lid in each snapshot
of the four simulations that reproduced the ligand pose of the x-ray crys-
tal structure (1RV1). Figure A is the simulation that had the smallest
RMSD, and Figures B, C and D had the second, third and fourth small-
est RMSD, respectively. Negative time from the simulation indicates the
equilibration time period. This is included in the figure since the ligand
does interact with the protein before the start of the production run.
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Figure B.4: This figure is a histogram of the distance between the center of mass of
the inhibitor in the snapshot and the center of mass of the inhibitor in
the x-ray structure (1RV1), and the openness of the pocket. The colors
represent the number of structures in each bin. Bins were created for
every 2 Å for the distance between the center of mass and 20 degrees for
the openness of the lid.
pocket when it is phosphorylated and p53 does not bind, the frequency at which it is
phosphorylated may have some impact on lid dynamics upon small-molecule binding
(86).
B.3.2 Pocket Dynamics
In each of the four cases that reproduced the conformation of the ligand in the
binding site, the pocket begins in an exposed conformation (˜500 Å2). In three of
the four cases the pocket decreases in exposed surface by ˜200-300 Å2 when the lig-
and bound, Figure B.5. Although in the simulation that most closely reproduces
the crystal structure position of the ligand, the pocket remains somewhat exposed
with SASA ≈400 Å2, which may be due to the lid being completely displaced in this
simulation (see Figure B.3). The change in SASA upon binding is in agreement with
previous molecular dynamics simulations by Espinoza-Fonseca and Trujillo-Ferrara
(75). They have noted that the SASA of the binding pocket is ˜100 Å2 less in the
complex bound to a p53 peptide compared to the apo-MDM2 system. Their study
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cites an experimental decrease in solvent accessible surface area of ˜200 Å2, but do
not a provide reference for the value (75). The change in surface area calculated in
their study is with respect to all the residues in the structure. However, we aimed to
investigate the surface area of the pocket, not the entire protein, and therefore only
calculated the SASA of the residues in the binding site. Our finding is also consistent
with high-temperature molecular dynamics simulations to investigate unfolding of
MDM2 performed by Chen and Luo, in which MDM2, upon unfolding, tertiary con-
tacts decrease as the number of native binding contacts of the p53 peptide decrease
(74). They suggested that this is, in actuality, a folding pathway as the p53 peptide
binds. Therefore, ligand binding induces folding of MDM2 (74).
Only the four simulations mentioned above of the 96 simulations have reproduced
the binding site ligand conformation. Therefore, we looked at the ensemble of all
snapshots across all simulations. From Figure B.6, we see that as the ligand ap-
proaches the pocket, or as the center of mass is getting closer to the bound ligand,
(up until about 20 Å from the pocket) the SASA remains about the same, but once
inside that range the pocket begins to become less exposed. The calculations of SASA
were performed with the ligand removed from the structure, therefore the change in
SASA of the residues around the pocket reflects a “closing” of the pocket. Breaking
the SASA down into contributions from the individual residues is possible. Future
analysis will break down the SASA of the binding pocket. This may indicate which
residues are contributing most to the change in surface area, and show which residues
in the binding site are most flexible and/or necessary for binding. We hypothesize
that the most flexible residues would be Leu57, Tyr67, His96, and Tyr100, as they
were determined to change the most upon p53 peptide binding by Espinoza-Fonseca
and Trujillo-Ferrara (75). This can be confirmed by examining the root-mean-square
fluctuation of these residues as the small molecule binds to the pocket. However,
initial investigations of the RMSD of these four residues do not indicate significant
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Figure B.5: This figure shows the RMSD between the snapshot pose and the x-ray
pose of the nutlin inhibitor, and the exposed surface area of the pocket
in each snapshot of the four simulations which reproduced the ligand
pose of the x-ray crystal structure (1RV1). Figure A is the simulation
that had the smallest RMSD, and Figures B, C and D had the second,
third and fourth smallest RMSD, respectively. Negative time from the
simulation indicates the equilibration time period. This is included in
the figure since the ligand does interact with the protein before the start
of the production run.
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Figure B.6: This figure is a histogram of the distance between the center of mass of
the inhibitor in each snapshot and the center of mass of the inhibitor in
the x-ray structure (1RV1), and the SASA of the binding pocket. The
colors represent the number of structures in each bin. Bins were created
for every 2 Å for the distance between the center of mass and 40 Å2 for
the SASA of the pocket.
dynamics.
B.4 Conclusion
From molecular dynamics simulations of the complete, apo-MDM2 NMR structure
we were able to investigate the dynamics of the lid and the binding pocket as a small
molecule enters the binding site. We notice that the lid provides different dynamics
than previously indicated when the p53 peptide bound. Here the lid appears to be
in a closed state when the small molecule is bound, and is potentially open when
unbound. Secondly, upon investigation of the binding pocket, it appears that as
the small molecule nears the pocket, the pocket closes and becomes less exposed to
solvent. Future directions of the study will continue to investigate the behavior of
the residues that line the pocket. Knowledge of the residues that display a change in
their SASA upon binding may provide insight into important motions in the binding
of the nutlin inhibitor.
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APPENDIX C
Protein Data Bank Filtering and Updating
Binding MOAD
First download the PDB, filter the PDB entries through a series of perl scripts,
and then hand check them. After these scripts, the PDBs are aligned against each
other using BLAST to put them into protein families of high sequence similarity. The
data is then ready to put up on wasabi (on bindingmoad.org).
C.1 Download PDB Files
1. Download the latest PDBs from the Protein Databank using rsync
source moad update scripts/rsync PDB.justPDB.sh
This script is downloaded from www.rcsb.org, and modified to have the correct
paths and directories on curry.
C.2 Filtering the PDB files
1. Create a list of all PDB files.
ls pdb directory > pdb date.txt
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2. Open “pdb date.txt” in vi or an editor of your choice and remove the .ent
extensions and save it.
diff MOAD [last year]/[last year] all entries already ran > differences file
grep ‘>’ differences file > new PDBs date.txt
3. Open the “new pdbs date.txt” file and remove the leading ‘>’, and save it.
4. Run the MOAD filtering scripts, these will take a day or so depending on how
you break it up):
5. The caution file and the caution covalency file have some duplicates. Therefore
you must merge the accept, caution, anc caution covalency files into one. To do
this I have written merge accept caution files.pl. The syntax for running this
is:
6. Make a list of PDBS to check.
C.3 Scrape HTML and load data into BUDA
1. Get a list of Pubmed IDs from NCBI and RCSB.
2. Merge the two lists (giving preference to NCBI over RCSB, as they have ap-
peared to be more recent, and more correct)
3. Get a list of the DOIs using the list of Pubmed IDs,
4. Get the HTML files using the DOIs.
5. Rename the DOI files based on Pubmed ID.
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C.4 Checking the heavy atoms
1. Run the get hets.pl script which will produce a file of all of the het groups in
the particular pdb files (This may take a while depending on how many new
structures there are):
2. Run the unique hets.pl script to only make a list of the unique het groups.
3. Run the check heavy atoms.pl. Be sure to change the names of the output files
that are listed on lines 51 and 52 of the script.
4. These two lists are checked by hand to see what is wrong and why there are
too many or too few atoms, this information should also be entered on columns
M (comment) and N (percentage missing or too many) on the .csv spreadsheet
generated in the first section.
5. Find the differences between the new het list and the old list of het groups that
have been checked. These are HETs that still need to be checked for validity.
6. Create a new .csv which has a comment regarding the new het atoms to check.
The new hets should be in a list with a single line for a het group with no
spaces.
C.5 Literature Searching
1. Log into BUDA (The web address will be given by Peter Dresslar).
2. Go through each pdbid, if it says caution in the comment section of the ligand
(or the first column has a 2 or a 3 three, check to see if the ligand/structure
is valid and that it is not just a crystal additive, otherwise check to see if the
ligand is on the list of new HET groups. If the ligand is on the list of new
HET groups make a decision if it should be rejected, cautioned, or accepted
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HET group (if it contains a metal check to see if part of the HET group should
be considered a ligand). If everything is valid search the paper for a binding
constant (Ki, Kd, or IC50). Search terms that I use to go through the .pdf file














(n) free energy of binding
(o) binds with millimolar affinity
(p) binds with micromolar affinity
(q) binds with nanomolar affinity
(r) Km
3. Once you find a binding constant, check to see what ligand and structure it
is associated with. The value must be for the same organism and form of the
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protein (mutant or wild-type). If multiple binding constants exist choose the
one that was determined at experimental conditions that most closely resembles
the crystal conditions, with preference of Kd over Ki over IC50.
4. Mark the entry as “COMPLETED”
C.6 Export Entries
1. Export the entries and download the “bindings” and “messages” files.
2. Run the create csv for binning.pl script with the csv’s fom the export.
3. Remove any structures that have been rejected in BUDA.
4. This list also has entries from previous years, therefore you need to use the list
of structure we had done in previous years to take them off the list. This only
should be the structures from the new update. This will then be used for the
merge.py script after binning.
C.7 Pre-Binning
1. Get the list of PDBs in current moad (with obsoletes remove) from directory.
2. Obtain the old csv from current MySQL database.
3. Obtain the list of obsolete entries from the Protein Data Bank (rcsb.org) and
remove any obsoleted entries from the old csv file.
4. Make a list of the old (without the obsolete) and new entries in MOAD.
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C.8 Binning
1. Run the script to get the ec numbers and fasta information: Running this script
produces three files: all.txt, ec.txt, and pdbchains.fasta - these are used for the
binning script.
2. Run getNonRedundantEntries.py script.
C.9 Merge Bins
1. The binning makes a directory called CurrentRun in the directory the program
was ran from. The new tab delimited file is CurrentRun/blastlist/scale2/90ec-
subbins.fancy.out This file needs to be copied to 90ec-subbins.fancy.edited.out,
and duplicate bins need to be removed. A list of the duplicate bins is located at
CurrentRun/blastlist/scale2/90ec-subbins.redundancy-warnings.out. The file
’2008 hand editing.txt’ has the list of bins and why they were deleted in the
past and can guide you through the hand editing process. When editing the
90ec-subbins.fancy.out make sure there is a tab after each pdbid. The merge.py
script will choke otherwise.
2. Run the merge.py script to combine the old and new data. Open merge.py and
change the variables on lines 62-65 to match the appropriate names. Then from
the command line type ’python /users/dicksmit/src/PLD/merge.py
3. Choosing Bin leaders: Open the new output file in Excel. For each of the
subbins if the subbin has an N in column F, a new leader must be chosen. The
rules for selection of bin leader are as follows:
(a) Highest affinity




(d) Wild-type over mutant protein
(e) Human over non-human protein
(f) Deposition Date
(g) Other criteria (Comments in papers, R-value, chemical intuition)
C.10 Getting Protein Information
1. Create a file with all the pdb information. To create this file run:
You will need this file to help classify the proteins that dont have ec numbers.
C.10.1 Classifying the enzymes that do not have EC numbers
2. Run the script to get the information for proteins that have already been clas-
sified.
3. Use the new entries output from step 1 and the output file from “Getting
Protein Information” to organize the information for each of the new proteins.
The output file is the list of entries that do not need to be checked.
4. With this output run the script to identify proteins. This script puts each
protein into one or more of twelve categories. It also produces a summary
output of which category each protein falls into (it is tab delimited
(pdb category.id prot (date)). You may want to change the output file names
in the script (identify proteins.pl) on lines 24-36 to reflect the new date. To run
the script
5. Open this new file in excel and sort the list by column A, this will tell you
which structures were identified in more than one group, read the paper and
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decide which class the protein should be in, change the name in column C to re-
flect your choice (binding, signal hormone, enzyme, mobile, transport, immune,
structural, transcript translate, toxin viral, folding, cell cycle, other) Then sort
the list by column C, and take a look at the ones that were categorized as en-
zyme, or other and see if they could be given EC number (1.-.-.-: oxidase, 2.-.-.-:
transferase, 3.-.-.-: hydrolase, 4.-.-.-: lyase, 5.-.-.-: isomerase, 6.-.-.-: ligase) or
placed in one of the other 11 classes (other than other). Use the the list of new
entries from step 2 to help you decide since that has the proteins already sub-
bin (you should have proteins in the same subbin have the same classification).
Change the unmatched classification in the new entry file from step 2 to reflect
the new subbins classification.
6. Concatenate the modified file of the new entries with the entries that already
were classified, to create the new classification file.
7. Make the final file into a comma separated file by using your favorite text editor.
You must also make sure the ec numbers are in the format 1.-.-.-, 2.-.-.- etc.
C.11 Processing the Biounit Files
C.11.1 Make Biounits
1. Download the biounit files from the PDB and copy the biounits for the new
structures in MOAD to a new directory.
2. Remove atoms that are greater than 10 Åfrom any protein atoms.
3. Determine which biounit files contain multiple models; these files will need the
waters rotated. Move thes fixed files corresponding to those structures into a
separate directory.
4. Go into this new directory and run the rotate waters.py script.
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5. Make a new directory to put these new files in, they are currently placed in the
same directory as the files with the 10 angstroms removed.
6. Move the output files from step 5 to the new directory.
7. Run the script to get the header information from the fixed file. The script that
removes the waters renames some of the chains so you must tell it where the
fixed files are and not the original biounit file.
8. Copy those files with the header to a new directory.
9. Pymol chops the ends of the lines off the pdb format so you must add spaces
to the end of the file to have a total of 80 characters.
10. Remove any waters that ended up more than 10 Åfrom the protein just as was
done in step 3.
11. Rename the final outputs [pdb id].bio[#].
C.12 Generate Multi-Part SMILES
1. Figure out which structures have multi-part ligands.
2. Copy biounit files of these structures to a new directory.
3. Make ligand files for these structures This creates a new directory called ligands
within the biounit directory
4. Run the perl script which runs the svl script to generate the SMILES string.
First you must change the file for the .mdb file on line 44 of the save db.svl
script.
5. Copy the .mdb file over to a windows machine and open it in MOE. Then save
it as a ’.csv’ file.
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6. Use a text editor to only keep the ’ligand name, SMILES’. Remove the pdbid,
chain name, residue number and other information from the first column (before
the first comma) leaving only the ligand name. After the first comma delete
everything before the SMILES string.
7. Concatenate this new file with the old file
C.13 Run Gocav on new biounits
1. Run the script to run gocav over all the structures in a directory. You may do
this on as many nodes as you would like to split up the list., be sure you run it
from the directory you would like to put the output (script on curry)
2. Run script to rename the files (script on curry).
3. Make a new directory to put divided entries in, and make two subdirectories,
nowater and water.
4. Run script to divide the files into a new directory (script on curry)
5. Run script to copy the files to the format for the viewer (script on curry).
6. Choose only one ligand for jar files.
7. Create linking shell script for jar files
8. Make directory for jar files
9. Change name of directories in script to reflect the desired xyz and jar directories.
10. move the jar files to /users/moaddata/jar
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C.14 Create the extracted references.csv and authors.csv
1. Change line 30 in extract reference.pl (found in
/home/moad 2008 update/moad update scripts on basil) to reflect the list of
all structures in binding moad.
(variable $source file)
2. Change line 35 in extract reference.pl to reflect where the pdb lives (variable
$pdb path)
3. Run the extract reference script.pl
4. Change line 11 in create authors.pl (found in same directory as
extract reference.pl) to reflect name of output file from previous step, variable
$file), and change line 12 to reflect where you would like the output to go
($output).
5. Run the create authors.pl
C.15 Create NEW Database and Load Data
1. Creating a mysql dump of the old data.
2. Create the new mysql database moad devel with password s3crtP2ss and user
moad. Also create a database jboss with password jbossmoad, and user jb.
3. The files you will need to run the loading scripts need to be in the base directory
where the run marathon scripts directory is located. These are:
(a) The final csv.
(b) The final list of rejected structure.
(c) The list of protein classifications.
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(d) The list of multi-part smiles.
(e) The extracted references files and the authors.csv files from the previous
steps.
4. Change the name of any input files in the directory run marathon scripts to
reflect where the new files are located.
5. Run run marathon.sh
C.16 Zip Biounits
1. You must first generate a list of the biounit files that have valid ligands. The
’old list’ is already located in /data/sandbox/2008 VALID BIOUNIT FILES.
2. Run generate biounit zips.pl
3. To genereate the new for xxxx.zip, run
generate new biounit zips.pl
4. Remove all files except new for xxxx.zip and the HiQ set of zips from
/users/moaddata/biou
5. Copy the new for xxxx.zip and zip directory to /users/moaddata/biou
C.17 Generate CSV files for downloadinig
1. First make the directories class/ family/ total/ and individual/ in whatever
directory you would like to work in.
2. Change the variable $license file in
generate csv from mysql.pl to reflect the location of the license file. The file is
currently on basil in /data/sandbox/BindingMOAD license.txt
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3. Run the script.
4. Generate a ‘.csv’ of only the new entries
5. First change line 20 to reflect where the license file is, and change line 218 on
generate new entry csv from mysql.pl to reflect where and what you would like
the new file to placed and named. Then run the script.
6. Remove all files from the /users/moaddata/csv except the new for xxxx.csv files
7. Copy the files from in class family individual and total to /users/moaddata/csv.
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